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Epidermal growth factor receptor (EGFR) mutation and overexpression promote tumorigenesis in multiple
cancers. Understanding the complex EGFR regulatory network is critical for developing effective therapeutic
interventions. To this end, this work investigated the functions of two incompletely characterized regulators of
EGFR trafficking and signaling, mitogen-inducible gene 6 (MIG6) and Sprouty2 (SPRY2), in two cancer
settings where EGFR mutation is common, non-small cell lung cancer (NSCLC) and glioblastoma
multiforme (GBM). In NSCLC cells, results indicate that MIG6, an endogenous inhibitor of EGFR activity
and endocytic adaptor, is surprisingly responsible for at least half of EGFR endocytosis, suggesting that a
substantial fraction of internalized EGFR may not be competent to drive signaling. Computational modeling
further suggested that in cells expressing kinase-activated, endocytosis-impaired EGFR mutants, the
importance of MIG6 relative to other endocytic pathways is increased, but that MIG6 internalization capacity
is reduced compared to cells expressing wild-type EGFR. Additional data indicate that SPRY2 expression
reduces EGFR endocytosis rate primarily by promoting EGFR expression, which overwhelms the saturable
EGFR endocytic pathway, but that SPRY2 also promotes ERK phosphorylation and resistance to EGFR
inhibition independent of EGFR expression level. In GBM cell lines, our data demonstrate that SPRY2
expression promotes proliferation, anchorage-independent growth, resistance to EGFR and c-MET co-
inhibition, and growth as mouse tumor xenografts. Additional studies identified SPRY2-mediated regulation
of the strength and effects of JNK and p38 MAP kinase pathways as important for controlling GBM cell
behaviors. Through analysis of public datasets and a collaborative analysis of human and rat tumors, we
further found that elevated SPRY2 expression is associated with reduced patient survival and expression of
EGFR variant III, an EGFR mutant linked to aggressive GBM. Thus, while SPRY2 is a candidate tumor
suppressor in other contexts, our results support a tumor promoter role for SPRY2 in GBM and identify
SPRY2 and the pathways it regulates as potential therapeutic targets or biomarkers for therapeutic response.
Overall, these findings add new qualitative and quantitative understanding of the complexities of EGFR
trafficking and signaling regulation and the functions of SPRY2 and MIG6 that may be leveraged to develop
improved cancer therapies.
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ABSTRACT 
 
REGULATION OF CELL SIGNALING BY MIG6 AND SPROUTY2 IN CANCERS WITH EGFR 
MUTATIONS 
Alice Macdonald Walsh 
Matthew Lazzara, PhD 
 
Epidermal growth factor receptor (EGFR) mutation and overexpression promote tumorigenesis in 
multiple cancers. Understanding the complex EGFR regulatory network is critical for developing 
effective therapeutic interventions. To this end, this work investigated the functions of two 
incompletely characterized regulators of EGFR trafficking and signaling, mitogen-inducible gene 6 
(MIG6) and Sprouty2 (SPRY2), in two cancer settings where EGFR mutation is common, non-
small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). In NSCLC cells, results 
indicate that MIG6, an endogenous inhibitor of EGFR activity and endocytic adaptor, is 
surprisingly responsible for at least half of EGFR endocytosis, suggesting that a substantial 
fraction of internalized EGFR may not be competent to drive signaling. Computational modeling 
further suggested that in cells expressing kinase-activated, endocytosis-impaired EGFR mutants, 
the importance of MIG6 relative to other endocytic pathways is increased, but that MIG6 
internalization capacity is reduced compared to cells expressing wild-type EGFR. Additional data 
indicate that SPRY2 expression reduces EGFR endocytosis rate primarily by promoting EGFR 
expression, which overwhelms the saturable EGFR endocytic pathway, but that SPRY2 also 
promotes ERK phosphorylation and resistance to EGFR inhibition independent of EGFR 
expression level. In GBM cell lines, our data demonstrate that SPRY2 expression promotes 
proliferation, anchorage-independent growth, resistance to EGFR and c-MET co-inhibition, and 
growth as mouse tumor xenografts. Additional studies identified SPRY2-mediated regulation of 
the strength and effects of JNK and p38 MAP kinase pathways as important for controlling GBM 
cell behaviors. Through analysis of public datasets and a collaborative analysis of human and rat 
tumors, we further found that elevated SPRY2 expression is associated with reduced patient 
survival and expression of EGFR variant III, an EGFR mutant linked to aggressive GBM. Thus, 
while SPRY2 is a candidate tumor suppressor in other contexts, our results support a tumor 
promoter role for SPRY2 in GBM and identify SPRY2 and the pathways it regulates as potential 
therapeutic targets or biomarkers for therapeutic response. Overall, these findings add new 
qualitative and quantitative understanding of the complexities of EGFR trafficking and signaling 
regulation and the functions of SPRY2 and MIG6 that may be leveraged to develop improved 
cancer therapies. 
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Chapter 1: Introduction 
1-1. Challenges in cancer treatment and targeted therapeutics  
 Over the last 30 years, the molecular understanding of cancer has expanded 
dramatically. Disappointingly, over the same period, cancer death rates have remained relatively 
stagnant (Siegel et al., 2013), indicating a gap in progress translating advanced knowledge of 
tumor biology into effective medicines. Furthermore, some reductions in cancer deaths can be 
attributed to lower smoking rates and early detection rather than treatment advances (Siegel et 
al., 2013). For many cancers, treatment remains limited to surgical resection, radiation, and/or 
chemotherapy. However, with growing mechanistic understanding of the specific proteins that 
promote cancer pathogenesis, there is an opportunity to rationally design new treatments 
targeting specific proteins. Many such targeted therapies have been developed and approved for 
clinical use, and more are in development. Ultimately, these therapeutics could lead to the 
improved patient outcomes that have been elusive for the last 30 years. This work is focused on 
one such class of targeted therapeutics that inhibit the epidermal growth factor receptor (EGFR). 
Before examining the details of EGFR inhibition, however, it is worth examining some general 
aspects of targeted therapeutics. 
There are several challenges facing the development of successful targeted cancer 
therapeutics. As for pharmaceuticals in general, consideration of adverse side effects and drug 
delivery mechanisms is necessary. More specific to targeted cancer therapies, however, one 
must also consider that many cancers are heterogeneous diseases driven by several diverse 
molecular mechanisms such that a drug targeting one mechanism will fail to be successful for the 
entire patient population. Another challenge is acquired resistance to targeted therapeutics that 
develops in tumors that may initially respond to treatment (Arora and Scholar, 2005; Branford et 
al., 2003; Sosman et al., 2012). Imatinib (Gleevec) exemplifies a generally successful targeted 
therapeutic, but also serves as an example to illustrate the challenges facing the development of 
effective targeted therapeutics. Imatinib targets the oncogenic fusion protein, BCR-ABL, a 
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tyrosine kinase found in chronic myeloid leukemia. Imatinib has a response rate of up to 90% and 
minimal side effects (Arora and Scholar, 2005). However, imatinib is only effective for patients 
with tumors driven by the BCR-ABL fusion protein and patients may acquire resistance to 
imatinib. Primarily, this resistance occurs through the development of point mutations in the BCR-
ABL kinase domain that interfere with imatinib binding (Shah et al., 2004). Additional examples of 
targeted cancer therapeutics include angiogenesis inhibitors that target vascular endothelial 
growth factor (VEGF) signaling, inhibitors of the kinase BRAF, inhibitors of aerobic glycolysis, 
cyclin-dependent kinase inhibitors, and the focus of this thesis, EGFR inhibitors (Ferrara and 
Kerbel, 2005; Flaherty et al., 2010; Hanahan and Weinberg, 2011). 
EGFR is a representative case where targeted inhibitors show promise, but have been 
disappointing clinically to date (Dutta and Maity, 2007; Wheeler et al., 2010). While EGFR is one 
of the best-studied receptor tyrosine kinases (RTKs), the factors contributing to resistance to 
EGFR inhibition are not well understood. Understanding the determinants of sensitivity and 
acquired resistance to EGFR inhibitors in order to develop more effective treatments provides the 
motivation for this thesis. In this chapter, we begin by briefly describing EGFR signaling, EGFR 
targeted inhibitors, and EGFR regulation through trafficking and feedback regulation. Next, we 
define the current understanding of mitogen-inducible gene 6 (MIG6) and Sprouty2 (SPRY2), the 
two signaling regulators that are the central focus of this work. Finally, we outline the motivation 
for the study of MIG6 and SPRY2 in lung and brain cancer and summarize the work presented in 
the following chapters.  
 
1-2. EGFR signaling and EGFR targeted inhibitors 
There are many excellent reviews of EGFR signaling (Lemmon and Schlessinger, 2010; 
Shilo, 2005; Wieduwilt and Moasser, 2008; Yarden and Sliwkowski, 2001) that describe in greater 
detail the current knowledge of EGFR signaling than space allows here. The following brief 
review describes some of the key features of EGFR regulation and the challenges remaining in 
understanding EGFR-mediated signaling.  
 
 3 
The ErbB family of RTKs consists of four family members: EGFR (ErbB1, HER1), ErbB2 
(HER2), ErbB3 (HER3), and ErbB4 (HER4). The ErbB receptors are single-chain transmembrane 
proteins with an extracellular domain (that mediates ligand binding), transmembrane domain, 
intracellular tyrosine kinase domain, and a C-terminal tail that contains multiple tyrosine residues. 
Receptors are activated through binding of the extracellular domain to one of several known 
peptide ligands (with the exception of ErbB2 that has no known ligand) that stabilize receptor 
homo- or hetero- dimers. For EGFR, the dimerization event creates an asymmetric dimer 
interface between the intracellular kinase domains, resulting in kinase activation and subsequent 
phosphorylation of C-terminal tyrosines (Zhang et al., 2006). These phosphotyrosine residues 
recruit cytosolic adaptor proteins that typically bind ErbB receptor phosphotyrosines through SH2 
domains and lead to subsequent activation of several signaling pathways including extracellular 
signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), protein kinase B (AKT), and signal 
transduction and activator of transcription (STAT) pathways.  
Due to the prevalence of EGFR overexpression, gene amplification, mutation, and 
aberrant autocrine signaling in cancers, EGFR represents an attractive drug target (Dutta and 
Maity, 2007; Normanno et al., 2006). In multiple cancers, EGFR expression also correlates with 
poor patient prognosis (Nicholson et al., 2001). Two classes of drugs targeting EGFR have been 
approved for use in cancers: antibodies that bind the extracellular domain (e.g., 
cetuximab/Erbitux, panitumumab/Vectibix) and tyrosine kinase inhibitors (TKIs) (e.g., 
gefitinib/Iressa, erlotinib/Tarceva) that inhibit intracellular EGFR enzymatic activity. Other 
inhibitors have been developed or are in trials that inhibit multiple ErbB receptors or irreversibly 
inhibit the EGFR tyrosine kinase domain (Bianco et al., 2007; Wieduwilt and Moasser, 2008). 
Despite the high incidence of EGFR activation observed in multiple cancers, EGFR 
inhibitors have not been overwhelmingly successful clinically. In non-small cell lung cancer 
(NSCLC), of the patients that respond to EGFR TKIs such as gefitinib or erlotinib, a large fraction 
express activating mutations of the EGFR tyrosine kinase domain (Lynch et al., 2004; Pao et al., 
2004). These mutations are primarily point mutations (e.g., substitution of arginine for leucine at 
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residue 858, L858R) and small in-frame deletions (e.g., deletion of residues 746 to 750, del746-
750), and alter the kinetics of ATP and drug binding, resulting in EGFR inhibition at lower drug 
concentrations (Carey et al., 2006; Yun et al., 2008). Unfortunately, the majority of tumors initially 
sensitive to EGFR inhibitors eventually develop resistance. Resistance mechanisms include 
upregulation of other receptors (Engelman et al., 2007; Sergina et al., 2007), secondary 
mutations in EGFR (e.g., substitution of methionine for threonine, T790M) (Kobayashi et al., 
2005; Yun et al., 2008), and activation of downstream signaling pathways (Ercan et al., 2012; Sos 
et al., 2009; Yao et al., 2010).  
Because tumors typically arise through multiple genetic alterations (Hanahan and 
Weinberg, 2011), it is likely that many tumors require interventions for more than a single target. 
There is promise in approaches that combine EGFR inhibitors with other inhibitors or traditional 
treatments such as radiation or chemotherapy or altering the scheduling of drugs (Dutta and 
Maity, 2007; Lee et al., 2012). Improving understanding of the complex network of EGFR 
regulation can help predict sensitivity to EGFR inhibitors as well as discover new drug targets that 
could be used alone or in combination with EGFR inhibitors in tumors that exhibit de novo or 
acquired EGFR inhibitor resistance. To this end, the work described here focuses on improving 
the understanding of EGFR trafficking and feedback regulation. These aspects of EGFR 
regulation are likely important for understanding drug response and are introduced in the 
following sections.  
 
1-3. EGFR trafficking 
 Attenuation of EGFR-mediated signaling is achieved through dephosphorylation of EGFR 
cytoplasmic phosphotyrosines by protein tyrosine phosphatases including DEP1 and protein-
tyrosine phosphatase 1B (PTP1B) (Berset et al., 2005; Haj et al., 2002), as well as endocytosis 
and subsequent degradation in lysosomes (Sorkin and Goh, 2009). The major features of EGFR 
trafficking are illustrated in Figure 1-1. Clathrin-mediated endocytosis is the best-studied pathway 
of EGFR endocytosis. This process involves the recruitment of EGFR to clathrin-coated pits and 
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subsequent pinching off of endosomes by the GTPase dynamin (Damke et al., 1994; Ferguson 
and De Camilli, 2012). The predominant view is that the E3 ubiquitin ligase CBL is recruited to 
tyrosine phosphorylated EGFR by the intracellular adaptor protein growth factor receptor-bound 
protein 2 (GRB2). CBL binding results in EGFR ubiquitylation and entrance into clathrin-coated 
pits (Schmidt and Dikic, 2005; Soubeyran et al., 2002). While clathrin-mediated endocytosis is 
generally accepted as the principal EGFR endocytosis pathway under normal conditions, several 
less well-understood pathways also exist (Sigismund et al., 2005; Sorkin and Goh, 2009). These 
pathways include caveolae-mediated endocytosis and basal membrane turnover (Kirkham and 
Parton, 2005). Because clathrin-mediated endocytosis is faster than these alternate mechanisms, 
if any components of clathrin-mediated endocytosis are limiting, the overall rate of endocytosis 
can be reduced (Lund et al., 1990; Sigismund et al., 2005). Once internalized, endosomes 
undergo acidification, altering the binding of ligands such as transforming growth factor alpha 
(TGFα), which dissociates from EGFR in endosomes, whereas EGF remains bound (Ebner and 
Derynck, 1991). Endosomal cargoes are recycled back to the plasma membrane or routed for 
degradation in lysosomes. This process may be regulated by EGFR ubiquitylation and is 
controlled by cytosolic protein complexes known as endosomal sorting complexes required for 
transport (ESCRT) (Sorkin and Goh, 2009). 
Importantly, the processes of EGFR internalization and signaling are interconnected, and 
internalization can serve roles other than signal attenuation (Sorkin and von Zastrow, 2009). 
Localization of the receptor determines proximity to substrates such as phosphatidylinositol 4,5-
bisphosphate (PIP
2) at the plasma membrane and adaptor proteins within the cell (Haugh, 2002). 
In some contexts, EGFR internalization is necessary for maximal signaling. For example, cells 
that cannot undergo clathrin-mediated endocytosis due to expression of a mutant form of 
dynamin undergo reduced EGF-stimulated ERK phosphorylation compared to wild-type dynamin 
expressing controls (Lazzara et al., 2010; Vieira et al., 1996).  
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Figure 1-1. EGFR trafficking.  
Upon activation, EGFR is rapidly recruited to clathrin-coated pits and subsequently internalized to 
endosomes. The canonical view is that CBL binding initiates clathrin-mediated endocytosis. Non-
clathrin dependent pathways can also internalize EGFR. Vesicle formation requires the GTPase 
dynamin. Once internalized, EGFR can continue to signal from endosomes and is routed for 
recycling or degradation in lysosomes. 
 
EGFR trafficking has also been linked to response to EGFR inhibitors. When EGFR 
endocytosis was blocked by expression of a dynamin mutant, cells that were previously 
insensitive to EGFR inhibition died in response to the EGFR TKI gefitinib (Lazzara et al., 2010). In 
NSCLC, cells with EGFR-activating mutations exhibit impaired EGFR endocytosis (Hendriks et 
al., 2006; Lazzara et al., 2010). This defect in endocytosis is potentially linked to drug response, 
but the basis for impaired endocytosis and EGF-induced EGFR degradation is poorly understood. 
In agreement with a relationship between EGFR internalization and sensitivity to EGFR inhibition, 
increased EGFR internalization was measured in NSCLC cells with acquired resistance to EGFR 
inhibition caused by ERK amplification (Ercan et al., 2012). Due to the complexity of EGFR 
trafficking processes, computational biology techniques that model EGFR trafficking have been 
very useful for understanding the system’s behavior and will be essential moving forward to 
improve the understanding of internalization regulation (Birtwistle and Kholodenko, 2009; 
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Wiley et al., 2003). 
 
1-4. Feedback regulators of EGFR signaling 
Similar to EGFR trafficking, feedback regulation of downstream signaling controls net 
EGFR signaling and therefore drug response. A traditional view of cell signaling frames signaling 
pathways as linear paths. In this view, ligand-binding initiates a signal at the cell surface, 
adaptors transport (and possibly amplify) this signal through the cell, and the ultimate result is 
changes in gene transcription in the nucleus or alternative non-transcriptional mechanisms that 
result in phenotypic changes. However, this interpretation disregards several essential aspects of 
signaling – mainly the importance of feedback loops, which are known to be an important feature 
of cell signaling systems. A feedback loop is generated when a downstream component affects 
an upstream component. For example, a protein might promote its own transcription, yielding a 
positive feedback loop. Feedback loops are essential for generating some of the basic behaviors 
observed in biology such as adaptation, oscillations, ultrasensitivity, and hysteresis (Kholodenko 
et al., 2010; Ma et al., 2009). 
A drug designed to bind and inhibit a target upstream in a signaling pathway with high 
potency may fail due to unanticipated upregulation of feedback pathways that result in net 
increases in the signaling output the drug was designed to repress. Feedback in the ERK MAP 
kinase pathway is a useful example. Active RAF leads to ERK activation, which causes 
upregulation of a host of negative feedback mechanisms that limit the duration and strength of 
ERK signaling. ERK can directly inhibit upstream components through phosphorylation of 
proteins such as son-of-sevenless (SOS) and RAF, resulting in inhibition of their function 
(Dougherty et al., 2005; Douville and Downward, 1997). ERK can also initiate feedback regulation 
through inducing expression of proteins that negatively regulate the pathway such as dual-
specificity phosphatases (DUSPs) that dephosphorylate ERK and other MAP kinases (Eblaghie 
et al., 2003). One example of the unforeseen consequence of feedback regulation is the case of 
melanomas with the BRAFV600E mutation. In these melanomas, high levels of negative 
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feedback driven by ERK results in suppressed RAS activity and insensitivity to growth factors 
(Lito et al., 2012). In these cells, RAF inhibition actually increases ERK activity. Another example 
was demonstrated in several cancer cell lines where MEK (the kinase that activates ERK) 
inhibition leads to activation of AKT, providing compensatory survival signaling and limiting the 
effectiveness of MEK inhibition (Turke et al., 2012). The work presented in this thesis focuses on 
two feedback regulators of EGFR signaling, mitogen-inducible gene 6 (MIG6; also known as 
RALT and gene 33) and Sprouty2 (SPRY2). The current understanding of MIG6 and SPRY2 
function is described in the following sections.  
 
1-5. MIG6  
MIG6 is a 50 kDa scaffolding protein without catalytic activity that binds to all ErbB family 
members and inhibits their tyrosine kinase activity (Anastasi et al., 2003). This regulation involves 
a unique mechanism where MIG6 binds EGFR at the asymmetric dimer interface between EGFR 
kinase domains and prevents kinase activation (Zhang et al., 2007a). Because MIG6 expression 
is induced by ERK activity, MIG6 functions as a negative feedback regulator of EGFR signaling 
(Fiorini et al., 2002). In addition to regulating tyrosine kinase activation, MIG6 also promotes 
EGFR internalization by acting as a scaffold for AP-2, Intersectin1 (ITSN1), and Intersectin2 
(ITSN2), adaptors of clathrin-mediated endocytosis, and human syntaxin 8 (STX8), a protein 
required for late endosome trafficking (Frosi et al., 2010; Ying et al., 2010). These two main 
activities of MIG6 are illustrated in Figure 1-2. 
In addition to regulating EGFR, MIG6 contributes to several other signaling pathways 
through known interacting proteins, although these aspects of MIG6 function are not as well 
understood (Figure 1-3). MIG6 binds to the small GTPase Cdc42, reducing cell migration 
(Makkinje et al., 2000; Pante et al., 2005). MIG6 also binds to the tyrosine kinase c-ABL, 
promoting apoptosis in mammary epithelial cells (Hopkins et al., 2012). Little is known about the 
regulation of MIG6 activity or the role of interactions with several other proteins such as 14-3-3, 
SRC kinase, GRB2, and phospholipase C gamma (PLC-γ) (Fiorentino et al., 2000; Makkinje et 
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al., 2000). Chk1 was shown to phosphorylate MIG6 at serine 251 and negatively regulate the 
inhibitory activity of MIG6 on EGFR activation (Liu et al., 2012). It is unknown how 
phosphorylation of serine 251 or other sites controls other aspects of MIG6 function. 
 
Figure 1-2. MIG6 regulation of EGFR activity and internalization.  
MIG6 is thought to function with two mechanisms to control EGFR signaling: (1) by blocking the 
key interactions at the asymmetric EGFR dimer interface thereby preventing EGFR 
phosphorylation and subsequent downstream signaling, and (2) by promoting interactions with 
other proteins, such as AP-2, that lead to internalization of EGFR and potential degradation. 
 
Previous work has suggested that MIG6 may play an important role in some types of 
cancer. In mice, loss of Mig6 results in lung, gallbladder, bile duct, and skin cancer (Ferby et al., 
2006; Zhang et al., 2007b). In human cancers, such as breast, brain, skin, pancreatic, and 
ovarian, MIG6 expression is frequently reduced (Anastasi et al., 2005; Ferby et al., 2006; Ying et 
al., 2010). In addition, mutations in MIG6 have been found in lung cancer cell lines (Zhang et al., 
2007b). These studies point to a tumor suppressor role for MIG6 in cancer. However, it remains 
unknown how MIG6 functions in the context of cancer cells with EGFR-activating mutations. 
Because MIG6 expression is induced by ERK activity, MIG6 expression may be elevated in the 
context of tumors with elevated ERK signaling (Fiorini et al., 2002). Indeed, MIG6 expression was 
found to be elevated in NSCLC cells with EGFR-activating mutations (Nagashima et al., 2009). 
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Figure 1-3. Domain map of MIG6 and SPRY2.  
(A) MIG6 and (B) SPRY2 interacting partners are shown at the regions where they bind. Proteins 
with unknown interaction sites are shown not contacting the protein. CRIB = Cdc42/Rac 
interactive binding; ED = endocytic domain; EBR = ErbB binding region; SH3 = SRC homology 3 
domain.  
 
1-6. SPRY2 
SPRY2 is one of four mammalian sprouty proteins and a regulator of several RTKs 
including EGFR (Edwin et al., 2009; Kim and Bar-Sagi, 2004; Mason et al., 2006). Sprouty 
proteins were identified in Drosophila melanogaster, where a single isoform, Spry, regulates RTK-
mediated processes including branching morphogenesis (Edwin et al., 2009; Hacohen et al., 
1998). SPRY2 has no catalytic activity, but regulates cellular signaling through several known 
protein interactions, although some of these are incompletely characterized (Figure 1-3). SRC 
kinase phosphorylates SPRY2 at tyrosine 55, forming a binding site for CBL and the phosphatase 
PP2A. Upon CBL binding, SPRY2 is poly-ubiquitylated, targeting it for destruction in the 
proteasome. PP2A binding, on the other hand, leads to dephosphorylation of serines 112 and 
121, which is thought to allow ERK inhibition via GRB2 interactions (Edwin et al., 2009). In 
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addition, SPRY2 can bind itself and other sprouty family members, although little is known about 
the role of sprouty oligomerization (Ozaki et al., 2005; Wu et al., 2005). SPRY2 is also known to 
interact with several other proteins such as the kinase TESK1 (Chandramouli et al., 2008) and 
the phosphatase SHP2 (Hanafusa et al., 2004). These proteins are involved in other mechanisms 
of SPRY2 signaling regulation that are not well understood. 
SPRY2 expression is promoted by ERK activity, but at the same time, SPRY2 functions 
to either inhibit or potentiate ERK activation, creating a feedback loop. SPRY2-mediated ERK 
regulation appears to be highly cell and context-specific. SPRY2 may inhibit ERK at the level of 
RAS by preventing GRB2/SOS recruitment (Hanafusa et al., 2004), preventing RAS activation 
downstream of GRB2/SOS (Gross et al., 2001), or at the level of RAF (Yusoff et al., 2002), 
depending on the cellular context. Although SPRY2 is generally thought to inhibit ERK signaling, 
SPRY2 can also potentiate ERK signaling downstream of EGFR. This occurs in a proposed 
mechanism where SPRY2 binds the ubiquitin ligase CBL, interfering with CBL-mediated EGFR 
internalization (Haglund et al., 2005; Rubin et al., 2003; Wong et al., 2002). It was also shown 
that SPRY2 can interact with hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs), 
a protein that promotes EGFR progression from early to late endosomes (Kim et al., 2007). In this 
manner, SPRY2 reduces EGFR trafficking to late endosomes. Due to the large number of studies 
that demonstrate a variety of functions of SPRY2 depending on the cell system and growth factor 
stimulation, no agreement on the SPRY2 mechanism of action has been established. Therefore, 
the function of SPRY2 in any given setting is extremely difficult to predict. The proposed 
mechanisms of SPRY2-mediated ERK regulation are shown in Figure 1-4. 
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Figure 1-4. ERK regulation by SPRY2.  
SPRY2 is proposed to function either (1) as an inhibitor of ERK signaling downstream of several 
RTKs that initiate ERK signaling or (2) as a promoter of ERK signaling downstream of EGFR. 
SPRY2 expression is promoted by ERK and can interfere with the ERK pathway by binding 
GRB2 or RAF. Conversely, SPRY2 can bind CBL and prevent EGFR/CBL association, preventing 
EGFR degradation and also the attenuation of EGFR signaling. 
 
 The role of SPRY2 has been studied in several cancers (Edwin et al., 2009; Normanno et 
al., 2006). In some cancers, such as hepatocellular carcinoma, breast cancer, and prostate 
cancer, SPRY2 expression is decreased and SPRY2 appears to act as a tumor suppressor (Fong 
et al., 2006a; Lo et al., 2006; Sutterluty et al., 2007). For example, in mice, Spry2 overexpression 
in osteosarcoma cells suppressed tumor growth and metastasis (Miyoshi et al., 2004). However, 
there is evidence that in colon cancer, SPRY2 expression may promote tumorigenesis 
(Barbachano et al., 2010; Holgren et al., 2010; Ordonez-Moran et al., 2013). There are several 
questions remaining about the role of SPRY2 in cancer. Because of the various proposed 
regulatory functions of SPRY2, it is difficult to predict the effect of SPRY2 expression in different 
settings or in the context of drug treatment. It is also unknown how SPRY2 regulates signaling in 
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cells with oncogenic receptors or receptor overexpression that could be driving high SPRY2 
expression and/or phosphorylation.  
 
1-7. Overview of thesis work 
 Significant progress has been made in recent years towards understanding response to 
EGFR inhibitors in cancer. However, several questions remain unanswered. One such poorly 
understood aspect of drug response is how feedback regulators such as MIG6 and SPRY2 
regulate EGFR-mediated signaling and ultimately response to EGFR inhibitors in cancer. The 
work described in the following chapters attempts to address this question in the settings of 
NSCLC and glioblastoma multiforme (GBM). EGFR mutations and EGFR overexpression are 
common in NSCLC and GBM, potentially leading to unforeseen perturbations in signaling 
networks due to feedback mechanisms. Due to the complex and interconnected nature of EGFR 
signaling and regulation, our approach combines experimental methods with computational 
methods to enable interpretation of experimental results. 
 In Chapters 2 and 3, we sought to determine the role MIG6 and SPRY2 play in regulating 
the impaired EGFR endocytosis, altered cellular signaling, and enhanced cellular sensitivity to 
EGFR tyrosine kinase inhibitors observed in NSCLC cells with EGFR mutations. We find that 
perturbations to MIG6 and SPRY2 expression control EGFR endocytosis and subsequent 
signaling in cell lines expressing wild-type EGFR as well as those expressing EGFR mutants. 
Data demonstrate that the already low EGFR endocytosis rate constant measured in cells 
expressing an EGFR mutant can be driven even lower by reducing MIG6 expression. Although 
MIG6 was only recently shown to regulate EGFR endocytosis, results indicate that MIG6 
internalizes a similar amount of wild-type EGFR as CBL. As suggested by previous studies, our 
analysis indicates that CBL-mediated internalization of mutant EGFR is impaired, but that MIG6-
mediated internalization of mutant EGFR is also diminished. This work indicates that MIG6 has a 
previously underappreciated role in EGFR internalization in NSCLC cells. This finding has 
important implications because internalized EGFR bound to MIG6 may not be competent for 
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driving downstream signaling. In addition, this work uncovers and quantifies the importance of 
differences in EGFR recycling between wild-type and mutant EGFR-expressing cells. We 
measured significantly increased recycling of mutant EGFR relative to wild-type EGFR and find 
that this difference explains observed reductions in EGF-stimulated EGFR degradation. Finally, 
we find that, due to the complex functions of MIG6 on both EGFR activity and trafficking, MIG6 
depletion does not significantly affect EGFR downstream signaling or response to EGFR 
inhibition. Conversely, we find that SPRY2 expression promotes ERK phosphorylation and 
resistance to EGFR inhibition. Data and modeling analysis demonstrated that SPRY2 depletion 
reduces EGFR expression, which results in increased endocytosis rate because of alleviated 
saturation of rapid endocytic pathways. Further detailed EGFR reconstitution studies indicated 
that, unlike endocytosis rate, the effects of SPRY2 on ERK phosphorylation and response to 
EGFR inhibition are independent of EGFR expression. 
 In Chapter 4, the role of SPRY2 is examined in GBM, the most common form of brain 
cancer in adults. Similarly to NSCLC, EGFR is frequently overexpressed and mutated in GBM, 
but a structurally distinct EGFR mutation is common. Our findings uncover an important role for 
SPRY2 in GBM tumorigenesis and response to EGFR and c-MET co-inhibition. We determined 
the expression of SPRY2 as a function of the most common EGFR mutation in GBM patients, the 
deletion mutation, EGFR variant III (EGFRvIII), which is associated with an aggressive tumor 
phenotype. We find that SPRY2 expression is elevated in EGFRvIII-positive human tumors and 
orthotopic rat tumors compared to EGFRvIII-negative tumors. Furthermore, SPRY2 expression is 
associated with the classical GBM subtype and reduced patient survival. In GBM cell lines, we 
find that SPRY2 promotes proliferation, colony formation in soft agar, and cellular resistance to 
EGFR and c-MET co-inhibition. In mouse xenografts, SPRY2 depletion significantly reduced 
proliferation. Interestingly, SPRY2 appears to control these phenotypes though regulation of p38 
and JNK MAP kinases or other signaling pathways, but not through ERK regulation. In addition, 
our results point to a novel mechanism of SPRY2-mediated regulation involving p38 and JNK 
MAP kinase regulation by MAP kinase phosphatases. Overall, our data suggest that SPRY2 or 
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the pathways it regulates could be promising therapeutic targets or prognostic biomarkers in 
GBM. 
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Chapter 2: Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung 
cancer cells
1
 
2-1. Abstract 
The duration and specificity of epidermal growth factor receptor (EGFR) activation and 
signaling are determinants of cellular decision processes and are tightly regulated by receptor 
dephosphorylation, internalization, and degradation. In addition, regulatory proteins that are 
upregulated or activated post-transcriptionally upon receptor activation may initiate feedback 
loops that play crucial roles in spatiotemporal regulation of signaling. We examined the roles of 
Sprouty2 (SPRY2) and mitogen-inducible gene 6 (MIG6), two feedback regulators of EGFR 
trafficking and signaling, in lung cancer cells with or without EGFR-activating mutations. These 
mutations are of interest because they confer unusual cellular sensitivity to EGFR inhibition 
through a mechanism involving an impairment of EGFR endocytosis. We found that the 
endocytosis of wild-type and mutant EGFR was promoted by SPRY2 knockdown and 
antagonized by MIG6 knockdown. SPRY2 knockdown also significantly reduced extracellular 
signal-regulated kinase (ERK) phosphorylation, EGFR expression, and EGFR recycling. In a cell 
line expressing mutant EGFR, this effect on ERK led to a marked increase in cell death response 
to EGFR inhibition. The effects of SPRY2 knockdown on EGFR endocytosis and recycling were 
primarily the result of the concomitant change in EGFR expression, but this was not true for the 
observed changes in ERK phosphorylation. Thus, our study demonstrates that SPRY2 and MIG6 
are important regulators of wild-type and mutant EGFR trafficking and points to an EGFR 
expression-independent function of SPRY2 in the regulation of ERK activity that may impact 
cellular sensitivity to EGFR inhibitors, especially in the context of EGFR mutation. 
 
                                                     
1
 A version of Chapter 2 was published as: Walsh, A. M., & Lazzara, M. J. (2013). Regulation of 
EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells. J Cell Sci, 
126(19), 4339-4348. (PMID:23868981)  
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2-2. Introduction 
Epidermal growth factor receptor (EGFR)-mediated signaling must be tightly controlled in 
order to ensure appropriate cellular outcomes. Such control is achieved through a variety of 
mechanisms, including feedback. Studies of biological networks have shown that feedback 
regulation is necessary to generate biologically observed signaling patterns such as adaptation, 
oscillations, and switch-like responses (Kholodenko et al., 2010; Ma et al., 2009). In addition, 
multiple positive and negative feedback loops can create systems that are tunable and insensitive 
to noise (Brandman et al., 2005). These and other observations have made it increasingly clear 
that a complete understanding of signaling initiated by EGFR will require a deeper understanding 
of the feedback regulators that control EGFR-mediated signaling (Avraham and Yarden, 2011). 
Two such feedback regulators of EGFR-mediated signaling are Sprouty2 (SPRY2) and mitogen-
inducible gene 6 (MIG6). 
SPRY2 belongs to a family of four mammalian Sprouty proteins and regulates signaling 
downstream of multiple growth factor receptors. SPRY2 expression is induced by extracellular 
signal-regulated kinase (ERK) activity (Ozaki et al., 2001). When phosphorylated at tyrosine 55 in 
response to growth factors such as EGF, SPRY2 binds and sequesters the E3 ubiquitin ligase 
CBL, impeding EGFR ubiquitylation and degradation (Egan et al., 2002; Haglund et al., 2005; 
Rubin et al., 2003; Wong et al., 2002). SPRY2 also inhibits EGFR passage from early to late 
endosomes in a proposed mechanism involving SPRY2 binding to hepatocyte growth factor-
regulated tyrosine kinase substrate (Kim et al., 2007). Downstream of receptors, SPRY2 may 
antagonize ERK activity by inhibiting RAS through binding to GRB2 or by inhibiting RAF, 
depending on the cellular context (Lao et al., 2006; Yusoff et al., 2002).  
MIG6 (also known as RALT) is transcriptionally regulated by ERK downstream of EGFR 
(Fiorini et al., 2002; Hackel et al., 2001) and inhibits EGFR activation by binding at the 
asymmetric interface between dimerized EGFR kinases (Zhang et al., 2006; Zhang et al., 2007a). 
MIG6 also promotes EGFR endocytosis by coupling the receptor to AP-2 and Intersectins (Frosi 
et al., 2010; Ying et al., 2010).  
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Although elevated expression and activating mutations of EGFR occur frequently in 
multiple cancers (Hirsch et al., 2003; Itakura et al., 1994; Mellinghoff et al., 2005; Sheng and Liu, 
2011), the functional role of EGFR feedback regulation by proteins such as SPRY2 and MIG6 has 
not been thoroughly studied. In cases where there is an important role for EGFR feedback 
regulation in oncogenesis or tumor progression, it could potentially be leveraged to overcome de 
novo or acquired resistance to EGFR inhibitors (Kobayashi et al., 2005; Kosaka et al., 2006; 
Mellinghoff et al., 2005; Sheng and Liu, 2011).  
We studied the roles of SPRY2 and MIG6 in non-small cell lung cancer (NSCLC) cells, 
where EGFR is frequently expressed at elevated levels. In a small fraction of NSCLCs, the 
expression of kinase-activated EGFR mutants confers unusual cellular sensitivity to EGFR 
inhibitors (Lynch et al., 2004; Mitsudomi and Yatabe, 2007; Paez et al., 2004) and leads to 
increased expression and phosphorylation of SPRY2 and MIG6 (Guo et al., 2008; Nagashima et 
al., 2009; Rubin et al., 2003). These EGFR mutations also lead to dramatic impairment of EGFR 
endocytosis, which has been linked to differential cellular sensitivity to EGFR inhibitors (Hendriks 
et al., 2006; Lazzara et al., 2010). We hypothesized that SPRY2 and MIG6 could participate in 
this perturbation to EGFR mutant endocytosis and in turn serve as important determinants of 
cellular response to EGFR inhibitors.  
In two different NSCLC cell lines, one with an EGFR-activating mutation and 
demonstrating the previously documented impairment in receptor internalization, EGFR 
endocytosis was augmented by SPRY2 knockdown and reduced by MIG6 knockdown. EGFR 
recycling, which we quantitatively determined to be roughly two-fold more efficient in the cell line 
with EGFR mutation, was also reduced by SPRY2 knockdown in both cell lines. Thus, SPRY2 
may play two roles that promote EGFR expression in NSCLC cells with or without EGFR 
mutation. Interestingly, the effects of SPRY2 knockdown on receptor endocytosis and recycling 
were explained by a concomitant decrease in EGFR expression, as revealed by EGFR 
reconstitution experiments. Downstream of the receptor, SPRY2 knockdown significantly reduced 
ERK phosphorylation. However, MIG6 knockdown had a relatively modest effect on ERK 
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phosphorylation. Moreover, as a result of reduced ERK phosphorylation, SPRY2 knockdown 
promoted apoptotic response to the EGFR inhibitor gefitinib. This increase in apoptosis was 
especially pronounced in PC9 cells, which express a deletion mutant of EGFR. Despite the 
rescue effects of EGFR reconstitution on top of SPRY2 knockdown on EGFR trafficking, EGFR 
reconstitution did not rescue the effects of SPRY2 knockdown on ERK phosphorylation or cellular 
response to gefitinib. Thus, our study identifies SPRY2 and MIG6 as important regulators of 
EGFR endocytosis and recycling in EGFR mutant-expressing cells, as well as cells expressing 
wild-type EGFR. Our results also point to an EGFR expression-independent function of SPRY2 in 
the regulation of ERK that impacts cellular sensitivity to EGFR inhibition. These findings provide 
new insights into the coupling between EGFR trafficking, signaling, and feedback regulation and 
suggest that interference with SPRY2 expression or function could be a useful therapeutic 
approach in lung cancer cells with acquired resistance to EGFR-targeted therapy. 
 
2-3. Materials and Methods 
Cell lines and cell culture. H1666 cells (EGFR wild-type) were obtained from the 
American Type Tissue Collection (Manassas, VA, USA) and maintained in ACL4 (Lazzara et al., 
2010). PC9 cells (EGFR delE746-A750) were a generous gift of Dr. Douglas Lauffenburger (MIT, 
Cambridge, MA, USA) and were maintained in RPMI supplemented with 10% fetal bovine serum 
(FBS), 1 mM L-Glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin (Life 
Technologies, Grand Island, NY, USA). For EGFR or MEK inhibition experiments, gefitinib or 
U0126 (both from LC Laboratories, Woburn, MA, USA) were added to the cells in complete 
media. PC9 cells are extremely sensitive to gefitinib, with an IC50 for cellular proliferation << 1 μM 
(Guo et al., 2008; Noro et al., 2006; Tracy et al., 2004). H1666 cells are moderately sensitive to 
gefitinib with an IC50 of ~2 μM (Tracy et al., 2004). Consistent with previously reported trends 
(Guo et al., 2008; Nagashima et al., 2009), PC9 cells expressed more MIG6 than H1666 cells 
(Figure 2-S1A). SPRY2 levels were similar for both cell lines. These general trends held in a 
broader panel of NSCLC cell lines (Figure 2-S1A).  
 
 20 
SPRY2 and MIG6 knockdown. The pSuper retroviral shRNA vector with neomycin 
resistance was purchased from Oligoengine (Seattle, WA, USA), and the pSicoR lentiviral shRNA 
vector with puromycin resistance was a generous gift from Dr. Tyler Jacks (MIT Koch Institute for 
Integrative Cancer Research, Cambridge, MA, USA; (Ventura et al., 2004)). An oligonucleotide 
encoding a hairpin targeting nucleotides 1649-1667 of human MIG6 was cloned into the pSuper 
plasmid. Oligonucleotides encoding hairpins targeting nucleotides 2061-2079 (main sequence 
used) or 1195-1213 of human SPRY2 were cloned into pSicoR. Controls were created for each 
vector using hairpins that do not target a known human mRNA, and control cells for simultaneous 
knockdown of SPRY2 and MIG6 expressed both control shRNAs. All oligonucleotides were 
purchased from IDT (Coralville, IA, USA). Retrovirus was produced by calcium-phosphate-
mediated transfection of amphotropic Phoenix cells (Dr. Gary Nolan, Stanford University, 
Stanford, CA, USA) with pSuper plasmids. Lentivirus was produced by transfection of 293FT cells 
(Life Technologies) with pSicoR, pCMV-VSVg, pMDL-gp-RRE, and pRSV-Rev plasmids (Dr. 
Marilyn Farquhar, UCSD, La Jolla, CA, USA) using calcium phosphate. Virus-containing 
supernatant was passed through 0.45 μm syringe filters prior to addition to target cells. Cells 
were selected in 1-2 μg/mL puromycin (Sigma, St. Louis, MO, USA) and/or 100-500 μg/mL 
geneticin (Life Technologies). Efficient stable knockdown of SPRY2 and MIG6 in PC9 and H1666 
cells was confirmed by western blot (Figure 2-S1B). 
EGFR expression. The pBabe.hygro wild-type human EGFR retroviral expression 
plasmid was constructed by sub-cloning from a pCDNA4/TO/Myc-HisB vector with a wild-type 
human EGFR insert (gift from Dr. Yi-Rong Chen, National Health Research Institutes, Taiwan). 
Retrovirus was prepared and cells were infected as described above. Cells were selected in 100 
μg/mL hygromycin B (Sigma). To express the human EGFR delE746-A750 mutant, a lentiviral 
expression plasmid (pLenti6/V5-DEST) with the appropriate insert was used (gift of Dr. Daniel 
Haber, Harvard Medical School, Boston, MA, USA). Lentivirus was prepared and cells were 
infected as described above. Target cells were selected in 2 μg/mL blasticidin (Life 
Technologies). 
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Western blotting. Whole cell lysates were prepared in a standard cell extraction buffer 
(Life Technologies) supplemented with protease and phosphatase inhibitors (Sigma). Lysates 
were cleared by centrifugation at 13,200 rpm for 10 min, and total protein concentrations were 
determined by micro-bicinchoninic assay (Thermo Scientific, Rockford, IL, USA). Approximately 
20 μg of total protein was loaded per lane on 4-12% gradient polyacrylamide gels (Life 
Technologies) under denaturing and reducing conditions and transferred to 0.2 μm nitrocellulose 
membranes (Life Technologies). After probing with antibodies, membranes were imaged on a LI-
COR Odyssey scanner (LI-COR, Lincoln, NE, USA). Membranes were stripped with 0.2 M NaOH 
as needed. 
EGFR immunoprecipitation. Whole cell lysates were prepared using a lysis buffer 
optimized for immunoprecipitation (Cell Signaling Technology, Danvers, MA, USA) supplemented 
with protease and phosphatase inhibitors. 600 μg of total protein was incubated overnight with 
protein G agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) that were pre-
conjugated to 400 ng of EGFR antibody. Immunoprecipitates were analyzed by western blot, as 
described above. 
Antibodies. Antibodies against EGFR (#2232), AKT (#9272), p-AKT S473 (#9271), ERK 
(#4695), ubiquitin (#3933), and p-ERK T202/Y204 (#4377) were purchased from Cell Signaling 
Technology. The CBL antibody was from Epitomics (#1486; Burlingame, CA, USA). The EGFR 
immunoprecipitation antibody was from Thermo Scientific (Ab-12). The SPRY2 antibody was 
purchased from Sigma (#S1444). The MIG6 antibody was purchased from Santa Cruz 
Biotechnology (#sc-137155), and the actin antibody was purchased from Millipore (#MAB1501; 
Billerica, MA, USA). Infrared dye-conjugated secondary antibodies were purchased from 
Rockland Immunochemicals (Gilbertsville, PA, USA). All antibodies were used according to 
manufacturer recommendations. 
Flow cytometry. Floating and adherent cells were pooled and stained with FITC-
conjugated Annexin V (Southern Biotech, Birmingham, AL, USA). Cells were analyzed within 1 hr 
of staining using a Becton Dickinson FACS-Calibur cytometer, and data were analyzed using 
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FlowJo. 
EGFR endocytosis rate constant and recycling fraction measurements. Rate constants of 
EGF-mediated EGFR endocytosis (ke) were measured using 
125
I-EGF and corrected for the 
effects of non-specific binding and surface spillover, as described previously (Lund et al., 1990; 
Wiley and Cunningham, 1982). For experiments using the dynamin inhibitor Dynasore (Millipore), 
cells were pretreated with 80 μM Dynasore or DMSO control for 2 hrs, and Dynasore was added 
to the 
125
I-EGF-containing media used to make ke measurements. Steady-state EGFR recycling 
fractions (fr), defined as the fraction of intact internalized ligand that is returned to and released 
from the plasma membrane, were measured as described previously (French et al., 1995), with 
intact and degraded 
125
I-EGF separated with 5 kDa molecular weight cutoff centrifugal filters 
(Millipore). 
qRT-PCR. Relative amounts of EGFR mRNA were determined using the comparative CT 
method. RNA samples were prepared using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) 
with on-column DNase I digestion. Equal amounts of RNA from each sample were reverse 
transcribed using the High Capacity cDNA Reverse Transcription Kit (Life Technologies). qPCR 
was performed using SYBR Green PCR Master Mix (Life Technologies) on an Applied 
Biosystems 7300 Real-Time PCR System. 
 
2-4. Results 
EGF-mediated EGFR endocytosis is promoted by SPRY2 knockdown and impaired by 
MIG6 knockdown. We reduced SPRY2 and/or MIG6 expression in PC9 (delE746-A750 EGFR) 
and H1666 (wild-type EGFR) NSCLC cells through stable shRNA expression. As expected based 
on previous studies of NSCLC cells (Hendriks et al., 2006; Lazzara et al., 2010), the rate constant 
for EGF-mediated EGFR endocytosis (ke) was larger in H1666 cells transduced with either of the 
control shRNA vectors than in corresponding PC9 cells (Figure 2-1). SPRY2 knockdown 
significantly increased ke in both cell lines (from 0.05 to 0.08 min
-1 
in PC9 cells, and from 0.16 to 
0.21 min
-1 
in H1666 cells). MIG6 knockdown reduced ke in PC9 and H1666 cells (from 0.06 to 
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0.03 min
-1
 in PC9 cells, and from 0.18 to 0.12 min
-1
 in H1666 cells). When SPRY2 and MIG6 
were simultaneously depleted, the net result was a decrease in ke in both cell lines (from 0.07 to 
0.045 min
-1
 in PC9 cells, and from 0.17 to 0.15 min
-1
 in H1666 cells). The effect of combined 
knockdown suggests a hierarchy between SPRY2 and MIG6 in controlling ke for both wild-type 
and mutant EGFR. Data used to generate the ke values are shown in Figure 2-S2. 
 
Figure 2-1. SPRY2 and/or MIG6 knockdown perturb EGF-mediated EGFR endocytosis. 
EGFR endocytosis rate constants (ke) were measured using 10 ng/mL 
125
I-EGF for PC9 and 
H1666 cells with knockdown of SPRY2, MIG6, or SPRY2 and MIG6, as described in Materials 
and Methods. Data were corrected for the effects of non-specific binding and spillover and 
represent an average of three experiments ± s.e.m. Asterisks indicate p < 0.05 for comparisons 
against controls. 
 
At EGF concentrations above or near 10 ng/mL (the condition used in Figure 2-1), EGFR 
endocytosis may occur through clathrin dependent and independent processes (Sigismund et al., 
2008; Sigismund et al., 2005). To determine whether the differences measured in Figure 2-1 
might reflect effects other than those attributable to clathrin-mediated endocytosis, we repeated 
ke measurements in H1666 cells at 1.5 ng/mL EGF. The differences observed at 10 ng/mL were 
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preserved at 1.5 ng/mL (Figure 2-S3A). We also found that inhibition of dynamin, a GTPase 
required for clathrin-mediated endocytosis of many receptor tyrosine kinases (Kirchhausen et al., 
2008), reduced ke in PC9 and H1666 cells, indicating that clathrin mediated endocytosis was 
relevant in both cell lines (Figure 2-S3B). Both CBL- and MIG6-mediated endocytosis pathways 
are clathrin-mediated (Frosi et al., 2010; Swaminathan and Tsygankov, 2006).  
SPRY2 and MIG6 knockdown alter ERK phosphorylation in qualitatively different ways, 
and SPRY2 knockdown reduces EGFR expression. Because normal EGFR trafficking is 
important for complete ERK activation in at least some cellular contexts (Vieira et al., 1996), and 
because ERK activity is a key determinant of NSCLC cell response to EGFR inhibition (Furcht et 
al., 2012; Lazzara et al., 2010), we tested whether the changes in endocytosis we measured due 
to SPRY2 and MIG6 knockdown correlated with any changes in ERK phosphorylation. In PC9 
and H1666 cells, SPRY2 knockdown resulted in an approximately two-fold reduction in ERK 
phosphorylation with or without gefitinib present (Figure 2-2A and Figure 2-S4A, B). ERK 
phosphorylation was increased by MIG6 knockdown, but the magnitude of this effect was more 
modest. With combined SPRY2 and MIG6 knockdown, there was a small (but statistically 
insignificant) reduction in ERK phosphorylation in PC9 cells and no change in ERK 
phosphorylation in H1666 cells. Qualitatively similar, but generally smaller, changes in AKT 
phosphorylation were observed with SPRY2 and MIG6 knockdown (Figure 2-S4C).  
In validating the stable knockdown of SPRY2 and MIG6, we also noticed a reduction in 
EGFR expression concomitant with SPRY2 knockdown. Western blot analysis revealed that, in 
PC9 and H1666 cells, SPRY2 knockdown resulted in decreases in EGFR protein levels of 54% 
and 40%, respectively (Figure 2-2B). Differences in absolute counts of 
125
I-EGF binding in PC9 
and H1666 cell lines from ke measurements also confirmed these decreases in EGFR expression. 
This effect repeated with an independent SPRY2 shRNA (Figure 2-S5A) and generally held when 
we probed the effects of SPRY2 knockdown in a larger panel of NSCLC cells (Figure 2-S5B). As 
will be shown later, we also verified these changes by flow cytometry. Because SPRY2 
knockdown led to the most dramatic changes in the activity of the ERK pathway and also 
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appeared to alter EGFR expression, effects that may alter cellular response to EGFR inhibition, 
we focused most of the remainder of our studies on the effects of SPRY2 knockdown. 
 
Figure 2-2. SPRY2 and/or MIG6 knockdown perturb ERK phosphorylation, and SPRY2 
knockdown reduced EGFR expression.  
(A) PC9 and H1666 cells expressing shRNAs targeting SPRY2, MIG6, or SPRY2 and MIG6 (KD, 
knockdown) or non-targeting control shRNAs were treated with the indicated concentrations of 
gefitinib for 24 (PC9) or 48 hrs (H1666), and western blots of whole cell lysates were probed with 
antibodies against phosphorylated or total ERK. Normalized densitometry data represent an 
average of three independent experiments ± s.e.m. Asterisks indicate p < 0.05 for comparisons 
against controls. (B) PC9 and H1666 cells expressing a SPRY2-targeting shRNA or a control 
shRNA (indicated by “-“) were cultured in complete media, and western blots of whole cell lysates 
were probed with antibodies against indicated proteins. Normalized densitometry data represent 
an average of three independent experiments ± s.e.m. Asterisks indicate p < 0.05 for comparison 
against control.  
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EGFR ubiquitylation and CBL association are enhanced by SPRY2 knockdown in cells 
expressing wild-type, but not mutant, EGFR. To further probe the mechanism of SPRY2-
mediated regulation of EGFR internalization and expression, we measured EGFR ubiquitylation 
and association with CBL. A previous report found that EGFR mutants are poorly ubiquitylated 
and do not associate with CBL in response to EGF (Padron et al., 2007), but the effects of  
SPRY2 on EGFR ubiquitylation and CBL association has not previously been explored in NSCLC 
cells with EGFR mutation. We did not detect significant EGFR ubiquitylation or CBL association in 
EGFR immunoprecipitates of PC9 cells treated with EGF (Figure 2-3A). In contrast, and 
consistent with previously hypothesized mechanisms of wild-type EGFR regulation by SPRY2 
(Egan et al., 2002; Haglund et al., 2005; Rubin et al., 2003; Wong et al., 2002), EGFR was 
ubiquitylated and CBL-associated in response to 10 ng/mL EGF in H1666 cells, and these effects 
were augmented by SPRY2 knockdown (Figure 2-3B). Even with EGF treatments for longer times 
and at higher concentrations than used in Figure 2-3, these differences between PC9 and H1666 
cells persisted (Figure 2-S6A-D). The absence of non-specific immunoprecipitation of EGFR, 
ubiquitin, and CBL was confirmed in a separate experiment (Figure 2-S6E).  
 
Figure 2-3. EGF-mediated EGFR ubiquitylation and CBL association occur in H1666 cells 
in a SPRY2-dependent manner, but ubiquitylation and CBL association do not occur in 
PC9 cells.  
PC9 and H1666 cells expressing SPRY2-targeting shRNA or a non-targeting control shRNA were 
serum starved overnight and treated with or without 10 ng/mL EGF for 2 min. EGFR was 
immunoprecipitated (IP) from whole cells lysates of (A) PC9 cells and (B) H1666 cells, and 
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immunoprecipitates were analyzed by western blot (WB) using antibodies against the indicated 
proteins. Densitometry data for H1666 cells represent averages from three independent 
experiments ± s.e.m. Asterisks indicate p < 0.05 for comparison against control. 
 
SPRY2 regulates EGFR transcription and ERK regulates EGFR expression in cells 
expressing an EGFR mutant. Because no differences in EGFR ubiquitylation or CBL association 
were detected in PC9 cells with SPRY2 knockdown (where EGFR expression was substantially 
reduced), we probed the effect of SPRY2 knockdown on EGFR mRNA levels. In PC9 cells, 
SPRY2 knockdown reduced EGFR mRNA levels by ~75% (Figure 2-4A). A reduction in EGFR 
mRNA was also measured for a second non-overlapping SPRY2 shRNA (Figure 2-S7). In 
contrast, no change in EGFR mRNA level was detected in H1666 cells with SPRY2 knockdown 
(Figure 2-4A and Figure 2-S7).  
Because EGFR expression can be regulated by ERK activity (Grassian et al., 2011), and 
since a large effect on ERK phosphorylation was found in cells with SPRY2 knockdown, we 
tested the effect of MEK inhibition on EGFR expression. As determined by western blot analysis, 
MEK inhibition decreased EGFR expression in PC9 cells, but had no effect in H1666 cells (Figure 
2-4B). Thus, changes in EGFR expression with SPRY2 knockdown are likely to occur via 
transcriptional effects in PC9 cells (due to decreased ERK phosphorylation) and through changes 
in trafficking (increased endocytosis and degradation) in H1666 cells. 
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Figure 2-4. SPRY2 knockdown decreases EGFR mRNA and protein levels in an ERK-
dependent manner in PC9 cells, but not in H1666 cells.  
(A) EGFR mRNA levels were determined by qRT-PCR in PC9 and H1666 cells expressing 
control or SPRY2 shRNA. Data represent an average of three independent experiments 
performed in triplicate wells ± s.e.m. Asterisks indicate p < 0.05 for comparison against control. 
(B) Parental PC9 and H1666 cells were treated for 24 hrs with the indicated concentrations of 
U0126, and whole cell lysates were analyzed by western blot using antibodies against indicated 
proteins. Images are representative of multiple independent experiments. Changes in EGFR/actin 
levels were quantified by densitometry and reported as values normalized to the untreated 
condition. Data reflect an average of three independent experiments ± s.e.m. Asterisks indicate p 
< 0.05 for comparison against the 0 μM U0126 condition. 
 
EGFR reconstitution in SPRY2 knockdown cells rescues changes in EGFR ke, but not 
changes in ERK phosphorylation. Because we found that SPRY2 knockdown increased ke in PC9 
cells without increasing EGFR ubiquitylation or CBL association, we examined whether SPRY2 
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knockdown could affect ke through changes in EGFR expression. This hypothesis was motivated 
by knowledge that clathrin-mediated endocytosis is a saturable process wherein relatively large 
numbers of receptors may decrease ke as clathrin-mediated machinery becomes limiting and 
receptors are forced to internalize through slower, non-clathrin-mediated pathways (Lund et al., 
1990; Sigismund et al., 2005). In PC9 and H1666 cells, reconstitution of mutant and wild-type 
EGFR, respectively, rescued the effect on ke observed with SPRY2 knockdown (Figure 2-5A, B). 
In the H1666 EGFR-reconstituted cells, ke was slightly lower than in the appropriate control cells 
(transduced with SPRY2 shRNA and empty expression vector). This difference may have 
occurred because EGFR reconstitution increased EGFR levels beyond those seen in the control 
cells. Data used to calculate these ke values are shown in Figure 2-S2. Despite the ability of 
EGFR reconstitution to rescue the effects of SPRY2 knockdown on EGFR ke, EGFR 
reconstitution did not augment ERK phosphorylation basally, in the presence of gefitinib, or with 
EGF stimulation compared to SPRY2 knockdown without EGFR reconstitution (Figure 2-5C, 
Figure 2-S8). We verified that effects due to EGFR reconstitution were not due to small sub-
populations of cells or mis-localized EGFR expression by measuring EGFR surface expression 
with flow cytometry (Figure 2-S9). 
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Figure 2-5. EGFR reconstitution reverses the effect of SPRY2 knockdown on EGFR 
endocytosis, but not ERK phosphorylation.  
PC9 and H1666 cells expressing SPRY2-targeting shRNA or non-targeting control shRNA were 
transduced with a retroviral vector encoding EGFR or an empty expression vector (EV). (A) 
Lysates were prepared from cells maintained in complete media and analyzed by western blot 
using antibodies against the indicated proteins. Images are representative of multiple 
independent experiments. (B) Endocytosis rate constants (ke) were measured with 10 ng/mL 
125
I-
EGF, as described in Materials and Methods and represent an average of three experiments ± 
s.e.m. Asterisks indicate p < 0.05 for comparisons indicated by horizontal bars. (C) Cells were 
treated with indicated concentrations of gefitinib for 24 (PC9) or 48 (H1666) hrs, and western 
blots of whole cell lysates were probed with antibodies against phosphorylated or total ERK. 
Densitometry data represent an average of three independent experiments ± s.e.m. Asterisks 
indicate p < 0.05 for comparisons with cells transduced with control shRNA and EV. 
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SPRY2 controls EGFR sorting in an EGFR expression-dependent manner. We further 
hypothesized that the reduction in ERK phosphorylation observed with SPRY2 depletion could be 
the result of changes in recycling of endocytosed EGFR that, unlike the effects on ke, might not 
be rescued by EGFR reconstitution. The general notion of a connection between receptor 
endocytic recycling and ERK activation has been previously discussed (Parachoniak et al., 2011; 
Robertson et al., 2006). In support of this hypothesis, treatment of PC9 or H1666 control cells 
with the trafficking inhibitor monensin reduced ERK phosphorylation to a similar degree as 
SPRY2 knockdown in cells with or without EGFR reconstitution (Figure 2-6A). We verified an 
effect of monensin on trafficking by showing that PC9 and H1666 cells pre-treated with 10 μM 
monensin released ~60% and 80% less internalized 
125
I-EGF compared to untreated controls 
(data not shown). We also directly measured the recycling fraction of internalized EGF (fr) in PC9 
and H1666 cells with SPRY2 knockdown and EGFR reconstitution (Figure 2-6B). It has been 
suggested previously based on receptor localization that mutant EGFR is preferentially recycled 
(Chung et al., 2009). However, enhanced recycling of mutant EGFR has never been quantified. 
The fr for mutant EGFR in PC9 cells was significantly higher than for wild-type EGFR in H1666 
cells (over 0.9 for control PC9 cells and 0.5 for H1666 cells). Interestingly, fr was reduced by 
SPRY2 knockdown in both cell lines, but this change was at least partially rescued by EGFR 
reconstitution. Thus, it seems unlikely that the change in EGFR recycling is responsible for the 
observed reductions in ERK phosphorylation with SPRY2 knockdown. 
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Figure 2-6. Monensin inhibits ERK phosphorylation, and SPRY2/EGFR levels control EGFR 
recycling.  
PC9 and H1666 cells expressing SPRY2-targeting shRNA or non-targeting control shRNA were 
transduced with a retroviral vector encoding EGFR or an empty expression vector (EV). (A) 
Western blots of whole cell lysates from PC9 and H1666 cells treated with or without 10 μM 
monensin in complete media for 4 hrs were probed with antibodies against indicated proteins. 
Images are representative of three independent experiments. Densitometry data reflect an 
average of three independent experiments ± s.e.m. Asterisks indicate p < 0.05 for comparisons 
with untreated cells transduced with the control shRNA and EV. (B) EGFR recycling fraction (fr) 
was measured using 10 ng/mL 
125
I-EGF, as described in Materials and Methods. Data reflect an 
average of three independent experiments ± s.e.m, with each experiment performed in triplicate 
(n = 3). Asterisks indicate p < 0.05 for comparisons indicated by horizontal bars. 
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SPRY2 knockdown increases cellular sensitivity to gefitinib, especially in a cell line 
expressing an EGFR mutant, in an ERK activity-dependent manner. To test whether the changes 
in EGFR trafficking, EGFR expression, and ERK phosphorylation due to SPRY2 and MIG6 
knockdown altered cellular response to EGFR inhibitors, we first treated PC9 and H1666 cells 
with gefitinib at appropriate doses to induce cell death. For PC9 cells treated with 0.1 μM gefitinib 
for 24 hrs, Annexin V staining increased from low basal levels for shRNA controls to > 25% with 
SPRY2 knockdown (Figure 2-7A). In contrast, Annexin V staining did not change significantly in 
response to gefitinib in PC9 cells as a result of MIG6 knockdown. There were significant 
increases in Annexin V staining in PC9 cells, however, when SPRY2 and MIG6 were 
simultaneously depleted. Qualitatively similar changes were observed in H1666 cells, but they 
were small by comparison to those observed in PC9 cells. This difference is likely a result of wild-
type EGFR expression in H1666 cells, which generally confers a much greater degree of cellular 
resistance to interference with survival signaling. Increased cell death in response to gefitinib was 
also observed in H1975 and H358 cell lines with SPRY2 knockdown compared to controls (Figure 
2-S10). 
To determine whether the reduction in ERK phosphorylation observed with SPRY2 
knockdown could cause increased cell death response to gefitinib, we used U0126 to reduce 
ERK phosphorylation to a similar degree in control PC9 and H1666 cells as observed with 
SPRY2 knockdown. Appropriate U0126 concentrations were found by U0126 titration in the 
presence of gefitinib to recapitulate the conditions in Figure 2-3 (Figure 2-S11). PC9 and H1666 
cells expressing control shRNA treated with the concentrations of U0126 we identified showed 
the anticipated augmentation in cell death response to gefitinib (Figure 2-7B). Consistent with the 
fact that EGFR reconstitution did not rescue the decrease in ERK phosphorylation due to SPRY2 
knockdown (Figure 2-5C), there was no effect of EGFR reconstitution on cellular response to 
gefitinib in H1666 or PC9 cells (Figure 2-7C). 
 
 34 
 
Figure 2-7. SPRY2 knockdown alters cellular sensitivity to gefitinib in an ERK-dependent 
and EGFR level-independent manner.  
(A) For PC9 and H1666 cells with knockdown of SPRY2, MIG6, or SPRY2 and MIG6, Annexin V 
staining was measured by flow cytometry for cells treated with gefitinib (PC9: 0.1 μM for 24 hrs; 
H1666: 0.1 μM for 48 hrs) or DMSO control. Data represent an average of three replicates ± 
s.e.m. Asterisks indicate p < 0.05 for comparisons indicated by horizontal bars. (B) PC9 and 
H1666 cells with our without SPRY2 knockdown were analyzed for Annexin V staining by flow 
cytometry after exposure to U0126 and/or gefitinib (PC9: 2 μM U0126 and 0.1 μM gefitinib for 24 
hrs; H1666: 0.5 μM U0126 and 0.1 μM gefitinib for 48 hrs) or DMSO control. Data represent an 
average of three replicates ± s.e.m. Asterisks indicate p < 0.05 for comparisons indicated by 
horizontal bars. (C) PC9 and H1666 cells expressing SPRY2-targeting shRNA or non-targeting 
control shRNA were transduced with a retroviral vector encoding EGFR or an empty expression 
vector (EV). Cells were analyzed for Annexin V staining by flow cytometry after exposure to 
gefitinib (PC9: 0.1 μM for 24 hrs; H1666: 1 μM for 72 hrs) or DMSO control. Data represent an 
average of three replicates ± s.e.m. Asterisks indicate p < 0.05 for comparisons with gefitinib-
treated cells transduced with control shRNA and EV. 
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2-5. Discussion 
To our knowledge, the data presented here constitute the first study of the functional 
roles of SPRY2 and MIG6 in EGFR endocytosis and recycling, EGFR-mediated signaling, and 
cellular response to EGFR kinase inhibitors in cells expressing the constitutively active EGFR 
mutants that arise in NSCLC. Our data demonstrate that feedback regulation can indeed play 
important roles in determining receptor trafficking and signaling in cells characterized by EGFR 
overexpression and activating mutations. Since the effects we measured were generally largest in 
a cell line with EGFR mutation, our results suggest that the role of feedback regulation through 
SPRY2 and MIG6 may be especially important in the context of receptor mutation. The main 
trends we found are illustrated schematically in Figure 2-8 and discussed in further detail below. 
 
Figure 2-8. SPRY2 and MIG6 regulate EGFR signaling with a complex network of feedback 
interactions. 
(A) Diagram of key regulatory mechanisms among EGFR, ERK, SPRY2, and MIG6. SPRY2 and 
MIG6 expression are promoted by ERK activity. ERK activity is driven by EGFR and promoted by 
SPRY2 independent of EGFR expression. SPRY2 can promote EGFR stability (and reduce 
EGFR endocytosis) by reducing EGFR/CBL association (as in H1666 cells) and through 
regulation of ERK (as in PC9 cells). MIG6 inhibits EGFR activity and promotes EGFR 
internalization. Ultimately, ERK activity promotes survival in gefitinib. (B) When SPRY2 is 
depleted, EGFR expression is reduced, resulting in faster EGFR endocytosis and reduced EGFR 
recycling. SPRY2 depletion also results in decreased ERK phosphorylation, which can reduce 
EGFR expression via transcriptional regulation (as in PC9 cells). Decreased ERK activity 
potentiates cellular death response to EGFR inhibition by gefitinib. (C) When MIG6 is depleted, 
EGFR endocytosis rate is reduced, and a modest increase in ERK phosphorylation is observed. 
Cellular response to EGFR inhibition is not altered.  
A B 
Figure 8
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We first hypothesized that SPRY2 and MIG6 might regulate cell signaling and cell fate 
determination through their effects on EGFR trafficking. Several studies have reported impaired 
ligand-mediated EGFR endocytosis in NSCLC cells expressing EGFR mutants versus those 
expressing wild-type EGFR (Hendriks et al., 2006; Lazzara et al., 2010). These studies point to 
EGFR mutation itself as playing a direct role in defective endocytosis in a receptor expression-
dependent manner, but the molecular basis for this defect is not fully understood. Consistent with 
the reported roles of MIG6 and SPRY2 in the endocytosis of wild-type EGFR in other cell types, 
we found that the endocytosis of mutant EGFR is promoted by MIG6 and antagonized by SPRY2. 
Since MIG6 expression tends to be elevated in NSCLC cells with EGFR mutation (Guo et al., 
2008; Nagashima et al., 2009), the finding that EGFR ke is greatly reduced in mutant-expressing 
cells relative to wild-type could indicate that MIG6-mediated endocytosis does not occur as 
efficiently for EGFR mutants as for wild-type EGFR. We do not have direct evidence for this 
hypothesis, but it should be noted that even with SPRY2 knockdown the measured ke value in 
PC9 cells was still lower than values typically measured in cell lines expressing wild-type EGFR. 
It is also worth noting that MIG6 is functionally impaired in other cancers through mechanisms 
including downregulation, deletion, or loss-of-function mutation (Anastasi et al., 2005; Li et al., 
2012; Ying et al., 2010; Zhang et al., 2007b). Thus, disruption of MIG6 function may be a general 
feedback perturbation across several cancer types. 
Focusing on SPRY2, we also found that SPRY2 exerts control over EGFR endocytosis 
rates in PC9 and H1666 cells by influencing EGFR expression. Specifically, the increased ke 
values we measured in PC9 and H1666 cells with SPRY2 knockdown were accompanied by 
reduced EGFR expression, and rescuing EGFR expression on top of SPRY2 knockdown 
returned ke values to their levels prior to SPRY2 knockdown. These data indicate that some 
component of the EGFR endocytosis rate process is at or near saturation in the context of the 
elevated EGFR expression characteristic of PC9 and H1666 cells. These results suggest that 
future studies of SPRY2-mediated EGFR regulation should control for EGFR levels to determine 
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whether the effects of SPRY2 are an indirect consequence of changes in EGFR expression. 
We also explored the basis of reduced EGFR expression with SPRY2 knockdown. In 
H1666 cells, SPRY2 knockdown promoted EGFR-CBL association and EGFR ubiquitylation, 
effects that are consistent with reduced EGFR expression. In PC9 cells, where SPRY2 
knockdown also reduced EGFR expression, we did not detect any EGFR-CBL association or 
EGFR ubiquitylation with or without SPRY2 knockdown. We did, however, find that impaired ERK 
activity reduced EGFR expression in PC9 cells, but not in H1666 cells. Consistent with this 
finding, PC9 cells with SPRY2 knockdown also displayed significant reductions in EGFR mRNA 
levels. Thus, reduced EGFR expression with SPRY2 knockdown resulted from the effect on ERK 
phosphorylation in PC9 cells uniquely. The fact that EGFR reconstitution did not restore ERK 
phosphorylation levels in PC9 cells identifies the ERK/EGFR connection as a one-way coupling 
and suggests that SPRY2 controls ERK phosphorylation in an EGFR expression-independent 
manner. 
In addition to the finding of receptor expression level-dependent endocytosis, we also 
found that the recycling of endocytosed EGFR was SPRY2 and EGFR expression level-
dependent. In both cell lines, SPRY2 knockdown reduced fr, and this change was at least partially 
reversed by EGFR reconstitution in cells with SPRY2 knockdown. These constitute the first 
results to examine the relationship between SPRY2 and EGFR expression on EGFR recycling in 
NSCLC. Although it was previously reported that mutant EGFR co-localized with transferrin 
(Chung et al., 2009), suggesting that mutant EGFR is preferentially recycled, our measurements 
are the first quantitative comparison of recycling between wild-type and mutant EGFR. We found 
that mutant EGFR was almost entirely sorted for recycling (fr > 0.9), whereas wild-type EGFR 
was split between degradation and recycling (fr ~ 0.5). Overall, these recycling results 
demonstrate an additional mode of regulation utilized by SPRY2 in setting EGFR expression 
levels. 
Part of our initial hypothesis was that SPRY2 and MIG6 could play a role in the previously 
documented impairment of ERK activation in the context of mutant EGFR expression (Lazzara et 
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al., 2010). This hypothesis was based in part upon the previously reported requirement of normal 
EGFR endocytosis for complete activation of ERK downstream of EGFR (Lazzara et al., 2010; 
Vieira et al., 1996). The trends we identified in this study did not align in a straightforward way 
with this previously established relationship between ke and ERK activity, due to the complex, 
coupled, and multi-faceted processes governed by SPRY2 and MIG6. For example, MIG6 
knockdown decreased ke but promoted ERK activity. This net effect of MIG6 knockdown may 
have been observed because, in addition to participating in EGFR endocytosis, MIG6 plays an 
important role as an inhibitor of the EGFR kinase. Although SPRY2 knockdown increased ke in 
PC9 and H1666 cells, ERK phosphorylation was reduced rather than enhanced. As already 
mentioned, this effect on ERK was not the result of reduced EGFR expression, but instead could 
have resulted from perturbations to signaling downstream of other RTKs such as c-MET, FGFR, 
and PDGFR, that are also regulated by CBL (Petrelli et al., 2002; Swaminathan and Tsygankov, 
2006). Our EGFR recycling results could also be partially explanatory of the reduction in ERK 
phosphorylation observed in PC9 cells since fr did not fully return to its control value with EGFR 
reconstitution.  
We briefly investigated the effects of SPRY2 and MIG6 knockdown on AKT 
phosphorylation as well, and found qualitatively similar but smaller effects as with ERK. 
Interestingly, previous studies in HeLa cells showed that SPRY2 expression promoted PTEN 
expression and reduced AKT phosphorylation (Edwin et al., 2006). However, our data indicate 
that SPRY2 promotes AKT phosphorylation in NSCLC cells, which would be inconsistent with 
decreased PTEN expression. Indeed, we found no change in PTEN expression with SPRY2 
knockdown in any of the cell lines we studied (Figure 2-S12). 
Our findings regarding SPRY2 expression and NSCLC cellular sensitivity to gefitinib are 
distinct from the findings of Feng et al. (Feng et al., 2010) in colon cancer cells where SPRY2 
expression correlated with cellular sensitivity to gefitinib. While the authors observed a 
relationship between SPRY2 and EGFR expression similar to what we observed, they did not 
investigate any possible perturbations to downstream signaling. Thus, the net effects of SPRY2 
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expression may have been qualitatively different from those we observed in NSCLC cells. 
 While our study utilized NSCLC cells as a model cell background, feedback regulation 
has recently emerged as an important determinant of response to clinically relevant inhibitors in 
many different cancers. ERK signaling drives oncogenic processes (e.g., proliferation and 
migration) and is often dysregulated in cancer, but MEK inhibitors have been largely unsuccessful 
in clinical trials (Adjei et al., 2008; Haura et al., 2010; Rinehart et al., 2004). It has been proposed 
that inhibition of the ERK pathway relieves negative feedback loops generated by ERK activity 
and that inhibition therefore has a net neutral effect or may even promote other signaling 
pathways such as AKT (Mirzoeva et al., 2009; Pratilas et al., 2009). Similarly to MEK inhibition, 
AKT inhibitors can induce the expression and phosphorylation of several receptor tyrosine 
kinases due to relief of feedback inhibition (Chandarlapaty et al., 2011). Along with the data 
presented in our study, these findings additionally suggest that much more must be known about 
the mechanisms of feedback regulation of cell signaling in order to design successful therapies 
for disease. 
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2-7. Supplemental Materials 
 
 
Figure 2-S1. SPRY2 and MIG6 expression are efficiently reduced by shRNA-mediated 
knockdown.  
(A) Western blots of whole cell lysates from six NSCLC cell lines maintained in complete media 
were probed with antibodies against indicated proteins. HCC827 (delE746-A750 EGFR; Douglas 
Lauffenburger, MIT, Cambridge, MA, USA), H358 (wild-type EGFR; Russ Carstens, University of 
Pennsylvania, Philadelphia, PA, USA), and H1975 (L858R/T790M EGFR; Eric Haura, Moffitt 
Cancer Center, Tampa, FL, USA) cells were grown in RPMI (Life Technologies, Grand Island, 
NY, USA) supplemented with 10% fetal bovine serum (Life Technologies), 1 mM L-Glutamine 
(Life Technologies), 100 units/mL penicillin, and 100 μg/mL streptomycin (Life Technologies). 
H3255 (L858R EGFR; Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA) were 
maintained in ACL4. H1666 (wild-type EGFR) and PC9 (delE746-A750 EGFR) were maintained 
as described in Materials and Methods. (B) Stable knockdown of SPRY2 and/or MIG6 was 
generated using pSicoR and pSuper vectors in PC9 and H1666 cells. Western blots of whole cell 
lysates from the indicated cells maintained in complete media were probed with antibodies 
against indicated proteins. Images are representative of at least three independent experiments. 
Percent knockdown (“KD”) calculations were made for each shRNA, and results are indicated in 
the figure. 
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Figure 2-S2. SPRY2 and/or MIG6 knockdown perturb EGF-mediated EGFR endocytosis. 
EGFR endocytosis rate constants (ke) were measured using 10 ng/mL 
125
I-EGF as described in 
Materials and Methods. Data represent an average of three experiments ± s.e.m. and were 
corrected for the effects of non-specific binding and spillover and then normalized to the 
maximum internal 
125
I-EGF or integral with respect to time of surface 
125
I-EGF value. The slopes 
of the linear fits shown were used to calculate the ke values in (A) Figure 2-1 for PC9 and H1666 
cells with knockdown (“KD”) of SPRY2, MIG6, or SPRY2 and MIG6; and in (B) Figure 2-5B PC9 
and H1666 cells expressing SPRY2-targeting shRNA or non-targeting control shRNA were 
transduced with a retroviral vector encoding EGFR or an empty expression vector (EV).  
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Figure 2-S3. Differences in EGF-mediated EGFR endocytosis measured with 1.5 ng/mL 
125
I-
EGF are consistent with measurements using 10 ng/mL 
125
I-EGF (Figure 2-1), and 
treatment with the dynamin inhibitor Dynasore reduces ke.  
(A) ke values were measured using 1.5 ng/mL 
125
I-EGF for H1666 cells with knockdown of 
SPRY2, MIG6, or SPRY2 and MIG6, as described in Materials and Methods. Data were corrected 
for the effects of non-specific binding and spillover and represent an average of three 
experiments ± s.e.m. Asterisks indicate p < 0.05 for comparisons against controls. (B) ke values 
were measured using 10 ng/mL 
125
I-EGF for PC9 and H1666 cells that were pre-treated with 80 
μM Dynasore (Millipore, Billerica, MA, USA). Cells were pretreated with 80 μM Dynasore or 
DMSO control for 2 hrs, and Dynasore was added to the 
125
I-EGF-containing media used to make 
ke measurements. Data were corrected for the effects of non-specific binding and spillover and 
represent an average of three experiments ± s.e.m. Asterisks indicate p < 0.05 for comparisons 
indicated by horizontal bars. 
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Figure 2-S4. Phosphorylation of ERK and AKT in response to gefitinib is perturbed in 
NSCLC cells with SPRY2 and/or MIG6 knockdown relative to controls.  
Whole cell lysates from PC9 (A) or H1666 (B) cells treated as described for Figure 2-2 were 
probed with antibodies against the indicated proteins. Images are representative of at least three 
independent experiments. (C) Band intensities were quantified and phosphorylated levels were 
normalized to total protein levels for AKT. Densitometry data represent an average of three 
independent experiments ± s.e.m. Asterisks indicate p < 0.05 for comparisons against controls. 
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Figure 2-S5. EGFR protein levels are reduced in PC9 and H1666 cells by a second 
independent shRNA, and SPRY2 knockdown reduces EGFR expression in a broader panel 
of NSCLC cell lines.  
(A) Western blots of whole cell lysates from PC9 and H1666 cells expressing control non-
targeting or two independent SPRY2-targeting shRNAs were probed with antibodies against 
indicated proteins. Cell lines were maintained in complete media prior to lysis. SPRY2 sh1 was 
used for results shown in the main figures. Images are representative of three independent 
experiments. Band intensities were quantified and data represent an average of three 
independent experiments ± s.e.m. Asterisks indicate p < 0.05 for comparisons against controls. 
(B) Five of six NSCLC cell lines had significantly reduced EGFR levels upon SPRY2 knockdown. 
Western blots of whole cell lysates from the indicated cell lines grown in complete media were 
probed with antibodies against the indicated proteins. Non-targeting control shRNA is indicated 
by “-“. Images are representative of three independent experiments. Band intensities were 
quantified and data represent an average of three independent experiments ± s.e.m. Asterisks 
indicate p < 0.05 for comparisons against controls. 
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Figure 2-S6. SPRY2 knockdown results in increased EGF-mediated EGFR ubiquitylation 
and CBL association in H1666 cells, but not in PC9 cells.  
PC9 and H1666 cells expressing SPRY2-targeting or control shRNA were serum starved and 
treated with or without 10 ng/mL EGF for 10 min (A and C) or 100 ng/mL EGF for 10 min (B and 
D). EGFR was immunoprecipitated (IP) from whole cells lysates of PC9 and H1666 cells, and 
immunoprecipitates were analyzed by western blot (WB) using antibodies against the indicated 
proteins. Images are representative of three independent experiments. (E) A control IgG did not 
immunoprecipitate ubiquitin, CBL, or EGFR from PC9 and H1666 lysates. PC9 and H1666 cells 
were serum starved prior to treatment with 10 ng/mL EGF for 2 min, as in Figure 2-3. Whole cells 
lysates were incubated with agarose beads conjugated to a control mouse IgG, following the 
immunoprecipitation protocol described in Materials and Methods. Immunoprecipitates (capture) 
and supernatants were analyzed by western blot (WB) using antibodies against the indicated 
proteins. 
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Figure 2-S7. EGFR mRNA levels are reduced in PC9 cells by a second independent shRNA. 
EGFR mRNA levels were measured by qRT-PCR in PC9 and H1666 cells expressing control 
non-targeting or two independent SPRY2-targeting shRNAs. SPRY2 sh1 was used for results 
shown in the main figures. Data represent an average of triplicate wells and are representative of 
multiple independent experiments. Error bars represent the range of possible relative mRNA 
values calculated from the standard error of the ΔCTs. 
 
 
 
Figure 2-S8. Reconstitution of EGFR in SPRY2 knockdown cells does not rescue 
diminished ERK phosphorylation.  
PC9 and H1666 cells expressing SPRY2-targeting or control shRNA were transduced with a 
retroviral vector encoding EGFR or an empty expression vector (EV). Cells were treated with the 
indicated concentrations of gefitinib for 24 (PC9) or 48 (H1666) hrs, and western blots of whole 
cell lysates were probed with antibodies against indicated proteins. Images are representative of 
three independent experiments. 
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Figure 2-S9. Flow cytometry measurements demonstrate differences in surface EGFR 
expression in PC9 and H1666 cells with SPRY2 knockdown and EGFR reconstitution.  
PC9 and H1666 cells expressing SPRY2-targeting or control shRNA were transduced with a 
retroviral vector encoding EGFR or an empty expression vector (EV). Cells were collected by 
trypsinization and stained with an anti-EGFR antibody (Ab225; K. Dane Wittrup, MIT, Cambridge, 
MA, USA) and a secondary antibody conjugated to Alexa-Fluor 488 (Cell Signaling Technology, 
Danvers, MA, USA). Cells were not permeabilized. Samples were analyzed as described in 
Materials and Methods. Data represent an average of duplicate samples from each of two 
independent experiments. 
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Figure 2-S10. SPRY2 knockdown alters cellular sensitivity to gefitinib in additional cell 
lines.  
Stable knockdown of SPRY2 was generated using pSicoR vectors in H1975 and H358 cells. 
Western blots of whole cell lysates from the indicated cells maintained in complete media were 
probed with antibodies against indicated proteins. Expression of non-targeting control shRNA is 
indicated by “-“. Images are representative of three independent experiments. Annexin V staining 
was measured by flow cytometry for cells treated with gefitinib (H1975: 10 μM for 72 hrs; H358: 5 
μM for 72 hrs) or DMSO control. Data represent an average of three replicates ± s.e.m. Asterisks 
indicate p < 0.05 for comparisons indicated by horizontal bars.   
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Figure 2-S11. Titration of the MEK inhibitor U0126 identifies a concentration of U0126 that 
reduces ERK phosphorylation to a similar level as SPRY2 knockdown.  
PC9 and H1666 cells expressing SPRY2-targeting shRNA or a non-targeting control shRNA 
(indicated by  “-“) were treated with the indicated concentrations of U0126 for 24 hrs in the 
presence of 0.001 μM gefitinib (PC9) or 48 hrs in the presence of 0.01 μM gefitinib (H1666). (A) 
Western blots of whole cell lysates were probed with antibodies against phosphorylated or total 
ERK. Images are representative of at least three independent experiments. (B) Normalized 
densitometry data represent an average of three independent experiments ± s.e.m. Asterisks 
indicate p < 0.05 for comparisons indicated by horizontal bars. 
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Figure 2-S12. PTEN expression is not affected by SPRY2 knockdown.  
NSCLC cells maintained in complete media expressing non-targeting control or SPRY2-targeting 
shRNA were probed by western blot for PTEN. Bands were quantified from a single experiment. 
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Chapter 3: Differential parsing of EGFR endocytic flux among parallel internalization 
pathways in lung cancer cells with EGFR-activating mutations
2
 
3-1. Abstract 
Due to the existence of parallel pathways for receptor endocytosis and the complexity of 
their regulation, a quantitative understanding of receptor endocytosis in normal and pathological 
settings requires computational analysis. Here, we develop a mechanistic model of epidermal 
growth factor receptor (EGFR) endocytosis to determine the relative contributions of three parallel 
internalization pathways: clathrin-dependent internalization mediated by mitogen-induced gene 6 
(MIG6), clathrin-dependent internalization mediated by CBL, or alternative pathways that may be 
non-clathrin mediated. We applied the model to interpret our previously reported measurements 
of EGFR endocytosis in non-small cell lung cancer (NSCLC) cells where expression of MIG6 and 
Sprouty2, two regulators of EGFR endocytosis, as well as the expression of EGFR itself, were 
perturbed. Interestingly, our results suggest that MIG6, an endogenous inhibitor of EGFR kinase 
activity recently discovered to regulate EGFR endocytosis, is responsible for approximately half of 
wild-type EGFR internalization. This MIG6 function appears to be impaired for EGFR kinase-
activated mutants that arise in NSCLC and display reduced endocytosis. Our results also suggest 
that Sprouty2 controls EGFR endocytosis primarily by regulating EGFR expression, rather than 
by sequestering CBL, and support the notion that CBL-mediated internalization is impaired for 
EGFR mutants. We further demonstrate that differences in internalization between wild-type and 
mutant EGFR cannot explain observed differences in EGF-mediated EGFR degradation without 
concomitant changes in EGFR recycling, which we previously quantified. This work provides new 
insight into the trafficking of wild-type and mutant EGFR in NSCLC and provides a framework for 
studying parallel endocytosis pathways for other receptors.  
 
                                                     
2
 A version of Chapter 3 was published as: Walsh, A. M., & Lazzara, M. J. (2014). Differential 
parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with 
EGFR-activating mutations. Integr Biol, 6(3), 312-323. (PMID: 24445374) 
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3-2. Introduction 
Endocytosis and degradation are important mechanisms in EGFR signaling regulation 
that involve the concerted action of many proteins connected through a complicated regulatory 
network (Sorkin and von Zastrow, 2009). Impaired receptor trafficking is observed in several 
cancers, promoting inappropriate growth and survival signaling (Abella and Park, 2009; 
Mosesson et al., 2008; Sorkin and Goh, 2009; Sorkin and von Zastrow, 2009). The complexity of 
the internalization process is due in part to the existence of multiple intracellular adaptor proteins 
that can facilitate clathrin-mediated internalization through parallel pathways, as well as the 
existence of non-clathrin-mediated internalization pathways. Few attempts have been made to 
quantitatively determine the relative importance of different adaptor proteins involved in mediating 
EGFR endocytosis through parallel pathways or to determine how these roles may be perturbed 
in various diseases. Computational modeling is a natural and useful approach for interpreting 
experimental data generated to probe this issue. 
The CBL ubiquitin ligase is one the most well-known mediators of ligand-mediated EGFR 
endocytosis. In the prevailing view, CBL is recruited to tyrosine phosphorylated EGFR by the 
intracellular adaptor GRB2, resulting in EGFR ubiquitylation and entrance into clathrin-coated pits 
(Schmidt and Dikic, 2005; Soubeyran et al., 2002). In contrast to CBL, mitogen inducible gene 6 
(MIG6) was only recently discovered to regulate EGFR endocytosis. MIG6 binds EGFR, 
simultaneously inhibiting kinase activity and promoting internalization by linking EGFR to AP-2 
and Intersectins (Anastasi et al., 2003; Frosi et al., 2010; Ying et al., 2010; Zhang et al., 2007a). 
The importance of MIG6-mediated endocytosis relative to CBL-mediated endocytosis has never 
been directly assessed (Frosi et al., 2010; Schmidt and Dikic, 2005; Soubeyran et al., 2002; Ying 
et al., 2010). Adding to this complexity, CBL can be regulated by proteins such as Sprouty2 
(SPRY2), a candidate tumor suppressor whose most well-studied function is to inhibit 
extracellular signal-regulated kinase (ERK) activity downstream of several receptor tyrosine 
kinases but may also antagonize EGFR internalization by binding and sequestering CBL 
(Haglund et al., 2005; Rubin et al., 2003; Wong et al., 2002). While CBL and MIG6 regulate 
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clathrin-mediated endocytosis, non-clathrin mediated pathways also exist. These are generally 
less well understood, but are thought to account for a relatively small fraction of EGFR 
endocytosis under normal conditions (Sigismund et al., 2005; Sorkin and Goh, 2009). 
Due to these and other complexities, computational models of EGFR-mediated signaling 
that include EGFR trafficking typically approximate receptor endocytosis with a coarse-grained 
approach. In such models, EGFR at the plasma membrane is converted to internalized EGFR in 
a reaction described by a single kinetic rate constant (Hendriks et al., 2006; Schoeberl et al., 
2009; Wiley and Cunningham, 1981). Some models have introduced additional steps by requiring 
binding of an intermediate species, such as a coated-pit protein, followed by EGFR endocytosis 
(Gex-Fabry and DeLisi, 1984; Starbuck and Lauffenburger, 1992), or by considering the potential 
influence of EGFR dephosphorylation at the plasma membrane (Monast et al., 2012). These 
models have been informative, but they do not provide insight into the parsing of EGFR endocytic 
flux among the various parallel pathways. In fact, to our knowledge, no EGFR model has explicitly 
included multiple internalization pathways, aside from consideration of ligand-induced and 
constitutive/basal internalization. 
We previously studied the effects of shRNA-mediated depletion of MIG6 and SPRY2 on 
EGFR endocytosis in non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR or 
kinase-activated EGFR mutants that display inefficient endocytosis and degradation in response 
to EGF (Amann et al., 2005; Hendriks et al., 2006; Lazzara et al., 2010; Lynch et al., 2004; 
Padron et al., 2007; Paez et al., 2004; Walsh and Lazzara, 2013; Yang et al., 2006). Our data 
showed significant and complex changes in EGFR endocytosis rates due to perturbations in 
MIG6, SPRY2, and EGFR expression for both wild-type and mutant EGFR. Here, we use that 
data to develop and apply a mechanistic model of EGFR endocytosis to determine the relative 
importance of parallel internalization pathways and to identify differences in such parsing 
between cells expressing wild-type EGFR or kinase-activated EGFR mutants that display 
impaired EGF-mediated EGFR endocytosis (Hendriks et al., 2006; Lazzara et al., 2010). Our 
model accounts for EGFR internalization regulated by MIG6 or CBL, as well as a third pathway 
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intended to account for other modes of EGFR internalization, and accounts for the ability of 
SPRY2 to regulate the pool of CBL available for EGFR binding. Our results indicate that MIG6-
mediated EGFR internalization accounts for at least half of wild-type EGFR endocytic flux and 
almost all of mutant EGFR endocytic flux, despite the fact that MIG6-mediated internalization 
appears to be less efficient for EGFR mutants than for the wild-type receptor. This surprising 
finding has important implications for EGFR signaling because MIG6 inhibits EGFR activity, thus 
potentially resulting in internalized receptors unable to activate downstream signaling pathways. 
Our model results are also consistent with previous experimental studies showing that CBL 
function is impaired for EGFR mutants relative to wild-type. We further show that these 
differences in internalization alone cannot explain observed differences in EGF-mediated EGFR 
degradation between mutant EGFR and wild-type EGFR-expressing cells without simultaneously 
considering our previous measurements of differences in recycling of wild-type versus mutant 
EGFR. The basic methodology we develop here could be applied to future efforts to model EGFR 
in different settings and to better understand the trafficking of other receptors. 
 
3-3. Materials and Methods 
Model topology. A diagram showing the major features of the model topology and 
parameters is shown in Figure 3-1. The model includes EGF binding to unoccupied receptor 
monomers and unoccupied and singly-occupied receptor dimers at the plasma membrane. EGFR 
dimerization is allowed for all receptor monomers, occupied or unoccupied. To reduce model 
complexity, EGFR tyrosine auto-phosphorylation is not explicitly modeled. Rather, ligand-bound 
EGFR dimers are considered phosphorylated unless bound to MIG6. MIG6 and CBL bind ligand-
bound EGFR dimers, in agreement with findings that these proteins are recruited to EGFR upon 
receptor activation and phosphorylation (Anastasi et al., 2003; Soubeyran et al., 2002; Ying et al., 
2010). However, binding of MIG6 and CBL to the same receptor complex is not allowed because 
MIG6-bound receptors are considered kinase-inactive and un-phosphorylated, which would 
prevent CBL binding (Schmidt and Dikic, 2005; Soubeyran et al., 2002; Zhang et al., 2007a). 
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MIG6- or CBL-bound receptors are internalized via reactions characterized by the rate constants 
ki,MIG6 and ki,CBL, respectively. To account for other mechanisms of EGFR endocytosis (e.g., non-
clathrin mediated internalization or clathrin-mediated internalization facilitated by other adaptor 
proteins(Sigismund et al., 2008; Sorkin and Goh, 2009)), internalization of ligand-bound dimers 
not bound to MIG6 or CBL is also allowed and characterized by rate constant ki,other. The model 
includes basal internalization of all receptor species with a rate constant, ki,basal, which is fitted to 
yield a simulated EGFR endocytosis rate constant ke = 0.03 min
-1 
in the absence of EGF, a typical 
value reported in the literature for basal EGFR internalization (Lund et al., 1990; Sigismund et al., 
2008). EGFR recycling to the plasma membrane and degradation is modeled as described 
previously (Hendriks et al., 2006; Schoeberl et al., 2009). Briefly, a fraction of internalized ligand-
bound receptors are recycled (fr) with a rate constant krec. The remaining fraction of internalized 
receptors (1-fr) is degraded with a rate constant kdeg (Hendriks et al., 2006; Schoeberl et al., 
2009). All unoccupied receptors are assumed to recycle. Because SPRY2 phosphorylation 
occurs in response to EGFR activation and is important for SPRY2 regulatory function (Mason et 
al., 2004), we assumed that SPRY2 binds its kinase (referred to as “SPRY2 kinase”) with a rate 
proportional to the fraction of ligand-bound EGFR dimers. SPRY2 phosphorylation is required for 
CBL binding (Rubin et al., 2003), and phosphorylated SPRY2 is assumed to become 
dephosphorylated in a first-order reaction. 
Model implementation. Model rate equations were formulated assuming mass action 
kinetics with proteins associating reversibly with a forward rate constant (kon) and a reverse rate 
constant (koff). SPRY2 phosphorylation was modeled as the reversible formation of a 
substrate/enzyme intermediate followed by catalysis characterized by a rate constant kcat. The 
resulting system of ordinary differential equations (ODEs) describing the change in concentration 
with respect to time for all model species was numerically integrated in MATLAB using the 
function ode15s. The basic model topology requires 25 model species and 24 unique kinetic 
parameters. The model equations are provided in Tables 3-S1, 3-S2, and 3-S3. 
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Figure 3-1. Key features of model topology.  
The model accounts for three parallel internalization pathways for ligand-bound EGFR and a 
basal internalization pathway for all receptor species. Although the kinetics of EGFR 
phosphorylation are not explicitly considered in the model, receptor phosphorylation status is 
shown in the figure to highlight that CBL binds phosphorylated EGFR and that MIG6-bound 
EGFR is kinase-inhibited and therefore assumed to be not phosphorylated. This assumption 
allows us to consider CBL- and MIG6-mediated EGFR internalization as independent processes. 
The model also includes the effects of EGFR recycling, degradation, dimerization, and ligand 
binding. 
 
To simulate an EGFR ke measurement, the model is initiated in the absence of EGF until 
a steady-state is reached (i.e., no model species are changing with respect to time). 10 ng/mL 
EGF is then added, and the model is numerically integrated for up to t = 7.5 min, the length of our 
experimental ke measurements. The simulated EGFR ke is calculated in the same way as the 
experimental ke, that is, by determining the slope of a plot of internalized ligand against the 
integral with respect to time of surface associated ligand for a series of time points up to and 
including 7.5 min (Lund et al., 1990). For simulations of EGF-induced EGFR degradation, we 
include EGFR synthesis, with a synthesis rate fit to maintain EGFR levels in the absence of EGF. 
Parameters. Where possible, kinetic parameters and protein concentrations were chosen 
based on published experimentally determined values. Parameters available from the literature 
are summarized in Table 3-S4. The model parameters and species concentrations we estimated 
are summarized in Table 3-S5. We set unknown cytosolic model species concentrations to be 
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near that of other cytosolic proteins that have been measured (Schoeberl et al., 2009). The 
relative values of total MIG6 and SPRY2 per cell line were set to match the relative differences 
measured by western blot for H1666 and PC9 cells. The cellular concentration of EGFR was 
based on measurements of 
125
I-EGF binding to PC9 cells (Figure 3-S1) and western blotting 
comparisons of PC9 cells to H1666 cells (Walsh and Lazzara, 2013). In our previous 
experiments, we found that EGFR expression was decreased by SPRY2 knockdown and 
combined MIG6/SPRY2 knockdown (Walsh and Lazzara, 2013). In a subset of experiments, we 
reconstituted EGFR expression in the context of SPRY2 knockdown. For model calculations, 
EGFR concentrations were scaled accordingly. The parameters for SPRY2 binding to its kinase 
were set to 10
-5
 #
-1
s
-1
 for kon and 0.1 s
-1
 for koff, similar to values used in previous models based 
on assumptions of diffusion-limited protein interactions and measurements of other protein 
interactions (Kholodenko et al., 1999; Northrup and Erickson, 1992). The parameters for SPRY2 
phosphorylation and dephosphorylation (kcat and kdephos, respectively) were estimated to agree 
with SPRY2 phosphotyrosine immunoprecipitation data from Mason et al. (Mason et al., 2004) 
demonstrating that peak SPRY2 tyrosine phosphorylation was reached 3 min after EGF addition 
(Figure 3-S2).  
The model parameters ki,MIG6, ki,CBL, and ki,other were fit to allow for model recapitulation of 
our previously measured EGFR ke values in H1666 and PC9 cells using a nonlinear optimization 
algorithm to minimize the sum of the squares error between the simulated and experimental data. 
Presumably because different vector backbones and control non-targeting shRNA sequences 
were used for each knockdown (SPRY2 or MIG6) and because cells were selected in different 
antibiotics, the measured ke values for the individual controls were slightly different. To address 
this difference, the ke values were scaled so that differences between each knockdown and its 
respective control were maintained compared to a single control value set to the average of the 
individual control values. MIG6, SPRY2, and EGFR concentrations for control or knockdown 
conditions were set to agree with differences observed by western blot (Walsh and Lazzara, 
2013). 
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Local sensitivity analysis and model robustness to perturbations in parameters. 
Normalized local sensitivity of predicted EGFR ke to perturbations in model parameters was 
calculated as described previously, with 10% perturbations to parameter values (Hendriks et al., 
2006; Schoeberl et al., 2009). The robustness of the fitted ki values to changes in other model 
parameters was calculated by randomly sampling selected parameters in a range an order of 
magnitude above or below their base values. The ki values were then fit to experimental data with 
this random parameter set. This process was repeated for 300 random parameter sets to 
calculate the range of fitted ki values. 
EGF-mediated EGFR degradation experimental data. H1666 (American Type Culture 
Collection) and PC9 cells (Douglas Lauffenburger, MIT) were maintained as described previously 
(Walsh and Lazzara, 2013). Cells were starved overnight in media containing 0.1% FBS and then 
treated with 10 ng/mL EGF (Peprotech) for up to 180 min. Cells were lysed in a standard buffer, 
and lysates were probed by western blot with antibodies against EGFR (no. MS-400, Thermo 
Scientific) or actin (no. MAB1501, Millipore). See Supplemental Materials and Methods for 
complete details on cell lysis and western blotting procedures.  
 
3-4. Results 
Model fit to experimental data from wild-type EGFR-expressing NSCLC cells. We 
previously measured the effects of shRNA-mediated depletion of MIG6 and SPRY2 (alone or 
together) on EGFR ke in the wild-type EGFR-expressing NSCLC cell line H1666 (Walsh and 
Lazzara, 2013). Consistent with previous studies on the effects of MIG6 and SPRY2 on wild-type 
EGFR (Frosi et al., 2010; Wong et al., 2002), we found that MIG6 depletion reduced ke and that 
SPRY2 depletion increased EGFR ke. Combined knockdown of MIG6 and SPRY2 reduced ke to a 
similar degree as MIG6 knockdown alone. With SPRY2 knockdown, we also noticed significantly 
decreased EGFR expression, and we found that the increase in EGFR ke due to SPRY2 
depletion was reversed by EGFR reconstitution in cells with SPRY2 depletion. Together, these 
findings suggest that the major effect of SPRY2 on ke in H1666 cells was related to relieving a 
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partial saturation of endocytosis at basal EGFR expression levels, rather than to antagonism of 
CBL sequestration. The same qualitative trends were also observed in PC9 cells that express 
one of the kinase-activated EGFR mutants observed in NSCLC (delE746-A750), for which the 
effects of SPRY2 and MIG6 on ke had not previously been investigated. 
 
Figure 3-2. Model agreement with experimental data in wild-type EGFR-expressing H1666 
cells and relative importance of MIG6 and CBL levels for EGFR internalization.  
(A) For base MIG6 and CBL concentrations ([MIG6] = 5×10
4 
cell
-1
 and [CBL] = 1×10
5
 cell
-1
), 
experimentally measured ke values (± s.e.m.) in H1666 cells are compared to ke values simulated 
using ki parameters fit to data for control and knockdown of MIG6 or SPRY2 alone. “KD” indicates 
knockdown, and “predicted” identifies data not used to fit model parameters. (B) Values of the 
fitted ki parameters are plotted. (C) The integral of EGFR internalized by MIG6- or CBL- mediated 
mechanisms over the time course of a ke measurement is plotted for a range of MIG6 and CBL 
concentrations. To make these calculations, ki parameters were fit to ke data for control and 
knockdown of MIG6 or SPRY2 alone for all combinations of MIG6 and CBL concentrations. The 
star indicates MIG6 and CBL concentrations used in A, B, and C. (D) The log of the sum of 
squares error (SSE) of the fit for the same range of MIG6 and CBL concentrations is plotted. The 
star indicates the base MIG6 and CBL concentrations used in A, B, and C.  
 
To determine whether the model could recapitulate those experimental findings, the 
model was first fit to our experimentally determined ke values for H1666 cells with MIG6 
knockdown, SPRY2 knockdown, or controls (Table 3-S6), with ki,MIG6, ki,CBL, and ki,other as the fitted 
parameters. As described in Materials and Methods, the condition of SPRY2 knockdown was 
simulated with reduced EGFR expression, consistent with our experimental findings that EGFR 
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expression was reduced by 40% with SPRY2 knockdown in H1666 cells. The resulting model fit 
of ke values for the individual knockdowns was good (Figure 3-2A). Based on these fit results, the 
model accurately predicted ke values for conditions of combined MIG6/SPRY2 knockdown or 
SPRY2 knockdown with EGFR reconstitution, neither of which were included in the fit. The model 
fit to experimental data suggests that the model topology allows for appropriate recapitulation of 
the behavior of the endocytic system and its dependence on MIG6, SPRY2, and EGFR 
expression. The internal and surface-bound EGF levels from model simulations are compared to 
experimental measurements used to calculate ke values in Figure 3-S3. 
For these model conditions, the fitted ki values are shown in Figure 3-2B. The fitted ki,MIG6 
and ki,CBL values are similar to each other and higher than the fitted value for ki,other, indicating that 
CBL- and MIG6-mediated pathways (both of which depend upon clathrin) are responsible for the 
vast majority of EGF-mediated EGFR internalization in H1666 cells. While the fitted rate 
constants may seem to suggest that MIG6- and CBL-mediated internalization occur at similar 
rates, the MIG6 and CBL concentrations and binding parameters are not equivalent (Table 3-S5), 
which may skew the extent to which relative ki values reflect relative endocytic fluxes. Moreover, 
uncertainty in the expression of MIG6 and CBL may also affect the fit results in Figures 3-2A and 
3-2B and their interpretation. To determine the relative contributions of MIG6 and CBL for EGFR 
internalization and to simultaneously determine the sensitivity of our results to changes in MIG6 
and CBL expression, we fit the model to the experimental data for a range of MIG6 and CBL 
concentrations (1×10
3
 to 1×10
7
 cell
-1
), including the base values for our model reflected in the 
results of Figures 3-2A and 3-2B. The parameters were fit to data for single knockdowns of MIG6 
or SPRY2 and simultaneous MIG6/SPRY2 knockdown, and the best-fit results are shown in 
Figure 3-S4. We used these results to calculate the integral of EGFR internalized by each 
pathway (MIG6- or CBL-mediated) over the time course of the simulated ke experiment (Figure 3-
2C). Interestingly, except where CBL levels were approximately an order of magnitude higher 
than MIG6 levels, MIG6 was predicted to drive more EGFR internalization than CBL. The fluxes 
of internalized EGFR at two time points after EGF addition demonstrate a similar trend (Figure 3-
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S5). It is important to note, however, that not all combinations of MIG6 and CBL concentrations fit 
the data equally well, as shown by calculation of the sum of squares errors (SSE) for each 
concentration combination (Figure 3-2D). Moderate MIG6 and CBL concentrations (~1×10
4 
to 
1×10
6
) fit the data best, suggesting that the estimated MIG6 and CBL concentrations used initially 
were reasonable. The quality of the fit to data for these concentrations is equivalent to the best fit 
generated in Figure 3-2A. For most of the region where CBL-mediated internalization dominated 
(high CBL and low MIG6), the model did not fit the data well. Therefore, in order to fit 
experimental data, MIG6-mediated internalization must account for a relatively large fraction of 
overall wild-type EGFR internalization in H1666 cells.  
Model fit to experimental data from mutant EGFR-expressing NSCLC cells. We also 
previously measured EGFR ke with the same perturbations to MIG6, SPRY2, and EGFR 
expression using PC9 cells that express one of the most common NSCLC-associated EGFR 
mutants (delE746-A750). These mutants fail to undergo efficient ligand-mediated endocytosis, 
which has been linked to the increased cellular sensitivity to EGFR inhibition that accompanies 
expression of the mutants in NSCLC cells (Furcht et al., 2012; Lazzara et al., 2010). A possible 
explanation for the observed defect in mutant EGFR internalization is that CBL fails to associate 
with mutant EGFR, but that other internalization pathways such as MIG6-mediated internalization 
remain fully functional. This hypothesis is based on previous findings that the EGFR mutants are 
poorly ubiquitylated and fail to associate with CBL in response to EGF (Padron et al., 2007; 
Walsh and Lazzara, 2013; Yang et al., 2006). To simulate this possibility, the CBL binding 
parameters were set to zero, and the ki,MIG6 and ki,other parameters were set to the values fit from 
consideration of the H1666 data. Concentrations of model species, such as EGFR, MIG6, and 
SPRY2, were set to values estimated for PC9 cells (Table 3-S5). As shown in Figure 3-3A, these 
assumptions yielded predicted ke values that greatly exceed PC9 experimental results, indicating 
that loss-of-function of CBL-mediated internalization alone is not sufficient to explain reduced 
mutant EGFR internalization. This poor prediction is also qualitatively consistent with our findings 
that MIG6 drives more than half of wild-type EGFR endocytosis in H1666 cells and that the EGFR 
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ke for PC9 cells is less than half that of H1666 cells. Fitting the model to PC9 data while allowing 
CBL binding and including results with MIG6 knockdown, SPRY2 knockdown, or control, yielded 
much more reasonable agreement between the model and experimental data (Figure 3-3B).  
When compared to parameters fit to H1666 data, the fitted value of ki,MIG6 was 
approximately three-fold lower for PC9 cells than H1666, and the fitted value of ki,CBL was over 
ten-fold lower (Figure 3-3C). Note that the slight differences in ki values for H1666 cells between 
Figures 3-2B and 3-3C arise because the fitted ki values in Figure 3-3C come from consideration 
of all ke data, including that for simultaneous knockdown of SPRY2 and MIG6 and for EGFR 
reconstitution on top of SPRY2 knockdown. The very low fitted value of ki,CBL for PC9 cells could 
suggest very slow CBL-mediated internalization or poor CBL/EGFR association. If the parameters 
are re-fit assuming no CBL binding, the quality of the fit is not greatly reduced (data not shown). 
We calculated the integral of EGFR internalized over 7.5 min (for standard model conditions) and 
normalized to the total number of EGFR for H1666 or PC9 conditions. This normalized integral of 
EGFR internalized by MIG6 was ~25% lower for PC9 than H1666, and the integral of EGFR 
internalized by CBL was ~90% lower for PC9 than H1666 (Figure 3-3D).  
As described previously for H1666 cells, we went on to fit the internalization parameters 
for a range of possible MIG6 and CBL concentrations and calculated the integral of EGFR 
internalized by MIG6 or CBL (Figure 3-3E). The fitted ki parameter values are shown in Figure 3-
S4. For most MIG6 and CBL concentrations, more EGFR was internalized by MIG6 than CBL. 
The fluxes of internalized EGFR at two time points after EGF addition demonstrate a similar trend 
(Figure 3-S5). As observed with H1666 cells, the model could not fit experimental data well in the 
region of parameter space where CBL-mediated internalization dominated (Figure 3-S3F). 
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Figure 3-3. Model agreement with experimental data in mutant EGFR-expressing PC9 cells 
and differences from results for wild-type EGFR-expressing H1666 cells.  
(A) Experimentally measured ke values in PC9 cells are compared to ke values (± s.e.m.) 
simulated using ki parameters from the fit to H1666 data but with CBL binding parameters set to 
zero. “KD” indicates knockdown. (B) For base MIG6 and CBL concentrations ([MIG6] = 1.2×10
5 
cell
-1
 and [CBL] = 1×10
5
 cell
-1
), experimentally measured ke values (± s.e.m.) in PC9 cells are 
compared to ke values simulated using ki parameters fit to PC9 cell data for control and 
knockdown of MIG6 or SPRY2 alone. “Predicted” identifies data not used to fit model parameters. 
(C) Values of the ki parameters found by fitting to all data points (including conditions for 
simultaneous knockdown of SPRY2 and MIG6 and for EGFR reconstitution on top of SPRY2 
knockdown) are plotted for H1666 and PC9 cells using base MIG6 and CBL concentrations. (D) 
The integral of EGFR internalized by MIG6 or CBL is plotted for H1666 or PC9 parameters 
normalized to the total EGFR cell
-1
 with the base model conditions. (E) The integral of EGFR 
internalized by MIG6 or CBL is plotted for a range of MIG6 and CBL concentrations. To make 
these calculations, ki parameters were fit to ke data for control and knockdown of MIG6 or SPRY2 
alone for all combinations of MIG6 and CBL concentrations. The star indicates the base MIG6 
and CBL concentrations used in A and B. (F) The log of the sum of squares error (SSE) of the fit 
for the same range of MIG6 and CBL concentrations is plotted. The star indicates the base MIG6 
and CBL concentrations used in A and B. 
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We also considered the possible effects of basal EGFR/MIG6 association due to basal 
phosphorylation of EGFR mutants (Greulich et al., 2005; Guo et al., 2008). In these calculations, 
MIG6 was allowed to bind non-ligand bound EGFR dimers (assumed here to be phosphorylated 
in the absence of ligand) and drive their internalization. Including these effects slightly lowered 
the fitted values of ki,CBL and ki,MIG6, as expected due to the slight augmentation of ligand-
mediated internalization arising from the existence of dimers bound by MIG6 prior to ligand 
binding. This modification did not change the result that the best fit to PC9 data required higher 
MIG6 internalization than CBL-mediated internalization (Figure 3-S6). As another way to assess 
the potential impact of such basal MIG6/EGFR binding, we simulated a measurement of non-
ligand mediated EGFR internalization made using the EGFR antibody cetuximab, with binding 
constants for cetuximab taken from published studies (Patel et al., 2007). Such experimental 
measurements are made as a means to determine fluid-phase rates of basal EGFR 
internalization. Allowing basal EGFR/MIG6 association increased the model-predicted basal non-
ligand mediated EGFR ke from 0.027 to 0.036 min
-1
. Overall, these modest effects of basal 
MIG6/EGFR mutant binding suggest that our basic model conclusions are not strongly dependent 
upon the capacity of EGFR mutants to demonstrate basal binding to some MIG6.  
Predicted effects of changes in EGFR, SPRY2, CBL, or MIG6 expression on EGFR ke. 
As discussed previously, rapid EGFR internalization is a saturable process, and sufficiently high 
receptor EGF occupancy can lead to reductions in EGFR ke (Lund et al., 1990). For our base 
model parameters fit to H1666 or PC9 data, we examined the predicted effects of changing 
EGFR expression (base EGFR cell
-1
 = 6×10
5 
for H1666 and 8×10
5
 for PC9) (Figure 3-4A). For 
standard model conditions, the predicted EGFR ke increases with increasing EGFR expression 
for < ~1×10
5
 EGFR cell
-1 
due to the increasing driving force for EGFR dimerization (Figure 3-S7). 
However, the predicted EGFR ke sharply decreased for > ~1×10
5
 EGFR cell
-1
, reflecting 
saturation effects. Increasing MIG6 or CBL expression ten-fold caused the downturn in ke to shift 
to a higher EGFR expression.  
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Figure 3-4. Effect of changing EGFR, SPRY2, CBL, and MIG6 levels on simulated EGFR ke. 
(A) EGFR concentration was varied from 10
4
 to 10
7
 cell
-1
, and the predicted EGFR ke was 
calculated for base model conditions or higher levels of MIG6, CBL, or both MIG6 and CBL for 
H1666 or PC9 cells. (B) SPRY2 concentration was varied from 10
2
 to 10
6
 cell
-1
, and the predicted 
EGFR ke was calculated for base model conditions for H1666 or PC9 cells. (C) CBL or MIG6 
concentration was varied from 10
2
 to 10
6
 cell
-1
, and the predicted EGFR ke was simulated for base 
model conditions for H1666 or PC9 cells. All panels use ki parameters fit to all data for H1666 or 
PC9 cells. The vertical dashed lines indicate the base EGFR, SPRY2, CBL, and MIG6 
concentrations used in Figure 3-2 and Figure 3-3.  
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We also plotted the predicted effect of changing the concentration of SPRY2 (keeping 
EGFR and all other model species concentrations constant) on ke (Figure 3-S4B). For SPRY2 
expression > ~1×10
4
 cell
-1
, the predicted ke decreased as SPRY2 levels increased, but the 
magnitude of change in ke was relatively small. In order for SPRY2 to have a larger influence on 
EGFR ke, SPRY2 would need to bind all CBL and CBL-mediated internalization would need to 
dominate other internalization pathways. Thus, for the best fit to our data, the difference in EGFR 
ke due to SPRY2 knockdown is attributable mainly to differences in EGFR levels and, to a lesser 
degree, to changes in available CBL levels. Similar plots are shown for changing expression 
levels of MIG6 and CBL with expected trends (Figure 3-S4C). For PC9 parameters, increasing 
CBL expression can actually decrease the predicted ke because higher CBL levels compete with 
MIG6 for EGFR binding. This occurs for PC9, but not for H1666, because CBL-mediated 
internalization is much slower than MIG-mediated internalization for PC9 parameters.  
Local parameter sensitivity analysis. To identify the key model reactions and species that 
influence the calculated value of ke, we computed the normalized sensitivities of simulated ke to 
10% perturbations in each parameter. The ten parameters with the largest normalized 
sensitivities for H1666 are plotted and compared to the same sensitivities for PC9 (Figure 3-S5A). 
Complete results for all parameters are shown in Table 3-S7. We also determined the sensitivity 
to changes in model species concentrations (Figure 3-S5B). Notably, the sensitivities to changes 
in ki,CBL or CBL concentration were relatively large for H1666, but very low for PC9. Similarly, the 
sensitivities associated with parameters for CBL binding to EGFR were also lower for PC9. The 
sensitivities to changes in ki,MIG6 or MIG6 concentration, however, were higher for PC9 than 
H1666. The large sensitivity to changes in ki,MIG6 for PC9 conditions reflects that MIG6-mediated 
internalization is substantially more important than CBL-mediated internalization in that cell line. 
Both H1666 and PC9 models were very sensitive to changes in EGFR levels, consistent with the 
results of Figure 3-4. As SPRY2 can modulate internalization via CBL, which is more important 
for H1666 conditions, a larger sensitivity to changes in SPRY2 concentration was found for 
H1666 conditions versus PC9 conditions. Of note, the sensitivities for perturbations in parameters 
 
 67 
related to recycling (krec and fr) were relatively high, indicating that recycling processes could be 
contributing to the EGFR ke calculation even for experiments lasting only 7.5 min after EGF 
addition. Finally, we note that the parameters in the top ten for PC9 that were not in the top ten 
for H1666 were the reverse rate constant for MIG6 binding (koff,M), the EGFR dimerization rate 
constant (k+dim), and the rate constant for EGFR degradation (kdeg), reflecting the reduced relative 
importance of CBL-associated parameters and increased relative importance of other model 
parameters.  
 
Figure 3-5. Local parameter sensitivity analysis for PC9 and H1666 models. 
(A) The ten model parameters with the highest normalized sensitivities for predicted ke for H1666 
parameters are plotted with the corresponding sensitivities for PC9 parameters. (B) The 
normalized sensitivities of predicted ke to changes in model species concentrations in PC9 or 
H1666 cells are plotted. 
 
Robustness of and basis for differences in internalization parameters for MIG6 and CBL. 
The best-fit values of the internalization rate constants depend on MIG6 and CBL expression (as 
described above), their binding parameters, and, of course, all other model parameters to at least 
some extent. We calculated the robustness of the fitted ki values to changes in other model 
parameters by randomly sampling the ten non-internalization parameters with the highest 
sensitivity for PC9 or H1666 conditions in a range an order of magnitude above or below their 
normal values. We fit the model with these random parameter sets and found that for H1666 
conditions, the fitted ki,MIG6 value was higher than the fitted ki,CBL value for 61% of the parameter 
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sets (183/300 fits) (Figure 3-6A). For PC9 conditions, the fitted ki,MIG6 value was higher than the 
fitted ki,CBL value for 97% of the parameter sets (290/300 fits). This result suggests that even if the 
model parameters are somewhat poorly estimated, MIG6 is still likely to be responsible for a 
significant fraction of EGFR internalization. Indeed, MIG6 is responsible for at least 25% of EGFR 
endocytosis in 88% of fits for H1666 and 98% of fits for PC9. 
 
Figure 3-6. Robustness of fitted ki,MIG6 and ki,CBL and model agreement with PC9 data. 
(A) The model was fit to H1666 or PC9 data for controls, MIG6 knockdown, SPRY2 knockdown, 
and MIG6/SPRY2 knockdown for 100 random parameter sets where the ten parameters with the 
largest normalized sensitivities for predicted ke were randomly sampled in a range an order of 
magnitude above or below their normal values. Model error was calculated for a range of ki,MIG6 
and ki,CBL values considering: (B) all data points with standard model conditions, (C) data 
excluding MIG6 knockdown data with [MIG6] = [CBL] = 1×10
5
 cell
-1
, kon,M = kon,C, and kon,S = 0, and 
(D) the same conditions for C including all data. Error is reported as the log of the sum of the 
squares error (SSE). Error minima are indicated by red circles, and the dashed lines represent 
ki,MIG6  = ki,CBL. 
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To identify what specific experimental data led to particular model conclusions and to 
assess the ability of the data to constrain the fitted parameters, the model error was calculated as 
a function of ki,MIG6 and ki,CBL for several conditions, focusing first on PC9 cells. Unlike the fits 
considered in Figures 3-2A and 3-3B, the model error here is calculated considering all 
experimental data, including effects of simultaneous MIG6 and SPRY2 knockdown and EGFR 
reconstitution on top of SPRY2 knockdown. Under normal model conditions for PC9 cells, the 
data constrained the parameters, and the error was minimized where ki,MIG6 > ki,CBL (Figure 3-6B), 
as expected based upon results from Figure 3-3C. As a control setting to demonstrate that there 
is no inherent bias in the model topology that causes MIG6-mediated internalization to be faster, 
the MIG6 concentration and binding parameters were set equal to those for CBL. In addition, 
SPRY2 binding to CBL was not permitted because such binding would decrease the amount of 
CBL available to bind EGFR. With these changes, CBL and MIG6 become equally capable of 
driving EGFR internalization. As expected, when the MIG6 knockdown and MIG6/SPRY2 
knockdown data were excluded, combinations of ki,MIG6 and ki,CBL with the same total sum fit the 
data equally well, indicating that MIG6 and CBL contribute equally in describing saturable EGFR 
endocytosis for this control case (Figure 3-6C). Thus, for this scenario, there is no single error 
minimum, but a family of minima that minimize the error equally. A similar result would be 
obtained if the SPRY2 knockdown data were excluded instead of MIG6 knockdown data. When 
the entire data set including the MIG6 knockdown data was considered (keeping MIG6 and CBL 
parameters and concentrations equal and without SPRY2 binding), the model again fit a ki,MIG6 > 
ki,CBL (Figure 3-6D). Similar error plots for H1666 data are shown in Figure 3-S8. Thus, the 
magnitude of change in EGFR ke due to MIG6 knockdown requires that ki,MIG6 be larger than 
ki,CBL, even when CBL and MIG6 levels and binding parameters are considered equal. If EGFR 
expression did not decrease with SPRY2 knockdown, however, the best fit value for ki,CBL would 
increase by ~2-fold for both H1666 and PC9 data (Figure 3-S9). Without changes in EGFR 
expression, however, the model error is increased.  
To summarize, optimally fitting the PC9 data requires a higher value of ki,MIG6 than ki,CBL 
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for several reasons. Internalization by CBL and MIG6 are both saturated at high EGFR 
expression. If all factors such as binding rates and expression levels were equivalent, MIG6 and 
CBL would be equally capable of driving EGFR internalization and any combination of MIG6 and 
CBL internalization rates that yield the correct rate to match changes in ke due to changes in 
EGFR expression would fit the data. However, the magnitude of the decrease in EGFR ke due to 
MIG6 knockdown, along with the fact that EGFR expression is reduced by SPRY2 knockdown, 
require MIG6 internalization to contribute more than CBL mediated internalization. Furthermore, 
perturbations to specific parameters and species concentrations used can increase the difference 
between the fitted ki,MIG6 and ki,CBL values, but our robustness calculations find that ki,MIG6 is still 
likely to be greater than ki,CBL when parameters are altered.  
Model fit to EGFR degradation data and differences in EGFR recycling. Cells expressing 
mutant EGFR do not display normal rapid EGFR degradation upon treatment with EGF (Yang et 
al.). EGFR degradation was quantified in H1666 and PC9 cells upon treatment with 10 ng/mL 
EGF by examining total EGFR levels by western blot. After 2 hours of EGF treatment, ~80% of 
EGFR in wild-type expressing H1666 cells had disappeared (Figure 3-7A). However, there was 
no measurable degradation of mutant EGFR in PC9 cells. The model parameter that determines 
sorting of internalized EGFR to recycling or degradation is the sorting fraction (fr). An fr = 0 or 1 
indicates that all receptors are degraded or recycled, respectively. All model simulations 
described above for PC9 and H1666 cells were performed with fr = 0.5, a value chosen based on 
measurements typical of other cell lines (French et al., 1994; Hendriks et al., 2003). With these 
conditions and the previously fit ki values, the model predicted far too much degradation for PC9 
cells, but did a reasonable job for H1666 cells (Figure 3-7B). Therefore, differences in 
internalization rates alone cannot explain the differences in EGFR stability between wild-type and 
mutant EGFR-expressing cells. We previously measured fr in H1666 and PC9 cells and found 
that fr was 0.57 ± 0.024. for H1666 cells and 0.90 ± 0.013 for PC9 cells (Walsh and Lazzara, 
2013). When the model fr was set to match experimental measurements, the simulated EGFR 
degradation fit experimental data much better (Figure 3-7C). Note that if the ki parameters are 
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refit using the experimentally measured fr values for H1666 and PC9 cells that the resulting 
values are not substantially different from those shown in Figures 3-2 and 3-3 (Figure 3-S10). 
The higher sorting fraction in PC9 cells could have an effect on the measured EGFR ke. 
Indeed, the parameter sensitivity analysis shown in Figure 3-5A suggests that the simulated ke is 
moderately sensitive to changes in parameters associated with recycling. Keeping other 
parameters constant for H1666 and PC9 parameters, fr was varied and the simulated ke 
calculated (Figure 3-7D). The simulated ke decreased as fr increased, but the simulated ke for 
PC9 cells never reached the value for H1666 cells. This result suggests that differences in 
recycling are not explanatory of the low EGFR ke in mutant EGFR-expressing cells. 
 
 
Figure 3-7. EGF-mediated EGFR degradation in wild-type and mutant EGFR-expressing 
NSCLC cells and the role of EGFR recycling differences in explaining the data. 
(A) Whole cell lysates from PC9 and H1666 cells treated with EGF were probed by western 
blotting with antibodies against EGFR and actin. (B) Experimental data are compared to 
simulations of EGFR degradation in response to 10 ng/mL EGF with the sorting fraction (fr) set to 
0.5 for both H1666 and PC9 parameters. Western blot band intensities from three independent 
experiments were quantified and normalized to the t = 0 point. Markers represent mean values ± 
s.e.m. (C) Experimental data are compared to simulations of EGFR degradation in response to 
10 ng/mL EGF with fr set to experimentally measured values for the two cell lines. (D) EGFR ke 
was simulated over the full range of fr for H1666 and PC9 parameters. 
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3-5. Discussion 
By considering the specific roles of SPRY2 and MIG6 in the regulation of EGFR 
endocytosis, the model developed here allows for a new level of quantitative understanding of 
how ligand-mediated EGFR endocytosis occurs in the wild-type setting and how endocytic flux 
may be perturbed for specific cancer-relevant EGFR mutations. The realistic development of 
these models depends on the availability of quantitative EGFR trafficking data, such as the data 
we previously gathered in NSCLC cell lines where alterations in SPRY2, MIG6, and EGFR 
expression had been engineered. In addition to endocytosis, we examined differences in EGFR 
recycling between the cell lines examined that were critical for explaining apparent differences in 
EGF-mediated EGFR degradation.  
We found that MIG6-mediated internalization was comparable to or more important than 
CBL-mediated internalization in both cell lines examined, and this result was robust to fluctuations 
in model parameters. Setting CBL expression to greatly exceed MIG6 expression can force a 
situation where CBL-mediated internalization dominates, but only at the cost of model agreement 
with experimental data. These results suggest that, at least in the context of the NSCLC cells 
examined, MIG6-mediated internalization is a major component of overall EGFR endocytosis and 
should be further studied to determine the extent to which the internalization function of MIG6 
may play a role in tumor suppression. Because MIG6 functions to inhibit EGFR tyrosine kinase 
activity, another important implication of our findings is that a significant fraction of internalized 
EGFR could be unable to signal within the cell interior. 
The results presented here also indicate that MIG6-driven EGFR internalization is 
impaired in mutant EGFR-expressing cells relative to wild-type EGFR-expressing cells. There are 
several possible explanations for this finding. A previous in vitro study found that MIG6 does not 
bind mutant EGFR as well as wild-type EGFR (Wang et al.). Because MIG6 binds EGFR at the 
asymmetric dimer interface,(Zhang et al., 2006; Zhang et al., 2007a) it is possible that this site is 
not as accessible in mutant EGFR. A second possibility is that MIG6 phosphorylation, which is 
elevated in NSCLC cells expressing mutant EGFR (Guo et al., 2008), antagonizes MIG6’s ability 
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to facilitate EGFR internalization. A recent study found that depletion of the Chk1, a kinase that 
phosphorylates MIG6 on Ser251, reduced MIG6 phosphorylation and decreased phosphorylation 
of EGFR (Liu et al.) This study suggests that MIG6 phosphorylation impairs MIG6’s ability to 
inhibit EGFR kinase activity, but it is unknown whether phosphorylation also reduces MIG6-
mediated EGFR internalization. Another explanation for our modeling results could be that some 
component not explicitly modeled, but whose function is lumped into the MIG6 internalization 
parameter, is impaired. This missing component could be a different part of internalization 
machinery that affects multiple internalization pathways. 
Another important result is that model fits are consistent with experimental studies 
showing that CBL/EGFR associations are impaired for EGFR mutants (Padron et al., 2007; 
Walsh and Lazzara, 2013). Yet, our experimental and model results suggest that SPRY2, which 
can regulate EGFR endocytosis by sequestering CBL, exerts control over mutant EGFR 
internalization. This apparent paradox is resolved by our demonstration that SPRY2 can also 
regulate EGFR endocytosis by regulating EGFR expression levels. This same mechanism of 
SPRY2-mediated control of ke was also identified in H1666 cells expressing wild-type EGFR. 
While it is tempting to propose that the reduced overall rates of EGF-induced EGFR 
mutant internalization explain the significant impairment of EGF-mediated EGFR mutant 
degradation that we and others have noted, our quantitative model demonstrates that EGFR 
mutants must also recycle more efficiently than wild-type receptors to explain experimental data. 
Indeed, when the sorting fraction was set equal for PC9 and H1666 parameters (using a value 
typical for wild-type EGFR), the model predicted far too much degradation in PC9 cells over a 2 
hr period, even with the reduced mutant endocytosis rate. Molecular mechanisms that could 
explain differential sorting of EGFR mutants have not been extensively researched, but our 
results highlight the need for further studies on the mechanisms of EGFR sorting and their 
potential role in aberrant signaling in disease.  
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3-6. Conclusion 
We created a mechanistic model of EGFR trafficking that captures EGFR internalization 
and degradation dynamics in NSCLC cells expressing wild-type or mutant EGFR through 
consideration of EGFR’s ability to internalize through parallel pathways. We find that MIG6 is a 
key mediator of EGFR internalization for wild-type and mutant EGFR, but that MIG6’s apparently 
impaired ability to drive mutant EGFR internalization underlies the overall impaired ability of 
mutant EGFR, which also fails to bind CBL efficiently, to undergo ligand-mediated endocytosis. 
Our analysis further demonstrates that large differences in wild-type and mutant EGFR recycling 
are also required to explain reduced EGF-mediated degradation of EGFR mutants, but that these 
differences in recycling do not account for reduced EGFR internalization rate constants. Our 
method for modeling distinct EGFR internalization pathways could be included in future models of 
EGFR dynamics and used to gain insight into the trafficking dynamics of other receptors. 
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3-8. Supplemental Materials 
Cell lysis and western blotting. Whole cell lysates were prepared in a standard cell 
extraction buffer (Life Technologies) supplemented with protease and phosphatase inhibitors 
(Sigma). Lysates were cleared by centrifugation at 13,200 rpm for 10 min, and total protein 
concentrations were determined by micro-bicinchoninic assay (Thermo Scientific). Approximately 
20 μg of total protein was loaded per lane on 4-12% gradient polyacrylamide gels (Life 
Technologies) under denaturing and reducing conditions and transferred to 0.2 μm nitrocellulose 
membranes (Life Technologies). After probing with antibodies, membranes were imaged on a LI-
COR Odyssey scanner (LI-COR). Membranes were stripped with 0.2 M NaOH as needed. 
Estimation of number of EGFR per cell. Recombinant human EGF (Peprotech) was 
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labeled with 
125
I as described previously (Walsh and Lazzara, 2013). Cells were starved overnight 
in media containing 0.1% FBS (Life Technologies) and then treated with 10 ng/mL 
125
I-EGF on 
ice for 30 min. After washing with buffer to remove un-bound 
125
I-EGF, the amount of cell surface-
associated radioactivity was quantified by stripping surface-bound ligand from receptors using a 
mild acid strip. These samples were used to calculate the number of EGFR per cell based on the 
known EGF/EGFR dissociation constant and the specific activity of the labeled
 
EGF. Three plates 
were reserved to determine the number of cells per plate by counting with a hemocytometer. 
 
 
Figure 3-S1. Measurement of number of EGFR per cell in PC9 cells. 
The number of EGFR per cell in PC9 cells was calculated using 
125
I-EGF binding as described in 
Supplemental Materials and Methods. Data represents the mean of three replicates ± s.d. 
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Figure 3-S2. Simulation of SPRY2 phosphorylation. 
SPRY2 phosphorylation with 10 ng/mL EGF treatment was simulated over the time course of an 
EGFR ke measurement. Base model conditions with standard parameters for H1666 cells were 
used. SPRY2 phosphorylation parameters were estimated to agree with data from Mason et al. 
(Mason et al., 2004) such that peak SPRY2 phosphorylation occurred by 3 min after EGF 
addition. 
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Figure 3-S3. Predicted and experimental measurements of internal and surface-bound EGF 
for H1666 cells. 
The ki parameters were fit to ke data from H1666 cells as described in Figure 3-2A. Shown here 
are the primary experimental data from the study by Walsh and Lazzara (Walsh and Lazzara, 
2013) used to experimentally determine ke values and the ability of the model to recapitulate the 
dynamics of surface and internal 
125
I-EGF. Markers represent the mean of three experimental 
replicates ± s.d. 
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Figure 3-S4. Values of fitted rate constants for a range of MIG6 and CBL concentrations. 
The ki parameters were fit to data from (A) H1666 cells or (B) PC9 cells as described in Figures 
3-2C and 3-3C. Stars indicate the base MIG6 and CBL concentrations ([MIG6] = 5×10
4 
cell
-1
 
(H1666) or 1.2×10
5
 cell
-1
 (PC9) and [CBL] = 1×10
5
 cell
-1
).  
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Figure 3-S5. EGFR internalization flux over a range of MIG6 and CBL concentrations. 
EGFR flux is plotted for receptors internalized by MIG6 or CBL pathways at t = 3.5 min or 7 min 
for (A) H1666 cells and (B) PC9 cells. Stars indicate the base MIG6 and CBL concentrations 
([MIG6] = 5×10
4 
cell
-1
 (H1666) or 1.2×10
5
 cell
-1
 (PC9) and [CBL] = 1×10
5
 cell
-1
).  
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Figure 3-S6. Effect of allowing basal MIG6/EGFR association on model fit to PC9 data. 
The ki parameters were fit to data from PC9 cells as in Figure 3-3 and then by allowing basal 
MIG6/EGFR association for non-ligand-bound EGFR dimers using standard MIG6 and CBL 
concentrations.  
 
Figure 3-S7. Predicted effect of changing dimerization rate on relationship between EGFR 
expression and predicted EGFR ke. 
For parameters fit to data from H1666 cells, k+dim was set to values between 10
-3 
and 10
-7
 cell #
-1
 
s
-1
, and the predicted ke was calculated for a range of EGFR concentrations as in Figure 2-4A. 
This demonstrates that the increase in ke with increasing EGFR expression arises due to an 
increased driving force for EGFR dimerization. 
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Figure 3-S8. Model agreement with H1666 data. 
Model error was calculated considering: (A) all data points with normal model conditions, (B) data 
excluding MIG6 knockdown data with [MIG6] = [CBL] = 1×10
5
 cell
-1
, kon,M = kon,C, and kon,S = 0, and 
(C) the same conditions for C including all data. The log of the sum of the squares error (SSE) is 
plotted for a range of ki,MIG6 and ki,CBL. Red circles indicate error minima. The dashed lines 
represent ki,MIG6  = ki,CBL. 
 
 
Figure 3-S9. Fitted parameters when changes in EGFR expression due to SPRY2 
knockdown are not considered. 
The ki parameters were fit to experimental EGFR ke data for controls, MIG6 knockdown, and 
SPRY2 knockdown from H1666 or PC9 cells using standard MIG6 and CBL concentrations as 
described for Figs. 2 and 3. The ki parameters were also fit without changing EGFR concentration 
for SPRY2 knockdown conditions. 
 
 82 
 
Figure 3-S10. Values of fitted rate constants when fr was set to experimentally determined 
values. 
The ki parameters were fit to all data points from H1666 or PC9 cells using standard MIG6 and 
CBL concentrations ([MIG6] = 5×10
4 
cell
-1
 (H1666) or 1.2×10
5
 cell
-1
 (PC9) and [CBL] = 1×10
5
 cell
-
1
) and setting fr to experimentally determined values. 
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Table 3-S1. Model equations for individual species. 
Species 
Number 
Model 
Species ODE Description 
1 R R1 -R2 -2*R3 -R5 -R28 -keb*R EGFR monomer 
2 RL R2 -R5 -2*R7 -R29 -keb*RL EGFR monomer + ligand 
3 D R3 -R4 -R30 -keb*D EGFR dimer 
4 DL 
R4 +R5 -R6 -R18 -R31 -R57 -
keb*DL Dimer + ligand 
5 DLL R6 +R7 -R23 -R32 -R58 -keb*DLL Dimer + 2 ligands 
6 M -R18 -R23 +R51 +R53 MIG6 
7 DLM R18 -R22 -R37 -keb*DLM Dimer + ligand + MIG6 
8 DLLM R22 +R23 -R39 -keb*DLLM Dimer + 2 ligands + MIG6 
9 Ri R28 -R41 +keb*R Internalized EGFR 
10 RLi R29 -R43 +keb*RL 
Internalized EGFR + 
ligand 
11 Di R30 -R44 +keb*D Internalized dimer 
12 DLi R31 -R45 +keb*DL 
Internalized dimer + 
ligand 
13 DLLi R32 -R46 +keb*DLL 
Internalized dimer + 2 
ligands 
14 DLMi R37 -R51 +keb*DLM 
Internalized dimer + 
ligand + MIG6 
15 DLLMi R39 -R53 +keb*DLLM 
Internalized dimer + 2 
ligands + MIG6 
16 C -R57 -R58 +R61 +R62 -R63 CBL 
17 DLC R57 -R56 -R59 -keb*DLC Dimer + ligand + CBL 
18 DLLC R58 +R56 -R60 -keb*DLLC dimer + 2 ligands + CBL 
19 DLCi R59 -R61 +keb*DLC 
Internalized dimer + 
ligand + CBL 
20 DLLCi R60 -R62 +keb*DLLC 
Internalized dimer + 2 
ligands + CBL 
21 Sp -R63 -R70 +R69 Phosphorylated SPRY2 
22 CSp R63 
CBL + phosphorylated 
SPRY2 
23 kin -R68 +R69 SPRY2 kinase 
24 S -R68 +R70 SPRY2 
25 kinS R68 -R69 SPRY2 kinase + SPRY2 
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Table 3-S2. Model reactions included in the ODEs in Table 3-S1. 
Reaction 
Name Reaction Equation Description 
R1 s1 EGFR synthesis 
R2 f2*R*L - r2*RL EGF binding 
R3 f3*R*R - r3*D EGF binding 
R4 2*f4*D*L - r4*DL Dimerization 
R5 f5*R*RL - r5*DL Dimerization 
R6 f6*DL*L - 2*r6*DLL EGF binding 
R7 f7*RL*RL - r7*DLL Dimerization 
R18 2*f18*DL*M - r18*DLM MIG6 binding 
R22 f22*DLM*L - 2*r22*DLLM EGF binding 
R23 2*f23*DLL*M - r23*DLLM MIG6 binding 
R28 k28*R - kr*Ri*fru Internalization/recycling 
R29 k29*RL - kr*RLi*fr Internalization/recycling 
R30 k30*D-  kr*Di*fru Internalization/recycling 
R31 k31*DL - kr*DLi*fr Internalization/recycling 
R32 k32*DLL - kr*DLLi*fr Internalization/recycling 
R37 k37*DLM - kr*DLMi*fr Internalization/recycling 
R39 k39*DLLM - kr*DLLMi*fr Internalization/recycling 
R41 kd*Ri*(fdu) Degradation 
R43 kd*RLi*(fd) Degradation 
R44 kd*Di*(fdu) Degradation 
R45 kd*DLi*(fd) Degradation 
R46 kd*DLLi*(fd) Degradation 
R51 kd*DLMi*(fd) Degradation 
R53 kd*DLLMi*(fd) Degradation 
R56 f56*DLC*L - 2*r56*DLLC EGF binding 
R57 2*f57*DL*C - r57*DLC CBL binding 
R58 2*f58*DLL*C - r58*DLLC CBL binding 
R59 k59*DLC - kr*DLCi*fr Internalization/recycling 
R60 k60*DLLC - kr*DLLCi*fr Internalization/recycling 
R61 kd*DLCi*(fd) Degradation 
R62 kd*DLLCi*(fd) Degradation 
R63 f63*C*Sp - r63*CSp CBL binding 
R68 
f68*S*kin*(Ligand-bound EGFR dimers/total EGFR) - 
r68*kinS; SPRY2/kinase binding 
R69 f69*kinS SPRY2 phosphorylation 
R70 
r70*Sp 
SPRY2 
dephosphorylation 
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Table 3-S3. Parameters for model equations. 
Parameter Description Typical Value 
s1 EGFR synthesis 0 #/s 
f2, f4 kon,L 1×10
6 
M
-1
s
-1
 
f3, f5 k+dim 2.6×10
-8
 cell #
-1
s
-1
 
f6, f22, f56 kon,L2 1×10
5 
M
-1
s
-1
 
f7 k+dim2 2.6×10
-5
 cell #
-1
s
-1
 
f18, f23 kon,M  2×10
-5 
cell #
-1
s
-1
 
r2, r4, r6, r22, r56 koff,L 2.7×10
-3 
s
-1
 
r3, r5, r7 k-dim  1×10
-1
 s
-1
 
r18, r23 koff,M 1 s
-1
 
keb ki,basal  3.8×10
-4 
s
-1
 
k28 R internalization  0 
k29 RL internalization 0 
k30 D internalization 0 
k31, k32 Other internalization  ki,other (fitted) 
k37, k39 MIG6 internalization  ki,MIG6 (fitted) 
k59, k60 CBL internalization ki,CBL (fitted) 
kd kdeg  6×10
-4 
s
-1
 
kr krec  3.4×10
-3 
s
-1
 
fr fr 0.5 
fru fr, unbound 1 
f57, f58 kon,C   4×10
-6
 cell #
-1
s
-1
 
r57, r58 koff,C  1 s
-1
 
f63 kon,S   1×10
-5 
cell #
-1
s
-1
 
r63 koff,S  1×10
-1
 s
-1
 
f68 SPRY2/kinase kon 1×10
-5
 cell #
-1
s
-1
 
r68 SPRY2/kinase koff 1×10
-1
 s
-1
 
f69 SPRY2 phosphorylation kcat  1×10
-1 
s
-1
 
r70 SPRY2 dephosphorylation 1×10
-3
 s
-1
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Table 3-S4. Parameter values based on literature. 
Parameter Value Reference 
kon,L [M
-1
s
-1
] 1×10
6
 
(Berkers et al., 1991; Felder et al., 
1992; French et al., 1995) 
koff,L [s
-1
] 2.7×10
-3
 
(Berkers et al., 1991; Felder et al., 
1992; French et al., 1995) 
kon,L2 [M
-1
s
-1
] 1×10
5
 
(Berkers et al., 1991; Felder et al., 
1992; Macdonald-Obermann and Pike, 
2009) 
k+dim [cell #
-1
s
-1
] 2.6×10
-8
 (Macdonald-Obermann and Pike, 2009) 
k+dim2 [cell #
-1
s
-1
] 2.6×10
-5
 
(Kholodenko et al., 1999; Monast et al., 
2012; Schoeberl et al., 2009) 
k-dim [s
-1
] 1×10
-1
 
(Kholodenko et al., 1999; Schoeberl et 
al., 2009) 
kdeg [s
-1
] 6×10
-4
 
(Hendriks et al., 2006; Hendriks et al., 
2003; Schoeberl et al., 2009) 
krec [s
-1
] 3.4×10
-3
 
(Hendriks et al., 2006; Hendriks et al., 
2003; Schoeberl et al., 2009) 
Cell volume [L] 5.2×10
-13
 Calculated 
H1666 fr 0.574 (Walsh and Lazzara, 2013) 
PC9 fr 0.899 (Walsh and Lazzara, 2013)  
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Table 3-S5. Estimated parameter values and initial model species concentrations. 
Parameter H1666 PC9 Reference 
MIG6 [# cell
-1
] 1.2×10
5
 5×10
4
 
Estimated and 
western blotting 
(Walsh and Lazzara, 
2013) 
SPRY2 [# cell
-1
] 5×10
4
 5×10
4
 
Estimated and 
western blotting 
(Walsh and Lazzara, 
2013) 
CBL [# cell
-1
] 1×10
5
 1×10
5
 Estimated 
EGFR [# cell
-1
] 6×10
5
 8×10
5
 
Based on 
125
I-EGF 
binding and western 
blotting (Walsh and 
Lazzara, 2013) 
EGFR (SPRY2 KD) [# cell
-1
] 3.6×10
5
 4×10
5
 
(Walsh and Lazzara, 
2013) 
EGFR (SPRY2 KD+EGFR) [# 
cell
-1
] 
1.2×10
6
 8×10
5
 
(Walsh and Lazzara, 
2013) 
SPRY2 kinase [# cell
-1
] 1×10
5
 1×10
5
 Estimated 
ki,basal [s
-1
] 3.8×10
-4
 3.8×10
-4
 fitted 
kon,C  [cell #
-1
s
-1
] 4×10
-6
 4×10
-6
 
(Hsieh et al., 2010; Ng 
et al., 2008; Nguyen et 
al., 2000) 
koff,C [s
-1
] 1 1 
(Hsieh et al., 2010; Ng 
et al., 2008; Nguyen et 
al., 2000) 
kon,M [cell #
-1
s
-1
] 2×10
-5
 2×10
-5
 (Zhang et al., 2007a) 
koff,M [s
-1
] 1 1 (Zhang et al., 2007a) 
kon,S  [cell #
-1
s
-1
] 1×10
-5
 1×10
-5
 (Ng et al., 2008) 
koff,S [s
-1
] 1×10
-1
 1×10
-1
 (Ng et al., 2008) 
SPRY2/kinase binding 
kon = 1×10
-5
 
cell #
-1
s
-1
; koff 
= 1×10
-1
 s
-1
 
kon = 1×10
-5
 
cell #
-1
s
-1
; koff 
= 1×10
-1 
s
-1
 
(Kholodenko et al., 
1999; Northrup and 
Erickson, 1992) 
SPRY2 phosphorylation kcat [s
-1
] 1×10
-1
 1×10
-1
 
Estimated based on 
Mason 2004 (Mason 
et al., 2004) 
SPRY2 dephosphorylation [s
-1
] 1×10
-3
 1×10
-3
 
Estimated based on 
Mason 2004 (Mason 
et al., 2004) 
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Table 3-S6. Normalized experimental ke data. 
Measurement H1666 PC9 
ke (min
-1
) control 0.170 0.058 
ke (min
-1
) MIG6 KD 0.116 0.034 
ke (min
-1
) SPRY2 KD 0.219 0.091 
ke (min
-1
) MIG6/SPRY2 KD 0.149 0.038 
ke (min
-1
) SPRY2 KD + EGFR 0.148 0.058 
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Table 3-S7. Full results of local parameter sensitivity analysis. 
H1666 
parameter 
|Normalized sensitivity| PC9 parameter |Normalized sensitivity| 
koff,kinS 4.65×10
-5
 ki,other 4.41×10
-7
 
kdephos 0.00117 kdephos 1.96×10
-5
 
kon,kinS 0.00132 kcat,S 5.65×10
-5
 
kcat,S 0.00180 koff,kinS 8.73×10
-5
 
kon,L2 0.00237 kon,kinS 0.000451 
fr,unbound 0.00363 kon,S 0.000481 
koff,L 0.00720 koff,S 0.000500 
k+dim2 0.00987 kon,C 0.00192 
k+dim 0.0187 koff,C 0.00222 
kon,S 0.0226 kon,L2 0.00340 
koff,S 0.0254 k+dim 0.00467 
k-dim 0.0270 fr,unbound 0.00513 
kdeg 0.0384 k-dim 0.00620 
koff,M 0.0600 koff,L 0.00665 
kon,M 0.0602 k+dim2 0.00755 
ki,basal 0.110 kdeg 0.0414 
koff,C 0.127 ki,CBL 0.0505 
kon,C 0.1303 kon,M 0.138 
ki,other 0.198 koff,M 0.139 
fr 0.207 fr 0.208 
krec 0.247 krec 0.252 
ki,CBL 0.273 ki,basal 0.265 
kon,L 0.284 kon,L 0.290 
ki,MIG6 0.302 ki,MIG6 0.629 
 
 
 
  
 
 90 
Chapter 4: Sprouty2 drives drug resistance and proliferation in glioblastoma
3
 
4-1. Abstract 
Due to the heterogeneity of cellular protein expression profiles in glioblastoma multiforme 
(GBM), the discovery of durable cures will require identification of broadly relevant regulators of 
tumorigenicity and survival. Here, we identify Sprouty2 (SPRY2) as one such regulator. SPRY2 
knockdown reduced proliferation in GBM cell lines and in mouse xenografts. Additionally, SPRY2 
knockdown reduced anchorage-independent growth and enhanced cell death response to co-
inhibition of EGFR and c-MET in cell lines, an effect that appears to involve regulation of the 
ability of the p38 mitogen activated protein kinase to drive cell death. Furthermore, analysis of 
data from human and rat tumors demonstrated that SPRY2 expression is elevated in especially 
aggressive GBMs (i.e., those expressing epidermal growth factor receptor variant III) and that 
elevated SPRY2 expression portends reduced GBM patient survival. Our results identify SPRY2 
and the pathways it regulates as biomarkers for response to therapy and potentially useful 
druggable targets in GBM. 
 
4-2. Introduction 
Glioblastoma multiforme (GBM) is the most common and deadliest form of brain cancer 
(Louis et al., 2007). Standard treatment includes surgical resection, radiotherapy, and 
chemotherapy, resulting in an average survival of 12-15 months (Wen and Kesari, 2008). 
Targeted approaches based on the molecular pathogenesis of GBM have shown some promise 
in clinical trials, but have failed to demonstrate significant benefit over traditional treatments (De 
Witt Hamer, 2010; Sathornsumetee et al., 2007). A significant challenge limiting the effectiveness 
                                                     
3
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AMW and the manuscript was written by AMW and MJL. 
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of available GBM treatments is diffuse spreading of GBM tumors and heterogeneity in the 
expression profiles of GBM cells (Bonavia et al., 2011; Claes et al., 2007). Therefore, 
identification of broadly relevant regulators of tumorigenicity and survival is necessary to improve 
GBM patient outcomes. Here, we examine the expression and function of one such signaling 
regulator, Sprouty2 (SPRY2), in GBM. 
 SPRY2 is a regulator of receptor tyrosine kinase signaling whose expression is promoted 
by extracellular signal-regulated kinase (ERK) activity (Egan et al., 2002; Reich et al., 1999), and 
whose most well-characterized role is regulation of ERK (Yusoff et al., 2002). However, studies in 
different systems have demonstrated varied, and sometimes conflicting, roles for SPRY2. SPRY2 
inhibits ERK downstream of several receptor tyrosine kinases through regulation of RAS, by 
preventing growth factor receptor-bound protein 2 (GRB2)-son of sevenless (SOS) binding 
(Hanafusa et al., 2002) or by preventing RAS activation downstream of GRB2-SOS (Gross et al., 
2001), or through regulation of RAF (Yusoff et al., 2002), depending on the cellular context. In 
contrast, SPRY2 can also potentiate epidermal growth factor (EGF)-induced ERK activation by 
interfering with CBL-mediated EGF receptor (EGFR) downregulation (Wong et al., 2002). 
Downstream of the fibroblast growth factor receptor, SPRY2 specifically inhibits ERK activation, 
without effect on p38 or JUN N-terminal kinase (JNK) activation, two other members of the 
mitogen-activated protein (MAP) kinase family (Yusoff et al., 2002). However, results showing 
that interferon-stimulated p38 phosphorylation is enhanced in SPRY1/SPRY2/SPRY4 knockout 
murine embryonic fibroblasts (Sharma et al., 2012) could indicate a broader role for SPRY2 in 
MAP kinase regulation. 
Given that the signaling regulatory functions of SPRY2 appear to be highly context-
dependent, it is difficult to predict SPRY2’s regulatory role in GBM, where the functional role of 
SPRY2 has not been explored in any detail. In several other human cancers, SPRY2 expression 
is reduced compared to normal tissue, and SPRY2 has been proposed to function as a tumor 
suppressor (Fong et al., 2006b; Lo et al., 2006; Sutterluty et al.). In addition, SPRY2 is 
downregulated by microRNA-21, which is elevated in some cancers, including GBM (Kwak et al., 
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2011; Sayed et al., 2008). SPRY2 promotes cellular resistance to EGFR tyrosine kinase inhibitors 
in lung cancer cells (Walsh and Lazzara, 2013), but enhances cellular response to EGFR 
inhibition in colon cancer cells (Feng et al., 2010), highlighting the notion that SPRY2 function is 
highly context-dependent.  
Here, we investigated the expression and function of SPRY2 in GBM cell lines, mouse 
xenografts, and human tumor samples. In a panel of GBM cell lines, SPRY2 knockdown reduced 
proliferation, antagonized colony formation in soft agar, and potentiated response to EGFR and c-
MET co-inhibition. Interestingly, SPRY2’s control of cell death response to inhibitors appears to 
involve regulation of the ability of p38, which is phosphorylated in response to EGFR and c-MET 
co-inhibition, to promote cell death. Moreover, in some cells, SPRY2 controls p38 activity directly 
through regulation of the expression of the dual specificity phosphatases MKP-1 and MKP-5. In a 
mouse xenograft model, SPRY2 knockdown highly impaired tumor proliferation. Analysis of gene 
expression from primary human tumor samples and rat tumor allografts revealed that SPRY2 is 
upregulated in EGFR variant III (EGFRvIII)-positive tumors compared to EGFRvIII-negative 
tumors. This is of interest because EGFRvIII is present in 41-67% of GBMs with EGFR 
amplification (Aldape et al., 2004; Frederick et al., 2000; Mellinghoff et al., 2005), promotes an 
invasive and proliferative GBM cell phenotype (Koochekpour et al., 1997; Nishikawa et al., 1994), 
and is associated with poor prognosis for patients with EGFR amplification (Shinojima et al., 
2003). SPRY2 protein expression was confirmed by immunohistochemical analysis of human 
tumor sections. Further demonstrating an important role for SPRY2 in GBM, we find that elevated 
SPRY2 expression portends reduced patient survival in The Cancer Genome Atlas (TCGA) GBM 
data set, regardless of EGFRvIII status. Overall, our study identifies SPRY2 and the pathways it 
regulates as useful prognostic biomarkers and candidate therapeutic targets in GBM. 
 
4-3. Materials and Methods 
Cell culture. Parental U87MG cells and U87MG cells and U373MG cells with EGFRvIII 
expression or expression of a kinase dead EGFRvIII were described previously (Huang et al., 
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1997; Huang et al., 2007) and were provided by Dr. Frank Furnari (UCSD, La Jolla, CA, USA). 
U251 and SF188 cells were a gift from Dr. Celeste Simon (University of Pennsylvania, 
Philadelphia, PA, USA). LN18, T98G, 9L, and U118MG cells were obtained from the American 
Type Culture Collection. All cells were maintained in DMEM supplemented with 10% fetal bovine 
serum, 1 mM L-Glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin (Life 
Technologies). Gefitinib, U0126, SB203580, SP600125 (all from LC Laboratories), and 
PHA665752 (Santa Cruz Biotechnology) were reconstituted in DMSO and added to cells in 
complete media. To measure cellular proliferation, cells were seeded at 50,000 cells per well in 6-
well plates and counted with a hemocytometer 5 days later. 
Knockdown of SPRY2, MKP-1, and MKP-5. Oligonucleotides encoding hairpins targeting 
nucleotides 2061-2079 (main sequence used; shRNA #1) or 1195-1213 (shRNA #2) of human 
SPRY2, nucleotides 2041-2059 of human MKP-1, or nucleotides 935-953 of human MKP-5 were 
purchased from IDT and inserted into pSicoR.puro (Dr. Tyler Jacks, MIT, Cambridge, MA, USA; 
(Ventura et al., 2004)). A control shRNA was created using a hairpin that does not target a known 
human mRNA. Lentivirus was produced by calcium-phosphate-mediated transfection of 293FT 
cells (Life Technologies) with pSicoR.puro, pCMV-VSVg, pMDL-gp-RRE, and pRSV-Rev 
plasmids (Dr. Marilyn Farquhar, UCSD, La Jolla, CA, USA). Virus-containing supernatant was 
filtered and target cells were selected in 1-2 μg/mL puromycin (Sigma).  
Retroviral protein expression. MEK2DD cDNA in the pBabe.puro vector was provided by 
Dr. Sylvain Meloche (Université de Montréal, Montreal, Quebec, Canada). Y55F SPRY2 cDNA 
(Dr. Dafna Bar-Sagi, NYU, New York, NY, USA) and MKK3 cDNA (Dr. Margaret Chou, University 
of Pennsylvania, Philadelphia, PA, USA) were sub-cloned into pBabe.hygro  For all constructs, 
retrovirus was produced by calcium-phosphate-mediated transfection of amphotropic Phoenix 
cells (Dr. Gary Nolan, Stanford University, Stanford, CA, USA). Virus-containing supernatant was 
filtered and target cells were selected in 150 μg/mL hygromycin B (Sigma) or 2 μg/mL puromycin 
(Sigma). 
Tumor xenografts. 8 female NIH-III mice (Charles River) were subcutaneously injected in 
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each flank with either 2 million control (left side) or SPRY2-depleted (right side) U87MG-L cells. 
Tumors were measured with a caliper starting 7 days later when measurable tumors had formed 
and every 2-3 days afterwards. Tumor volume was calculated as π/6 × A × B
2
, where A and B are 
the larger and smaller tumor diameters, respectively. After final caliper measurements, animals 
were sacrificed and dissected tumors from the 6 animals with both control and SPRY2 
knockdown tumors were weighed. All experiments were approved by the University of 
Pennsylvania Institutional Animal Care and Use Committee and performed in accordance with 
NIH guidelines. 
Western blotting. Whole cell lysates were prepared and western blotting performed as 
described previously (Walsh and Lazzara, 2013). Details, including information on antibodies 
used, are provided in Supplemental Materials and Methods. 
Flow cytometry. Floating and adherent cells were pooled and stained with ToPro3 (Life 
Technologies). Cells were analyzed using a Becton Dickinson FACS-Calibur cytometer. 
Quantitative real-time PCR. RNA was extracted from cells using the RNeasy kit (Qiagen) 
with on-column DNase I digestion. Equal amounts of RNA were reverse transcribed using the 
High Capacity cDNA Reverse Transcription Kit (Life Technologies). PCR was performed using 
SYBR Green PCR Master Mix (Life Technologies) on an Applied Biosystems 7300 Real-Time 
PCR System. Relative amounts of mRNA were determined using the comparative CT method.  
Anchorage-independent growth assay. 5,000 cells were seeded per 35 mm dish in 0.3% 
low melting temperature agarose (Lonza) on top of a bottom layer of 0.6% agarose. Media was 
replaced every three days with or without inhibitors. At three weeks, plates were stained with 
0.1% crystal violet (Sigma) and colonies were counted. 
Immunohistochemistry. Immunohistochemistry of formalin fixed paraffin embedded tissue 
was performed on a Leica Bond instrument using the Bond Polymer Refine Detection System and 
antibodies against SPRY2 (Sigma, #S1444; 1:200 dilution). Heat-induced epitope retrieval was 
required for SPRY2 and done for 20 min with ER1 solution (Leica Microsystems). 
Analysis of TCGA GBM data set. Methods for preprocessing of TCGA exon-array data 
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and analysis to determine EGFRvIII status are described in Supplemental Materials and Methods. 
A two-sided student’s t-test was applied to determine whether SPRY2 expression varied among 
GBM subtypes and normal brain samples using TCGA exon-array data. A student’s t-test was 
also used to determine whether SPRY2 was differentially expressed between EGFRvIII-positive 
and EGFRvIII-negative samples based on TCGA RNA-seq samples. The upper quartile 
normalized RSEM (Li and Dewey, 2011) count estimates were base-10 log transformed before 
the t-test. The R package “survival” was used to analyze the TCGA survival data (Therneau and 
Grambsch, 2000). The log-rank test was applied to test for differences between the survival 
curves. 
Statistics. Data were analyzed by a student’s t-test, and differences with p-values < 0.05 
were considered statistically significant.  
Accession numbers. Microarray data presented in this study were deposited in the 
National Center for Biotechnology Information’s GEO database (GSE51062, GSE51147). 
 
4-4. Results 
SPRY2 knockdown slows cellular proliferation and reduces anchorage-independent 
growth. Using a set of commonly used GBM cell lines, including U87MG GBM cell lines with low 
(U87MG-L), medium (U87MG-M), or high (U87MG-H) engineered ectopic EGFRvIII expression or 
high expression of a control dead kinase EGFRvIII (U87MG-DK; K721M) (Huang et al., 2007), we 
sought to investigate the effects of SPRY2 in GBM cell lines. SPRY2 was depleted by stable 
expression of SPRY2-targeting shRNA (Figure 4-S1). SPRY2 knockdown reduced cellular 
proliferation compared to controls in U87MG-DK, U87MG-L, U251, and U118MG cells (Figure 4-
1A). A second independent shRNA was expressed in a subset of the cell lines and produced a 
similar effect (Figure 4-S2A). Colony formation in soft agar was also reduced by > 50% in 
U87MG-L, U87MG-H, U251, and U118MG cells with SPRY2 knockdown compared to controls 
(Figure 4-1B). Note that data are not available for U87MG-DK cells due to lack of colony 
formation. Similar reductions in colony formation were observed in a panel of EGFRvIII-
 
 96 
expressing cell lines transfected with SPRY2 siRNA compared to control siRNA (Figure 4-S2B).  
SPRY2 knockdown enhances cellular sensitivity to EGFR and c-MET co-inhibition. 
Despite frequent EGFR overexpression and mutation in GBM, EGFR kinase inhibitors are not 
clinically effective in GBM (Dutta and Maity, 2007; Mellinghoff et al., 2005; Thiessen et al., 2010; 
Vivanco et al., 2012). GBM cell lines are generally resistant to EGFR kinase inhibitors, but co-
inhibition of c-MET can augment response (Furcht et al., In press; Huang et al., 2007; Mellinghoff 
et al., 2005). We thus tested whether SPRY2 knockdown affects cellular response to EGFR and 
c-MET co-inhibition using the EGFR inhibitor gefitinib and the c-MET inhibitor PHA665752. This is 
a highly clinically relevant target combination as multiple therapeutics that simultaneously target 
EGFR and c-MET are currently in pre-clinical and clinical development (Castoldi et al., 2013). In 
multiple cell lines, the amount of cell death observed was significantly higher with SPRY2 
knockdown than for controls (Figure 4-1C). In U87MG-DK cells, SPRY2 knockdown also 
promoted cleavage of poly ADP ribose polymerase (PARP) in response to EGFR and c-MET co-
inhibition compared to controls (Figure 4-1D). The same general effect on response to inhibitors 
was also observed in parental U87MG cells with stable SPRY2 knockdown and U87MG-DK cells 
with transient SPRY2 knockdown (Figure 4-S3A, B). Because the expression of functional 
phosphatase and tensin homolog (PTEN) has been shown to regulate GBM cell response to 
EGFR inhibition (Mellinghoff et al., 2007; Mellinghoff et al., 2005), we also investigated whether 
PTEN status influenced the effects of SPRY2 knockdown. Ectopic expression of wild-type PTEN 
in U87MG cells, which do not express functional PTEN, did not reverse the increased cellular 
sensitivity to PHA665752 and gefitinib observed with SPRY2 knockdown (Figure 4-S3C). In two 
cell lines that express wild-type PTEN, LN18 and SF188, SPRY2 knockdown also increased 
death response to the inhibitors (Figure 4-S3D). Consistent with the effects of SPRY2 
knockdown, expression of dominant negative Y55F SPRY2 in U87MG-DK cells also enhanced 
cellular sensitivity to EGFR and c-MET co-inhibition (Figure 4-1E). This effect also repeated in 
multiple cell lines expressing a second non-overlapping SPRY2-targeting shRNA (Figure 4-S3E). 
Enhanced response to EGFR and c-MET inhibitors due to SPRY2 knockdown was also observed 
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in a glioma stem cell (GSC) cell line maintained in non-adherent sphere culture conditions (Figure 
4-S4). 
 
Figure 4-1. SPRY2 knockdown reduces cellular proliferation and anchorage-independent 
growth and enhances cellular sensitivity to EGFR and c-MET co-inhibition. 
 (A) Cellular proliferation and (B) colony formation in soft agar were measured with expression of 
control or SPRY2-targeting shRNA in a panel of GBM cell lines including U87MG cells expressing 
dead kinase (“DK”), low (“L”), or high (“H”) EGFRvIII. (C) The indicated cell lines were treated with 
DMSO or a combination of PHA665752 and gefitinib (“PHA+gef”; 5 μM PHA665752+10 μM 
gefitinib for U87MG-DK, U87MG-L, U118MG; 2 μM PHA665752+10 μM gefitinib for U251) for 48 
hrs prior to flow cytometry analysis for ToPro3 permeability. (D) U87MG cells expressing DK 
EGFRvIII and control or SPRY2-targeting shRNA were treated with DMSO or PHA+gef (2 μM 
PHA665752+20 μM gefitinib) for 72 hrs. Whole cell lysates were probed by western blot using 
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antibodies against the indicated proteins. (E) Whole cell lysates of U87MG cells expressing DK 
EGFRvIII and transduced with an empty vector (“EV”) or Y55F SPRY2 were probed by western 
blot using antibodies against the indicated proteins. Cells were also treated with DMSO or 
PHA+gef (5 μM PHA665752+10 μM gefitinib) for 48 hrs prior to flow cytometry analysis for 
ToPro3 permeability. Throughout the panels, data are represented as the average of three 
independent experiments ± s.e.m., and asterisks indicate p < 0.05.  
 
SPRY2 knockdown inhibits tumor xenograft growth. Female NIH-III mice were injected 
subcutaneously with U87MG-L cells with control or SPRY2-targeting shRNA. Tumors arising from 
SPRY2 knockdown cells were significantly smaller than those arising from control cells at all time 
points measured (Figure 4-2). Strikingly, SPRY2 knockdown cells failed to give rise to discernable 
tumors in 2 out of 8 mice. At 16 days post-injection, the average volume and weight of tumors 
from SPRY2 knockdown cells was approximately one-quarter of that for control tumors. 
 
 
Figure 4-2. SPRY2 depletion suppresses xenograft growth.  
Mice were subcutaneously injected with U87MG cells expressing low EGFRvIII and either control 
or SPRY2-targeting shRNA. (A) 16 days post-injection, animals were sacrificed and 
representative images of resected tumors were taken. (B) Tumor volume was measured every 2-
3 days (n=8 mice; p < 0.05 at all time points). (C) Tumor weight was measured 16 days post-
injection (n=6 mice with both control and SPRY2 knockdown tumors; p < 0.05). Data are 
represented as the mean ± s.e.m.  
 
SPRY2 controls p38’s ability to regulate anchorage-independent growth and response to 
inhibitors. In multiple cellular settings, SPRY2 regulates signaling through the ERK pathway 
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(Gross et al., 2001; Hanafusa et al., 2002; Yusoff et al., 2002). In the panel of U87MG cells, 
SPRY2 knockdown produced a small increase in basal ERK phosphorylation in U87MG-DK cells, 
but did not affect ERK phosphorylation in cells expressing active EGFRvIII (Figure 4-3A), where 
SPRY2 knockdown produces phenotypic effects. Although SPRY2 has been reported to 
specifically inhibit ERK among MAP kinase pathways (Yusoff et al., 2002), a recent study found 
enhanced p38 phosphorylation in SPRY1/SPRY2/SPRY4 knockout murine embryonic fibroblasts 
(Sharma et al., 2012). We thus hypothesized that JNK and/or p38 MAP kinases could be affected 
by SPRY2 knockdown. Indeed, basal JNK and p38 phosphorylation were increased in U87MG 
cells with SPRY2 knockdown compared to controls (Figure 4-3A). We did not observe similar 
basal increases in p38 or JNK phosphorylation in other GBM cell lines with SPRY2 knockdown, 
but we did observe increased p38 and JNK phosphorylation in U87MG-DK, U251, and U118MG 
cells in response to EGFR and c-MET co-inhibition (Figure 4-3B, Figure 4-S5A). We also 
observed increased p38 and JNK phosphorylation in U87MG cells expressing Y55F SPRY2 
(Figure 4-S5B). 
To determine whether JNK and/or p38 activity control the cellular phenotypes affected by 
SPRY2 knockdown, we treated cells with the p38 inhibitor SB203580 and/or the JNK inhibitor 
SP600125. p38 inhibition promoted colony formation, but JNK inhibition decreased colony 
formation (Figure 4-3C). When p38 and JNK inhibitors were combined, colony formation was 
reduced compared to DMSO-treated controls, but increased compared to JNK inhibition alone 
(Figure 4-S5C). While neither inhibitor rescued the decreased cellular proliferation observed in 
U87MG-DK cells with SPRY2 knockdown, JNK inhibition decreased cellular proliferation relative 
to DMSO-treated controls (Figure 4-3D), suggesting an important role for JNK in cellular 
proliferation. 
 
 
 100 
 
Figure 4-3. p38 and JNK phosphorylation are increased in U87MG cells with SPRY2 
knockdown and in cells co-treated with EGFR and c-MET inhibitors, and control cellular 
proliferation, anchorage-independent growth, and response to EGFR and c-MET co-
inhibition.  
(A) Whole cell lysates from U87MG cells expressing dead kinase (“DK”), low (“L”), medium (“M”), 
or high (“H”) EGFRvIII and control (“-“) or SPRY2-targeting (“+”) shRNA were probed 
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by western blot using antibodies against the indicated proteins, and blots were analyzed by 
densitometry. (B) The indicated cell lines expressing control (“-“) or SPRY2-targeting (“+”) shRNA 
were treated with DMSO or a combination of PHA665752 and gefitinib (“PHA+gef”) (5 μM 
PHA665752+10 μM gefitinib for U87MG and U118MG; 2 μM PHA665752+10 μM gefitinib for 
U251) for 48 hrs. Whole cell lysates were probed by western blot using antibodies against the 
indicated proteins. (C) Colony formation in soft agar was measured in the indicated cell lines 
treated with DMSO, 20 μM SB203580 (“p38i”), or 20 μM SP600125 (“JNKi”). (D) Cellular 
proliferation was measured in U87MG cells expressing DK EGFRvIII and control or SPRY2-
targeting shRNA treated with DMSO, 20 μM p38i, 20 μM JNKi, or both 20 μM p38i and 20 μM 
JNKi (“p38i+JNKi”). (E) U87MG DK EGFRvIII and U251 cells expressing control or SPRY2-
targeting shRNA were treated with DMSO or 20 μM p38i for 24 hrs and then treated with DMSO 
or PHA+gef (5 μM PHA665752+10 μM gefitinib for U87MG; 3 μM PHA665752+10 μM gefitinib for 
U251) for 48 hrs prior to flow cytometry analysis for ToPro3 permeability. (F) Whole cell lysates 
from U87MG DK EGFRvIII and U251 cells expressing control empty vector (“EV”), constitutively 
active MKK3 (“MKK3-Glu”), or inactive MKK3 (“MKK3-Ala”) were probed by western blot with a 
Flag antibody to detect Flag-MKK3 expression. (G) MKK3-expressing cells were treated with 
DMSO or PHA+gef (5 μM PHA665752+10 μM gefitinib for U87MG; 3 μM PHA665752+10 μM 
gefitinib for U251) for 48 hrs prior to flow cytometry analysis for ToPro3 permeability. (H) Whole 
cell lysates from the indicated EV control or MKK3-expressing cells were probed by western blot 
using antibodies against the indicated proteins. Throughout the panels, data are represented as 
the average of at least three independent experiments ± s.e.m. Asterisks indicate p < 0.05, and 
“NS” indicates lack of statistical significance. 
 
We further found that pre-treatment of U87MG-DK and U251 cells with the p38 inhibitor 
eliminated the increase in cell death response to co-inhibition of EGFR and c-MET in cells with 
SPRY2 knockdown compared to controls (Figure 4-3E). Conversely, expression of constitutively 
active mitogen-activated protein kinase kinase 3 (MKK3; (Raingeaud et al., 1996)), the kinase for 
p38, enhanced cell death response to EGFR and c-MET co-inhibition in U87MG-DK and U251 
cells (Figure 4-3F, G). Expression of an inactive MKK3 mutant did not affect drug response in 
either cell line. As expected, expression of constitutively active MKK3 increased p38 
phosphorylation in cells where EGFR and c-MET were co-inhibited (Figure 4-3H, Figure 4-S5D). 
Note that U87MG-DK cells were used for these studies because they exhibited a larger increase 
in cell death due to SPRY2 knockdown than U87MG cells with active EGFRvIII expression.  
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SPRY2 knockdown reduces MKP-1 and MKP-5 mRNA levels in U87MG cells. Although 
we observed basal increases in p38 and JNK phosphorylation in U87MG cells with SPRY2 
knockdown, there is no known mechanism for SPRY2-mediated inhibition of p38 or JNK. We 
postulated that SPRY2 could negatively regulate JNK and p38 phosphorylation by promoting 
expression of regulatory phosphatases, as had been shown with the protein tyrosine 
phosphatase PTP1B in the cytosolic fraction of HeLa cells (Yigzaw et al., 2003). We found that 
mRNA levels of the dual-specificity MAP kinase phosphatases MKP-1 and MKP-5, which act 
upon JNK and p38 (Owens and Keyse, 2007; Theodosiou and Ashworth, 2002), were indeed 
reduced in U87MG-DK cells with SPRY2 knockdown compared to controls (Figure 4-4A). We 
measured no change in MKP-3 mRNA levels, which primarily acts upon ERK (Owens and Keyse, 
2007; Theodosiou and Ashworth, 2002). We reduced MKP-1 and MKP-5 expression in U87MG-
DK and U87MG-H cells using shRNA (Figure 4-S6), which enhanced phosphorylation of p38, 
JNK, and ERK (Figure 4-4B) and significantly increased cell death response to EGFR and c-MET 
co-inhibition (Figure 4-4C). The effects were greatest with MKP-5 knockdown, perhaps due to 
relatively poor reduction of MKP-1 mRNA levels by MKP-1-targeting shRNA (Figure 4-S6).  
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Figure 4-4. In U87MG cells, SPRY2 knockdown reduces MKP-1 and MKP-5 mRNA 
expression, and MKP-1 or MKP-5 knockdown enhances cellular response to EGFR and c-
MET co-inhibition.  
(A) MKP-1, MKP-5, and MKP-3 mRNA levels were measured in U87MG dead kinase (“DK”) 
EGFRvIII cells expressing control or SPRY2-targeting shRNA. (B) Whole cell lysates from 
U87MG DK or high (“H”) EGFRvIII cells expressing a control, MKP-1-targeting, or MKP-5-
targeting shRNA were probed by western blot using antibodies against the indicated proteins, and 
blots were analyzed by densitometry. (C) The indicated cell lines were treated with DMSO or 5 
μM PHA665752+10 μM gefitinib (“PHA+gef”) for 48 hrs prior to flow cytometry analysis for 
ToPro3 permeability. Throughout the panels, data are represented as the average of three 
independent experiments ± s.e.m. Asterisks indicate p < 0.05, and “NS” indicates lack of 
statistical significance.  
 
SPRY2 is expressed in human GBM tumors and elevated in EGFRvIII-positive tumors in 
humans and rats. SPRY2 protein expression in human tumors was analyzed by 
immunohistochemistry. The majority of tumors analyzed showed positive SPRY2 staining. 
SPRY2 staining patterns included moderate focal, moderate granular, and strong diffuse staining 
(Figure 4-5). As a positive control, SPRY2 protein expression was also probed by 
immunohistochemistry in sections of kidney and cerebellum (Figure 4-S7). We additionally 
probed SPRY2 protein expression by western blot in patient-derived xenografts, GSC cell lines, 
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and a neurosphere cell line and observed SPRY2 protein levels comparable or greater than that 
observed in representative GBM cell lines (Figure 4-S8). In the analysis of GBM tumors, it was 
noted that there was a possible trend for lower intensity staining overall in tumors without 
expression of EGFRvIII compared to those positive for EGFRvIII expression.  
 
 
Figure 4-5. SPRY2 protein expression in GBMs is confirmed by immunohistochemical 
analysis.  
SPRY2 protein expression was probed in sections of EGFRvIII+ and EGFRvIII- GBMs. In both 
tumor types, the majority of tumors analyzed showed definitive SPRY2 staining with SPRY2 
patterns including moderate focal, moderate granular, and strong diffuse staining. The 
neuropathologist who analyzed these images noted a possible tendency for less intense staining 
overall in EGFRvIII- tumor sections.  
 
This trend for higher SPRY2 expression in EGFRvIII-positive GBMs was confirmed in an 
analysis of EGFRvIII-induced gene signatures in orthotopic rat tumor allografts and primary 
human GBM tumors. For the analysis in rats, 12 animals received intracranial injections of 9L rat 
gliosarcoma cells expressing EGFRvIII or an empty vector control. Three weeks after 
implantation and subsequent growth, tumors were analyzed for gene expression profiling using 
the RatRef12 Illumina chip array. This analysis revealed 1498 gene probes that were increased 
(p < 0.05) by at least 1.5-fold in EGFRvIII-expressing tumors compared to empty vector control 
tumors. We also examined gene expression in 52 primary GBM tumors, which were stratified 
based on the presence or absence of EGFRvIII expression using EGFRvIII-specific RT-PCR 
(Tykocinski et al., 2012). The extracted RNA samples from these tumors were subjected to 
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microarray analysis using HG-U133 2.0 Plus Affymetrix gene chips. This analysis revealed 355 
gene probes whose expression was significantly increased (p < 0.05) by at least 1.5-fold in 
EGFRvIII-positive tumors compared to EGFRvIII-negative tumors. These gene probes were 
aligned against the gene probes upregulated in EGFRvIII-positive rat tumors. SPRY2 was one of 
9 upregulated genes that were shared by both rat 9L EGFRvIII-expressing tumors and human 
EGFRvIII-expressing GBMs (Table 4-S1).  
We further examined SPRY2 expression in GBM cell lines, where we observed a positive 
correlation between SPRY2 expression and ERK phosphorylation that was supported by 
pharmacological and genetic perturbation (Figure 4-S9A, B, C), consistent with the documented 
ability of ERK to regulate SPRY2 expression (Egan et al., 2002; Reich et al., 1999). Among cell 
lines engineered to express EGFRvIII, we continued to observe good correlation between SPRY2 
expression and ERK phosphorylation, but we did not observe a consistent trend between 
EGFRvIII and SPRY2 expression (Figure 4-S9E). The apparent lack of good SPRY2/EGFRvIII 
expression correlation may arise because of the limited number of isogenic cell backgrounds 
tested or because the method used to drive EGFRvIII expression in cell lines differs drastically 
from the way that EGFRvIII expression is regulated in GBM (Li et al., 2008a). 
Analysis of TCGA data reveals that elevated SPRY2 expression correlates with EGFRvIII 
expression, the classical GBM subtype, and reduced patient survival. We next probed the TCGA 
GBM data set to ask if SPRY2 expression correlates with EGFRvIII expression in a larger set of 
patient samples and to determine whether SPRY2 expression correlates with previously defined 
GBM tumor subtypes and patient survival. TCGA samples were classified by EGFRvIII 
expression status based on RNA-seq data, which was available for 161 samples. 41/161 samples 
(25%) were EGFRvIII-positive. SPRY2 expression was increased in EGFRvIII-positive samples 
compared to EGFRvIII-negative samples (p = 1.00×10
-8
), with a fold difference of 1.49 (Figure 4-
6A), consistent with the results in Table 4-S1. Based on the definitions of four clinically relevant 
GBM subtypes determined by gene signatures (Verhaak et al., 2010) and using TCGA GBM 
exon-array data (173 “core” representative samples), we further found that SPRY2 expression 
 
 106 
was lower in the proneural subtype than the other three subtypes (p = 8.06×10
-9
 and fold 
difference of 0.60) (Figure 4-6B). SPRY2 expression was highest in the classical subtype (p < 
2.20×10
-16
 and fold difference of 1.58 for comparison to other subtypes), which exhibits a high 
rate of EGFR amplification and mutation.  
 
 
Figure 4-6. TCGA GBM data reveals that elevated SPRY2 expression correlates with 
EGFRvIII expression, the classical GBM subtype, and reduced patient survival.  
(A) SPRY2 expression (log base 10 transformed RPKM) is higher in EGFRvIII-positive RNA-seq 
samples (n = 41) than EGFRvIII-negative RNA-seq samples (n = 120) (p = 1.00×10
-8
; fold 
difference of 1.49). (B) SPRY2 expression (log base 2 transformed data) is shown for normal 
brain samples (n = 10) and the four GBM subtypes: proneural (n = 54, p = 8.06×10
-9
 and fold 
difference of 0.60 compared to other three subtypes), neural (n = 27), mesenchymal (n = 55), and 
classical (n = 37, p < 2.20×10
-16 
and fold difference of 1.58 compared to other three subtypes). 
The p-value for tumor versus normal brain samples is 0.154 with a fold difference of 1.13. (C) 
Survival probability is shown as a function of time after diagnosis classified by SPRY2 expression 
with the median SPRY2 expression used as a cutoff for all patients and patients parsed by age 
using the median age (59 yrs) as a cutoff. 
 
We also determined the relationship between SPRY2 expression and patient survival 
(Figure 4-6C), using median SPRY2 expression as a cutoff between low and high expression. 
Across all patients, low SPRY2 expression was associated with reduced mortality compared to 
high SPRY2 expression (p = 0.0123), with median survival for low or high SPRY2 expression of 
469 or 393 days, respectively. Because age is an established important prognostic factor in GBM 
(Lee et al., 2008; Siker et al., 2011), we further looked at the effect of SPRY2 expression in 
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patients stratified by age. Parsing patients into age groups using the median age (59 yrs) as a 
cutoff, we found that the effect of SPRY2 expression differences was more pronounced in the 
younger patient cohort (p = 0.000416), with median survival of 631 or 451 days for low or high 
SPRY2 expression, respectively, and that there was no effect of SPRY2 expression on survival in 
the older cohort. The difference in survival was even further increased using an age cutoff of 40 
yrs (p = 0.00316), with median survival of 1024 or 538 days for low or high SPRY2 expression, 
respectively (Figure 4-S10). 
 
4-5. Discussion 
In GBM cell lines with or without EGFRvIII expression, we find that SPRY2 acts as a 
driver of GBM cell proliferation, anchorage-independent growth, and resistance to inhibition of 
receptor tyrosine kinases that promote GBM survival. Furthermore, SPRY2 knockdown had a 
dramatic effect on tumor xenograft growth. In at least some cases, SPRY2 may exert this control 
over GBM cell phenotypes by regulating the ability of p38 and JNK to influence cell outcomes, as 
summarized in Figure 4-7. We also find that SPRY2 gene expression is elevated in human GBMs 
and rat tumor grafts expressing EGFRvIII, which tend to be especially aggressive, and that high 
SPRY2 expression is associated with reduced patient survival and the classical GBM subtype. 
These central findings point to SPRY2 as a potential therapeutic target in GBM and may help to 
explain the established connection between EGFRvIII expression and GBM aggressiveness.  
The finding that SPRY2 promotes growth and resistance to inhibition of receptor tyrosine 
kinases was initially surprising given SPRY2’s purported role as a tumor suppressor in 
hepatocellular carcinoma, lung cancer, breast cancer, and prostate cancer (Fong et al., 2006b; Lo 
et al., 2006; Sutterluty et al., 2007). While SPRY2 appears to negatively regulate tumor growth in 
these other settings, an oncogenic role for SPRY2 has recently been demonstrated in colon 
cancer where elevated SPRY2 expression is a marker of poor prognosis (Holgren et al., 2010; 
Ordonez-Moran et al., 2013). In colon cancer cells, SPRY2 may promote tumorigenesis through 
regulation of c-MET (Holgren et al., 2010) or E-cadherin (Barbachano et al., 2010). Because the 
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net outcome of SPRY2 expression and its mechanism of action appear highly dependent on 
cellular context, additional work is clearly needed to clarify the determinants of SPRY2’s function 
in different contexts and to develop strategies to interrupt SPRY2’s pro-tumorigenic functions in 
GBM and other cancers. 
Another question raised by our study is how SPRY2 expression is promoted in EGFRvIII-
positive tumors. Across many GBM cell lines and with multiple genetic and pharmacological 
perturbations, SPRY2 expression correlated very well with ERK phosphorylation. It has been 
suggested, however, that EGFRvIII-driven tumors do not activate canonical EGFR downstream 
signaling pathways such as ERK, STAT3, and AKT (Zhu et al., 2009). It is possible that tumor 
microenvironment features altered by EGFRvIII expression allow for increased ERK activation, or 
that an alternative pathway not explored here promotes SPRY2 expression in GBM. If it is true 
that ERK regulates SPRY2 expression in vivo, MEK inhibition could be a useful approach to 
downregulate SPRY2 expression in GBM. It should also be noted that SPRY2 is post-
transcriptionally regulated by miR-21, which could potentially complicate the relationship between 
SPRY2 transcript and protein levels in some settings (Kwak et al., 2011; Sayed et al., 2008).  
Although the best-studied role of SPRY2 is regulation of the ERK pathway, our results 
suggest that p38 and JNK activity are important for regulating anchorage-independent growth, 
proliferation, and response to tyrosine kinase inhibitors in GBM. Specifically, we interpret the 
results of Figure 4-3 to indicate that JNK activity is required for normal GBM cell proliferation and 
anchorage-independent growth, but that p38 activity antagonizes anchorage-independent growth 
and promotes cellular response to EGFR and c-MET co-inhibition. Since p38 inhibition mitigated 
the effects of SPRY2 knockdown on death response to EGFR and c-MET co-inhibition, even in a 
cell line where SPRY2 knockdown did not generate basal increases in p38 phosphorylation 
(U251), p38 activation may only be a necessary step along the path leading to apoptosis. 
SPRY2’s absence (or reduced expression) may potentiate this effect of p38 activity through 
specific mechanisms yet to be identified. The results of Figure 4-3 also suggest JNK as an 
interesting therapeutic target to consider in GBM moving forward.  
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Figure 4-7. SPRY2 promotes GBM cell proliferation, anchorage-independent growth, and 
resistance to tyrosine kinase inhibition. 
The schematic highlights our study’s key findings regarding regulation of SPRY2 expression and 
SPRY2-mediated regulation of signaling and cellular phenotypes. In tumors expressing EGFRvIII, 
SPRY2 expression is increased compared to tumors lacking EGFRvIII, an effect that may involve 
differential ERK activity in the tumor context of EGFRvIII expression. In GBM cells, SPRY2 
promotes anchorage-independent growth and proliferation in adherent cultures, and drives 
resistance to targeted inhibitors of oncogenic kinases. SPRY2 regulates these phenotypes by 
permitting p38 activity to play a more prominent role in cell fate determination, and this regulation 
of p38 may involve regulation of the expression of the MKP-1 or MKP-5 dual specificity 
phosphatases in some cases. JNK activity and functional role may also be regulated by SPRY2, 
but JNK and p38 generally play opposing roles in the regulation of GBM cell phenotypes. 
 
To our knowledge, our data constitutes the first report of SPRY2’s ability to regulate p38 
and JNK MAP kinase signaling through regulation of the expression of dual specificity 
phosphatases (MKP-1 and MKP-5). This is also the first study relating MKP-1 and MKP-5 
expression and response to clinically relevant inhibitors in GBM. Previous studies have not 
focused on MKP-1 or MKP-5 in GBM, but published gene expression data indicate that MKP-1 
expression is higher in GBM samples than normal brain (Bredel et al., 2005; Lee et al., 2006). 
Together with our finding that MKP-1 or MKP-5 knockdown potentiated U87MG cell response to 
EGFR and c-MET co-inhibition, this suggests that MKPs merit further study in GBMs and could 
be useful therapeutic targets.  
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Overall, our findings highlight the surprising results that in GBM SPRY2 appears to play 
the role of promoting cancer phenotypes, including proliferation, anchorage-independent growth, 
and resistance to targeted inhibitors of oncogenic kinases, and that elevated SPRY2 expression 
is associated with expression of EGFRvIII (which tends to make GBM tumors especially 
aggressive) and reduced patient survival. These results stand in stark contrast to findings in 
several other cancer contexts where SPRY2 has been reported to function as a tumor 
suppressor. Looking forward, SPRY2 and the pathways it regulates should be assessed for their 
value as therapeutic targets or as prognostic markers for response to therapy in GBM. 
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4-7. Supplemental Data 
 
 Human GBM cohort (n=52) Rat tumors (n=12) 
gene 
symbol 
gene name 
probe 
sets 
p-value 
fold 
difference 
p-value 
fold 
difference 
CKAP4 
cytoskeleton-
associated protein 4 
1 
 
0.0033 2.2 0.0051 1.6 
LRP5 
low density 
lipoprotein receptor-
related protein 5 
1 0.0086 1.6 0.0019 2.0 
FAT3 
fat tumor 
suppressor homolog 
3 
2 0.0131 1.5 0.0098 44.9 
SPRY2 sprouty homolog 2 1 0.0191 1.5 0.0131 1.7 
SLC7A1 
solute carrier family 
7 (cationic amino 
acid transporter, y+ 
system) 
1 0.0279 1.6 0.0095 1.9 
AEBP1 ae binding protein 1 1 0.0287 1.5 0.0009 2.4 
CDK6 
cyclin-dependent 
kinase 6 
3 
0.0299 range 
(0.012-0.041) 
1.9 range 
(1.8-2.1) 
0.0046 1.6 
SOCS2 
suppressor of 
cytokine signaling 2 
3 
0.0299 
range(0.012-
0.041) 
1.9 range 
(1.8-2.1) 
0.0212 1.7 
AQP1 
aquaporin 1 (colton 
blood group) 
1 0.0405 1.7 0.0028 4.5 
 
Table 4-S1. Upregulated genes shared by human GBMs expressing EGFRvIII and 
9L.EGFRvIII rat tumors compared to wild-type EGFR human GBMs or 9L.EV rat tumors. 
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Figure 4-S1. SPRY2 is efficiently knocked down by shRNA in GBM cell lines. 
Whole cell lysates from U87MG cells with dead kinase (“DK”), low (“L”), medium (“M”), or high 
(“H”) EGFRvIII expression and U251, SF188, LN18, U118MG, and T98G cells with expression of 
control or one of two SPRY2-targeting shRNA were probed by western blot using antibodies 
against the indicated proteins. shRNA #1 is the hairpin used throughout the main figures, and 
shRNA #2 is an independent, non-overlapping shRNA made to validate the effects of shRNA #1. 
ERK was used as a loading control. Data are representative of three independent experiments. 
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Figure 4-S2. SPRY2 depletion by a second non-overlapping shRNA reduces cellular 
proliferation, and SPRY2 depletion by siRNA transfection reduces colony formation in soft 
agar in EGFRvIII-expressing cells. 
(A) Cellular proliferation was measured by counting cells 5 days after plating for the indicated cell 
lines with expression of control or a second non-overlapping SPRY2-targeting shRNA (shRNA 
#2, described in Experimental Procedures). Data are represented as the average of three 
independent experiments ± s.e.m., and asterisks indicate p < 0.05. (B) Colony formation in soft 
agar was assessed in the indicated cell lines with EGFRvIII expression transfected with control or 
SPRY2-targeting siRNA. Images are representative of two experiments. 
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Figure 4-S3. SPRY2 depletion increases cellular sensitivity to EGFR andc-MET co-
inhibition. 
(A) Whole cell lysates of parental U87MG cells (without EGFRvIII expression) expressing control 
or SPRY2-targeting shRNA were probed by western blot using antibodies against the indicated 
proteins. Cells were treated with DMSO or PHA665752 and gefitinib (“PHA+gef”) (5 μM 
PHA665752 and 10 μM gefitinib) for 48 hrs prior to cell death analysis. (B) Whole cell lysates of 
U87MG cell expressing dead kinase (“DK”) EGFRvIII transfected with control or SPRY2-targeting 
siRNA smartpools were probed by western blot using antibodies against the indicated proteins. 
Cells were also treated with DMSO or PHA+gef (5 μM PHA665752 and 10 μM gefitinib) for 48 hrs 
prior to cell death analysis. (C) Parental U87MG cells expressing an empty vector control (“EV”) 
or wild-type PTEN and either control or SPRY2-targeting shRNA were probed by western blot 
using antibodies against the indicated proteins. Cells were treated with DMSO or PHA+gef (5 μM 
PHA665752+10 μM gefitinib) for 48 hrs prior to cell death analysis. (D) SF188 and LN18 
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cells with control or SPRY2-targeting shRNA were treated with DMSO or PHA+gef (5 μM 
PHA665752+10 μM gefitinib for SF188; 2 μM PHA665752+10 μM gefitinib for LN18) for 48 hrs 
prior to cell death analysis. (E) U87MG cells with DK, low (“L”), or medium (“M”) EGFRvIII 
expression, U251, and SF188 cells expressing control or a second non-overlapping SPRY2-
targeting shRNA (shRNA #2, described in Materials and Methods) were treated with DMSO or 
PHA+gef (5 μM PHA665752+10 μM gefitinib for U87MG and SF188; 2 μM PHA665752+10 μM 
gefitinib for U251) for 48 hrs prior to cell death analysis. Throughout the panels, cell death was 
measured by flow cytometry for ToPro3 permeability, and data are represented as the average of 
three independent experiments ± s.e.m. Asterisks indicate p < 0.05. 
 
 
Figure 4-S4. SPRY2 knockdown promotes response to EGFR/c-MET co-inhibition in GSC 
cells. 
The distribution of sphere size is shown for 3691 GSC cells transduced with control or SPRY2-
targeting shRNA that were treated with DMSO or 3 μM PHA665752 (“PHA”) and 20 μM gefitinib. 
Cells were seeded at a density of 10 cells per well in 96-well format (16 wells per treatment per 
cell line) and then treated with DMSO or PHA and gefitinib at 72 hrs post-plating and every 2-3 
days subsequently. Cell spheres were analyzed after 8 days of treatment. Analysis included 
spheres with volume above 50,000 μm
3
, below which cells clusters were loosely associated and 
non-spherical. Representative spheres at equal magnification for different size bins are shown.  
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Figure 4-S5. p38 and JNK control anchorage-independent growth and response to EGFR 
and c-MET co-inhibition. 
(A) Whole cell lysates from U87MG dead kinase (“DK”) EGFRvIII cells, U251 cells, or U118MG 
cells expressing control or SPRY2-targeting shRNA were treated with DMSO or a combination of 
PHA665752 and gefitinib (“PHA+gef”) (5 μM PHA665752+10 μM gefitinib for U87MG and 
U118MG; 2 μM PHA665752+10 μM gefitinib for U251) for 48 hrs. Whole cell lysates were probed 
by western blot and analyzed by densitometry. (B) Whole cell lysates from U87MG DK EGFRvIII 
cells transduced with empty vector control (“EV”) or Y55F SPRY2 were probed by western blot 
using antibodies against the indicated proteins. (C) Colony formation in soft agar was measured 
in U87MG cells with low (“L”) EGFRvIII expression that were treated with DMSO, 20 μM 
SB203580 (“p38i”), or a combination of 20 μM SB203580 and 20 μM SP600125 (“p38i+JNKi”). 
(D) The indicated cell lines expressing control EV, constitutively active MKK3 (“MKK3-Glu”), or 
inactive MKK3 (“MKK3-Ala”) were treated with DMSO or PHA+gef (5 μM PHA665752+10 μM 
gefitinib for U87MG-DK; 3 μM PHA665752+10 μM gefitinib for U251). Whole cell lysates were 
probed by western blot using antibodies against phosphorylated p38 and ERK. Blots were 
analyzed by densitometry. Throughout the panels, data are represented as the average of at 
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least three independent experiments ± s.e.m., and asterisks indicate p < 0.05. 
 
 
Figure 4-S6. shRNA-mediated knockdown of MKP-1 or MKP-5 reduces MKP-1 or MKP-5 
mRNA level. 
MKP-1 or MKP-5 mRNA levels were measured in U87MG cells expressing dead kinase (“DK”) 
EGFRvIII and control, MKP-1-targeting, or MKP-5-targeting shRNA. mRNA expression is shown 
relative to cells expressing control shRNA. Data are represented as the average of three 
independent experiments ± s.e.m., and asterisks indicate p < 0.05.  
 
 
 
Figure 4-S7. SPRY2 protein expression in kidney and cerebellum sections by 
immunohistochemical analysis. 
SPRY2 protein expression was probed in sections of kidney and cerebellum as positive controls. 
In the kidney, SPRY2 was observed in the tubules (“T”) but not in glomeruli (“G”). In cerebellum, 
diffuse SPRY2 expression was observed throughout the molecular layer (“ML”) and in the dentate 
nucleus (“DN”), with moderate staining in Purkinje cells (“PC”) and strong staining in Bergmann 
glia (“BG”), but was not observed in the granule cell layer (“GCL”) or white matter (“WM”). 
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Figure 4-S8. SPRY2 protein expression is confirmed in patient-derived cells by 
immunoblot. 
SPRY2 protein expression in patient-derived xenografts (“PDX”) exhibiting EGFRvIII expression 
was compared against that observed in two glioma stem cell (“GSC”) lines, a neurosphere (“NS”) 
line with EGFRvIII expression, and in a panel of GBM cell lines and one lung cancer cell line 
(H1666) cultured on tissue culture polystyrene (“TCPS”). For U251 cells, lysates are shown for 
cells transduced with control (“ctrl”) or SPRY2-targeting shRNA (“sh”).  
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Figure 4-S9. SPRY2 correlates well with ERK phosphorylation in a panel of GBM cell lines. 
(A) Whole cell lysates from the indicated cell lines were probed by western blot using antibodies 
against the indicated proteins, and blots were analyzed by densitometry. (B) U87MG cells with 
dead kinase (“DK”) or high (“H”) EGFRvIII expression were treated with the indicated 
concentrations of U0126 in complete media for 24 hrs. Whole cell lysates were probed by 
western blot using antibodies against the indicated proteins. (C) SPRY2 mRNA levels were 
measured in U87MG cells with DK or H EGFRvIII expression after 24 hrs treatment with 25 μM 
U0126. (D) U87MG cells with H EGFRvIII expression and transduced with either control empty 
vector (“EV”) or constitutively active MEK (“MEK2DD”) were probed by western blot using 
antibodies against the indicated proteins. (E) Whole cell lysates from the indicated cells lines with 
EGFRvIII expression (“+”), control EV expression, or control DK EGFRvIII expression were 
probed by western blot using antibodies against the indicated proteins, and blots were analyzed 
by densitometry. In U87MG cells, “+” indicates high EGFRvIII expression. Throughout the figure 
panels, data are represented as averages of three independent experiments ± s.e.m., and 
asterisks indicate p < 0.05. 
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Figure 4-S10. TCGA GBM dataset analysis reveals that SPRY2 expression is associated 
with reduced patient survival. 
Survival probability is shown as a function of time after diagnosis for patients classified by SPRY2 
expression using the median SPRY2 expression used as a cutoff. This analysis is shown for 
patients of all ages (left panel) and for patients parsed by age using 40 yrs as a cutoff (center and 
right panels). 
 
4-8. Supplemental Materials and Methods 
Western blotting. Whole cell lysates were prepared in a standard cell extraction buffer 
(Life Technologies) supplemented with protease and phosphatase inhibitors (Sigma). Total 
protein concentrations were determined by micro-bicinchoninic assay (Thermo Scientific). 
Lysates were loaded on 4-12% gradient polyacrylamide gels (Life Technologies) under 
denaturing and reducing conditions and transferred to 0.2 μm nitrocellulose membranes (Bio-
Rad). Membranes were imaged on a LI-COR Odyssey scanner (LI-COR) and stripped with 0.2 M 
NaOH as needed. 
Antibodies. Antibodies against PARP (#9542), p-p38 (#4631), p-JNK (#4671), PTEN 
(#9552), ERK (#4695), and p-ERK T202/Y204 (#4377) were purchased from Cell Signaling 
Technology. The EGFR antibody (Ab-12) was purchased from Thermo Scientific. The SPRY2 
antibody (#S1444) and the Flag antibody (#F3165) were purchased from Sigma. The p-EGFR 
antibody (#1727) was purchased from Epitomics. The GAPDH antibody (#sc-32233) was 
purchased from Santa Cruz Biotechnology. Infrared dye-conjugated secondary antibodies were 
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purchased from Rockland Immunochemicals. All antibodies were used according to manufacturer 
recommendations. 
Cell culture for supplemental data. All cells (except GSC cells) were maintained in DMEM 
supplemented with 10% fetal bovine serum, 1 mM L-Glutamine, 100 units/mL penicillin, and 100 
μg/mL streptomycin (Life Technologies). LN229 cells were obtained from the American Type 
Culture Collection. EGFRvIII or empty vector expressing 9L, U373MG, and LN229 cells for 
anchorage-independent growth assay were created by transfection with pcDNA3.1(+) (Life 
Technologies) using Lipofectamine 2000 (Life Technologies) according to manufacturer 
recommendations. Transfected 9L cells were supplemented with 600μg/ml zeocin (Life 
Technologies). Transfected U373MG and LN229 cells were supplemented with 2µg/ml of 
puromycin (Sigma). U87MG cells with PTEN expression were created by infection with retrovirus 
as described in Methods using PTEN cDNA (Dr. Frank Furnari, UCSD, La Jolla, CA, USA) 
subcloned into pBabe.hygro. 3691 GSC cells (Dr. Celeste Simon, University of Pennsylvania, 
Philadelphia, PA, USA) were maintained in neurobasal medium supplemented with B27 1:50 (Life 
Technologies), 20 ng/mL EGF (Sigma), and 20 ng/mL basic fibroblast growth factor. Sphere 
cross-sectional areas were analyzed using ImageJ and were used to calculate sphere volume. 
PDX, GSC, and NS cell lysates (Figure 4-S8) were provided by Dr. Frank Furnari (UCSD, La 
Jolla, CA, USA). H1666 lysates were prepared as described in Walsh et al. (Walsh and Lazzara, 
2013). 
Transient knockdown of SPRY2. For U87MG cells (Figure 4-S3B), cells were transfected 
with a smartpool of four SPRY2 siRNAs or a control siRNA (Thermo Scientific) using 
DharmaFECT1 transfection reagent (Thermo Scientific) according to the manufacturer’s 
recommendations. EGFRvIII-expressing U373MG, LN229, and 9L cells (Figure 4-S2B) were 
transfected with control or SPRY2-targeting siRNA using Lipofectamine RNAiMAX transfection 
reagent (Life Technologies) according to the manufacturer’s recommendations. The siRNA 
sequences used were: SPRY2 siRNA, 5' -CCUGUGGCUGAUGGCAUAA- 3' and control siRNA, 
5'- CCUUCGUGUAGACGUGUAA- 3'. 
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Rat tumor allografts and gene expression analysis. EGFRvIII-expressing 9L rat 
gliosarcoma cells (Sibenaller et al., 2005) were created by transfection with pcDNA3.1(+) (Life 
Technologies) with Lipofectamine 2000 (Life Technologies) according to the manufacturer’s 
recommendations and selected with 600 μg/ml zeocin (Life Technologies) for 2-3 weeks. 
Syngeneic female Fischer rats (4-6 weeks old, 120–150 g) bearing either 9L.empty vector (n = 6) 
or 9L.EGFRvIII (n = 6) tumors were used. General anesthesia was induced by intraperitoneal 
injection of a ketamine/acepromazine mixture at a dose of 91/9.1 mg/kg. A 10 μL suspension of 5 
× 10
4
 9L.empty vector or 9L.EGFRvIII cells in phosphate buffered saline was injected into the 
cortex at a depth of 2 mm using a stereotactic apparatus (3 mm lateral and 3 mm posterior to the 
bregma). Three weeks after orthotopic implantation, tumors were removed and stored at -80
o
C in 
RNALater (Life Technologies). RNA was extracted using the TriZol method and purified using the 
RNeasy kit (Qiagen). 100 ng of RNA was amplified into biotinylated cRNAs using the Illumina 
TotalPrep RNA amplification kit (Ambion) according to manufacturer recommendations. The 
labeled cRNAs were subjected to hybridization on RatRef-12 Expression BeadChip array 
(Illumina Inc.). Gene identities and expression intensities were determined using the Partek 
Genomic suite (Partek Incorporated). The raw data were subjected to quantile normalization. The 
protocol was approved by the Institutional Animal Care and Use Committee at the University of 
Pennsylvania. 
Human GBM samples. A retrospective analysis was conducted of 52 patients with 
primary GBMs (WHO grade IV), who had tissue harvested from standard image-guided surgical 
resections and banked between January 2002 and January 2009 at the Hospital of the University 
of Pennsylvania (HUP). There were no exclusion criteria. The protocol was approved by the 
Institutional Review Board at HUP, and informed consent from each participant or the 
participant’s guardian was obtained. An experienced neuropathologist performed the 
histopathologic evaluation, using the WHO classification criteria. Tumors were categorized on the 
basis of EGFRvIII expression using EGFRvIII-specific RT-PCR reactions (28). The 52 patients 
used in this study are a sub-set of the 132 patients studied by Tykocinski et al. (28). 13/52 (25%) 
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tumors were EGFRvIII-positive, and 39/52 (75%) tumors were EGFRvIII-negative. The median 
patient age was 63.1 years with EGFRvIII-positive tumors and 60 years with EGFRvIII-negative 
tumors. All personnel were blinded to all clinical data, including outcome.  
Human GBM gene expression analysis. HG-U133 2.0 Plus Affymetrix Gene Chips 
(Affymetrix Inc.) were used to profile primary human GBMs according to the manufacturer’s 
protocol. Briefly, ~1 μg of total RNA was converted to first-strand cDNA using Superscript II 
reverse transcriptase (Life Technologies) primed by a poly(T) oligomer that incorporated the T7 
promoter. Second-strand cDNA synthesis was followed by in vitro transcription to generate 
labeled cRNAs. The cRNAs were subjected to hybridization at 45
o
C for 16 hrs, followed by 
washing, staining, and scanning of the chip according to the manufacturer’s instructions. A 
confocal scanner was used to collect fluorescence signal at 3 μm resolution after excitation at 
570 nm. The average signal from two sequential scans was calculated for each microarray 
feature. Affymetrix Microarray Suite 5.0 was used to quantify expression levels for targeted 
genes. The raw data were subjected to quantile normalization. The default values provided by 
Affymetrix were applied to all analysis parameters. 
Preprocessing of TCGA exon-array data. The unprocessed Affymetrix exon-array 
datasets for 173 GBM core samples used by Verhaak et al. (Verhaak et al., 2010) and 10 normal 
brain control samples were downloaded from the TCGA data portal (https://tcga-
data.nci.nih.gov/tcga). The gene-level expression estimates were obtained by the Multi-Mapping 
Bayesian Gene eXpression (MMBGX) algorithm (Turro et al., 2010) for Affymetrix whole-
transcript arrays, based on Ensemble database (version 56). The estimated expression values 
were then normalized across the samples, using the locally weighted scatter plot smoothing 
(loess) algorithm (Workman et al., 2002).  
Analysis of TCGA RNA-seq data to identify EGFRvIII-positive samples. Level 3 GBM 
RNA-seq data that had been analyzed by the MapSpliceRSEM pipeline were downloaded from 
the TCGA data portal. The MapSplice genome alignment was used for overlap counting. The 
exon level quantifications were provided by normalized number of reads mapping to each exon 
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(RPKM). 161 RNA-seq samples were available for further analysis. For each tumor sample, the 
difference between mean RPKM of exon 2-7 and the other 22 exons were computed. In 
EGFRvIII-positive samples, exon 2-7 should have lower signal than other exons. The null 
empirical distribution of the signal difference between any 5 exons and the others was computed 
by randomly sampling the 28 exons of the 161 samples 3000 times. Samples with a low p-value 
are considered likely EGFRvIII-positive candidates. Using a p-value threshold of 0.05, 41 out of 
161 samples were considered EGFRvIII-positive.  
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Chapter 5: Conclusions and future directions 
5-1. Introduction 
With the introduction of targeted therapeutics for cancer treatment, it has become clear 
that in order to create successful drug interventions and identify the patients who could benefit 
from these drugs, the incredible complexity of cellular signaling needs to be taken into 
consideration. With this motivation in mind, the work presented here has attempted to uncover 
the function of two regulators of EGFR signaling and trafficking in the context of cancer cells 
where aberrant EGFR signaling frequently occurs. This work uncovers important roles for MIG6 
and SPRY2 in regulating EGFR trafficking in NSCLC, develops a framework for studying multiple 
EGFR endocytosis pathways with computational models, and points to a previously unknown and 
surprising role for SPRY2 in promoting GBM tumorigenesis. Given the complexity of the 
processes studied, it is perhaps not surprising that there remain several important questions 
related to this work that could be addressed in the future.  
 
5-2. Future work and interpretation related to SPRY2 and MIG6 function in NSCLC 
This investigation began by questioning the role of known EGFR feedback regulators in 
NSCLC cells with or without EGFR-activating mutations. It was unknown how MIG6 or SPRY2 
would control mutant EGFR trafficking and signaling. This question was of clinical importance 
because EGFR inhibitors have enhanced efficacy against EGFR mutants found in NSCLC, but 
little was known about the mechanisms underlying impaired internalization of mutant EGFR. We 
measured EGFR endocytosis rate constants in NSCLC cells expressing wild-type EGFR or a 
common EGFR mutant. We found that MIG6 and/or SPRY2 knockdown modulated the measured 
EGFR endocytosis rate constant in both cells lines, demonstrating that MIG6 and SPRY2 were 
able to regulate endocytosis of internalization impaired mutant EGFR. Indeed, reduction of MIG6 
expression reduced the measured EGFR endocytosis rate constant in cells expressing mutant 
EGFR even lower than controls. As a result of the complexity of signaling involved, there are 
 
 126 
several aspects of this experimental study that could be pursued further.  
For one, we found that SPRY2 depletion significantly reduced EGFR protein levels in 
most NSCLC cell lines tested, independent of EGFR mutational status. Additional experiments 
could be performed to understand how SPRY2 functions to control EGFR expression. While other 
groups have reported that SPRY2 expression modulates EGFR expression (Edwin and Patel, 
2008; Feng et al., 2010; Grassian et al., 2011), these studies did not examine SPRY2 function 
independent of EGFR expression changes or investigate the mechanism of EGFR expression 
regulation. In PC9 cells that express mutant EGFR, we observed that SPRY2 depletion reduced 
EGFR mRNA levels, an effect that is potentially linked to reduced ERK activity in those cells. It is 
known that ERK can directly phosphorylate EGFR and ERK-mediated phosphorylation of 
threonine 669 has been implicated in EGFR degradation. In a published study of CHO cells, 
expression of EGFR with threonine 669 mutated to alanine, resulted in rapid EGF-induced EGFR 
degradation compared to cells expressing wild-type EGFR (Li et al., 2008b). These results 
suggest that ERK could directly regulate EGFR expression in some settings, but do not propose 
any possible mechanisms of ERK-mediated EGFR transcriptional or post-transcriptional 
regulation. An investigation to determine what cell-context-dependent features dictate whether 
EGFR transcription is controlled by SPRY2 through ERK activity would be of interest to many 
researchers both in cancer biology and other fields where EGFR or SPRY2 have been shown to 
play important roles.  
While we found that SPRY2 depletion promoted cellular sensitivity to EGFR inhibition in 
NSCLC cells, MIG6 depletion had a more modest effect on drug response. This result was initially 
surprising, given that MIG6 is known to negatively regulate both EGFR tyrosine kinase activity 
and surface expression through internalization. Interestingly, another group recently published a 
study on MIG6 expression and response to EGFR inhibitors. These researchers found that MIG6 
expression correlated with resistance to EGFR inhibitors in several cancers that did not express 
the EGFR-activating mutations observed in lung cancer patients (Chang et al., 2013). While their 
study agrees with our work that MIG6 depletion does not affect cellular sensitivity to EGFR 
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inhibitors, they propose that MIG6 expression could be a useful marker for identifying patients 
most likely to benefit from anti-EGFR therapeutics. In a panel of cell lines from multiple cancer 
types, increased MIG6 expression was associated with resistance to EGFR inhibition. In our 
study, MIG6 expression had the opposite relationship to response to EGFR inhibition. Mutant 
EGFR-expressing cell lines had higher MIG6 expression and also demonstrated enhanced 
response to EGFR inhibitors compared to wild-type EGFR expressing cells. In fact, H1975 cells 
that express the secondary T790M “gatekeeper” mutation and are resistant to gefitinib treatment 
(Pao et al., 2005), had lower MIG6 expression than cells expressing L858R EGFR, suggesting 
that MIG6 expression correlates well with response. Overall, the use of MIG6 expression as a 
marker for response to EGFR inhibition is potentially complicated by the presence or absence of 
sensitizing EGFR mutations. To summarize, MIG6 expression may be associated with resistance 
to EGFR inhibition in cells expressing wild-type EGFR, but not in cells with mutant EGFR 
expression, where MIG6 expression is increased. 
 
5-3. Future work and interpretation related to predictions of the EGFR trafficking model 
Our study of EGFR endocytosis in NSCLC cells led naturally to computational analysis. 
Models of EGFR trafficking and signaling have been essential to the understanding of these 
processes. However, existing models of EGFR endocytosis were insufficient for our purposes and 
we required a new model to analyze our complex data set. One of the key results of the 
computational study presented in Chapter 3 was the finding that MIG6 is responsible for at least 
half of EGFR endocytosis in NSCLC cells, suggesting that a substantial fraction of internalized 
EGFR may not be competent to drive downstream signaling. Additionally, analysis suggested that 
MIG6-mediated internalization was impaired for mutant EGFR expressing cells compared to wild-
type EGFR expressing cells. The model results also pointed to the importance of differences in 
EGFR recycling for maintaining high levels of EGFR expression in mutant EGFR expressing 
cells. Besides the results presented, this work also generated some testable hypotheses that 
could be pursued in the future.  
 
 128 
We hypothesized that impaired MIG6 internalization capacity in cells with mutant EGFR 
expression could be the result of impaired MIG6 and EGFR association. MIG6 binding to EGFR 
could be measured with and without EGF addition by EGFR immunoprecipitation to compare the 
relative association between MIG6 and wild-type or mutant EGFR. This study would potentially be 
best undertaken in an isogenic background with exogenous wild-type and mutant EGFR are 
expressed to a similar level. Zhang and coworkers published in 2007 a crystal structure of a 25 
residue fragment of MIG6 bound to the distal surface of the C-lobe of the EGFR kinase domain 
(Zhang et al., 2007a). This study identified methionine 346, phenylalanine 352, and tyrosine 358 
as key residues of MIG6 required for this binding event as mutation of any of these residues 
decreased MIG6 and EGFR binding. This study suggests the possibility that phosphorylation of 
MIG6 at tyrosine 358 (or serine 337 and serine 361, which were also near the MIG6 and EGFR 
interface) could impair MIG6 binding to EGFR. Furthermore, Wang and coworkers demonstrated 
in 2011 that near full-length EGFR (residues 25-1022) was able to tyrosine phosphorylate a 77 
residue fragment of MIG6 containing the EGFR binding site in vitro (Wang et al., 2011). 
Therefore, it is possible that direct MIG6 phosphorylation by EGFR, which might be expected to 
be enhanced in cells expressing EGFR-activating mutations, could impair MIG6’s affinity for 
EGFR. To test whether enhanced MIG6 phosphorylation downstream of EGFR mutation inhibits 
MIG6’s ability to bind EGFR, MIG6 mutants could be expressed. Endogenous MIG6 could be 
depleted using shRNA and then shRNA-resistant MIG6 with candidate important phosphorylation 
sites mutated to alanine could be introduced followed by measurements of MIG6 binding to 
EGFR. 
As an alternative possibility to explain the reduction of MIG6 internalization capacity in 
cells expressing mutant EGFR, we hypothesized that MIG6 activity could be reduced due to 
phosphorylation in mutant EGFR expressing cells. If expression of MIG6 mutants as discussed 
above does not affect MIG6 binding to EGFR, but still results in increased mutant EGFR 
internalization, this would support an important role for that phosphorylation site in inhibiting 
MIG6-mediated EGFR endocytosis. Recent studies have suggested candidate MIG6 residues to 
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mutate in addition to those identified by Zhang et al. (Zhang et al., 2007a). Serine 302 and serine 
251 of MIG6 can be phosphorylated by the kinase Chk1 and may be involved in MIG6’s ability to 
inhibit EGFR activity (Liu et al., 2012). In addition, tyrosine 394 of MIG6 was identified using mass 
spectrometry as differentially phosphorylated in human bronchial epithelial cells expressing 
mutant EGFR compared to wild-type EGFR (Guha et al., 2008).  
In addition to the main findings described in Chapter 3, our modeling study also has 
implications for designing experiments to measure internalization rate constants. Local parameter 
sensitivity analysis revealed that the simulated EGFR ke was relatively sensitive to changes in 
parameters that determined recycling (krec and fr). This sensitivity to recycling parameters was 
greater for simulations with mutant EGFR than wild-type EGFR. Ideally, an experimental 
measurement of EGFR ke should be designed so that recycling and degradation do not affect the 
measurement. The measurement of EGFR ke using radiolabeled EGF was introduced in a 1981 
study by Wiley and Cunningham (Wiley and Cunningham, 1981). Using human fibroblasts and 1 
ng/mL 
125
I-EGF, they determined that EGFR ke could be measured with time points up to 15 min. 
Their study did not explicitly consider receptor recycling, but they noted that other cell lines tested 
had different "observational windows" for determining EGFR ke, suggesting that different cell 
types require different measurement times. Our model does not include endosomal retention 
components that delay the processes of recycling or degradation (French and Lauffenburger, 
1996), due to lack of data to constrain the unknown parameters related to these processes. 
Therefore, the simulated recycling and degradation processes affect the simulated EGFR ke at 
time points as early as 1-2 min after EGF addition, but the magnitude of the resulting effect on 
EGFR ke is more pronounced at late time points. Another consideration is that in cell lines with 
high EGFR expression, saturation of rapid internalization mechanisms also leads to time-
dependent EGFR ke measurements. The initial rate of internalization could be fast, but then 
decrease as early as 1-2 min because rapid internalization becomes limited. These details should 
be considered when designing experiments to measure EGFR endocytosis rates in the future. 
For cell lines with high EGFR expression or high receptor recycling, lower EGF concentrations 
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and shorter measurements could improve accuracy. 
More generally, our work on EGFR trafficking has implications beyond diseases involving 
EGFR signaling. Impaired receptor trafficking has emerged as a common theme in several 
cancers, including leukemia, breast cancer, lung cancer, and GBM (Abella and Park, 2009; 
Mosesson et al., 2008). Maintenance of polarity in epithelial cells and adhesion structures such 
as adherens junctions are regulated by endocytosis, recycling, and transcytosis. Loss of polarity 
and adhesion are thought to be crucial steps in metastasis, and therefore improper trafficking can 
contribute to metastasis (Ramsay et al., 2007). In addition, several regulators of endocytosis are 
downregulated or mutated in human cancers. For example, CBL missense mutations have been 
identified in leukemia (Sargin et al., 2007; Slape et al., 2008). Therefore, methods developed to 
study EGFR trafficking have implications beyond the EGFR system. 
 
5-4. Future work and interpretation related to study of SPRY2 in GBM 
Our findings on the role of SPRY2 in NSCLC cells led us to think about SPRY2 function 
in other cancers where EGFR mutations are common and SPRY2 function is poorly defined. 
Further motivation was provided to investigate GBM because there is a large unmet clinical need 
to develop novel treatments or advance existing treatments to improve patient outcomes. Our 
study is one of the first to investigate functional role of SPRY2 in GBM and significantly advances 
the knowledge of SPRY2 function in GBM. We demonstrated an important role for SPRY2 in 
promoting GBM proliferation, anchorage-independence, and resistance to RTK inhibitors. We 
also found that SPRY2 expression promotes proliferation of GBM cells in mouse tumor 
xenografts. We also presented evidence supporting the usefulness of SPRY2 as a therapeutic 
target or prognostic biomarker by examining SPRY2 mRNA expression and protein expression in 
human patient samples. All these studies provide a convincing argument that SPRY2 is important 
for GBM tumorigenesis and has potential therapeutic and prognostic significance. There are 
several directions that could be pursued to continue the work presented here. 
In addition to the study presented in Chapter 4, we also examined the effect of SPRY2 on 
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cellular adhesion and the observation that SPRY2 knockdown promoted non-adherent cell growth 
(Appendix 1). We found that SPRY2 depletion and EGFRvIII expression promoted a non-
adherent growth pattern in U87MG cells and that p38 and JNK signaling controlled this effect. 
This observation of non-adherent growth patterns is of interest because of its relationship to the 
study of so-called glioma stem cells (GSCs). it is known that primary GBM cells can be isolated 
and cultured in a non-adherent “neurosphere” system with serum-free media supplemented with 
EGF and fibroblast growth factor (FGF) (Tabatabai and Weller, 2011). These cells are referred to 
as GSCs or tumor-initiating cells because they express markers of neural stem cells, exhibit self-
renewal, and form tumors that better resemble GBM in animal models compared to traditional 
GBM cell lines. These GSCs grown as neurospheres are visually reminiscent of the non-adherent 
cell growth we observed in U87MG cells with SPRY2 depletion or high EGFRvIII expression. Our 
preliminary results using established GSC cells presented in Chapter 4 indicate that SPRY2 may 
function similarly in GSCs to the other traditional cell lines examined. Therefore, further 
investigation of the role of SPRY2 in GSC survival and development is merited. Additional studies 
could be undertaken to evaluate whether SPRY2 expression controls cellular markers of neural 
stem cells that are typically measured in GSCs. To date, our studies have focused on a relatively 
limited panel of proteins assayed by western blot, but in future studies, a broader “omics” 
approach would be advantageous to examine a large range of proteins or genes for changes in 
phosphorylation and expression. 
Another important consideration for future studies is the potential compensatory effect of 
other members of the sprouty family. SPRY1, SPRY2, and SPRY4 are expressed in all tissues 
(Minowada et al., 1999), while much less is known about the final sprouty family member, 
SPRY3. There appears to be some degree of redundancy in function of sprouty proteins, but they 
cannot fully compensate for the loss of a different sprouty family member. This is illustrated by the 
finding that while single Spry2 or Spry4 knockout mice are viable, Spry2/Spry4 double knockout 
mice are embryonic lethal (Taniguchi et al., 2007). Like SPRY2, SPRY1 and SPRY4 gene 
expression is increased in EGFRvIII-positive samples compared to EGFRvIII-negative samples in 
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TCGA GBM data set and high SPRY1 or SPRY4 expression are associated with reduced survival 
in patients (Appendix 2). Therefore, concurrent knockdown of SPRY1/SPRY2/SPRY4 could 
demonstrate a more potent effect than reduction of SPRY2 alone.  
Another area of future work that is suggested by our GBM study concerns the 
relationship between SPRY2 and EGFRvIII expression and how SPRY2 expression is driven in 
GBM. As described in Chapter 4, in the tumor setting, EGFRvIII expression could promote ERK 
signaling and therefore promote SPRY2 expression. To test this possibility, ERK phosphorylation 
could be examined by immunohistochemistry or western blotting in tumor samples with or without 
EGFRvIII-expression. Another possible explanation is that an alternate pathway is elevated in 
tumors expressing EGFRvIII and this pathway promotes SPRY2 expression in vivo. A promising 
candidate pathway is the Wnt/β-catenin pathway that plays critical roles in development, 
proliferation, and migration. In colon cancer cells, SPRY2 was identified as a target gene of the 
Wnt/β-catenin pathway and SPRY2 expression was induced by β-catenin through the 
transcription factor FOXO3a (Ordonez-Moran et al., 2013). There are also studies that suggest 
that Wnt signaling is dysregulated in GBM (Zhang et al., 2012). In TCGA GBM RNA-seq data, 
four Wnt genes (WNT10A, WNT16, WNT3, and WNT7A) were significantly upregulated (p < 0.05) 
in EGFRvIII-positive samples compared to EGFRvIII-negative samples. However, four other Wnt 
genes (WNT4, WNT5A, WNT7B, and WNT2) were also significantly decreased (p < 0.05) by the 
same comparison. To test whether SPRY2 expression is induced by β-catenin and FOXO3a in 
GBM cells, FOXO3a and stabilized β-catenin could be expressed in cells and resulting changes 
in SPRY2 expression could be measured. 
While we found that SPRY2 gene expression was elevated in tumors expressing 
EGFRvIII and this relationship was supported by further analysis of patient-derived xenograft 
samples and immunohistochemistry of human tumors, this relationship was not found in all cell 
lines tested. It should be noted that this result that data from ectopic EGFRvIII expression in GBM 
cells lines does not always agree with tumor findings implies (as has been suggested by others 
(Johnson et al., 2012; Tabatabai and Weller, 2011)) that traditional immortalized GBM cell lines 
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with ectopic EGFRvIII expression are poor models of GBM in patients. Therefore, other models, 
such as the GSC cultures discussed above may be more appropriate models for any ongoing 
studies.  
A final consideration that arises from the identification of SPRY2 as a potential 
therapeutic target is how to develop strategies to interrupt SPRY2 function. Because SPRY2 has 
no catalytic activity, a molecule that binds and prevents the binding of key interacting partners 
would be necessary. There is precedent for this type of inhibitor. For example, researchers have 
designed small molecule inhibitors to block interactions essential for adaptor protein function such 
as inhibitors of the SH2 domain of GRB2 (Gay et al., 1999). To pursue SPRY2 inhibitors, it will 
first be important to determine what molecular interactions are of the greatest importance for the 
pro-oncogenic properties of SPRY2 and whether systemic inhibition of SPRY2 would lead to side 
effects outside the brain. As discussed previously, if SPRY1 and SPRY4 act similarly in GBM, this 
could provide clues as to what conserved domains of these sprouty proteins are essential for their 
pro-tumor properties. Of course, an alternative strategy would be a different therapeutic platform, 
such as RNAi-based treatment, or inhibition of a key SPRY2-interacting partner or a different 
protein in the key pathway controlled by SPRY2. 
 
5-5. Main conclusions 
Overall, the work presented in this thesis contributes significantly to the knowledge of 
EGFR function in the context of two deadly cancers where EGFR mutation is common. We 
focused on two protein regulators of EGFR trafficking and downstream signaling that we 
hypothesized could be differentially important in the context of cells expressing mutant EGFR. 
First, we quantified the effects of MIG6 and SPRY2 knockdown on EGFR trafficking and signaling 
in NSCLC cells to better understand differences between wild-type EGFR and clinically relevant 
EGFR mutants. Second, we developed a novel model of EGFR trafficking to develop testable 
hypotheses about mutant EGFR trafficking based on independent pathways of endocytosis. 
Third, we identified SPRY2 as an important regulator of GBM that is potentially upregulated in the 
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context of an EGFR mutation common in GBM. While SPRY2 may function as a tumor 
suppressor in other cancers, we found that SPRY2 promoted proliferation, anchorage-
independent growth, resistance to EGFR and c-MET co-inhibition in GBM cells, and proliferation 
as mouse tumor xenografts. As a whole, this work supplements the understanding of the 
incredibly complex signaling regulatory network in cancer, underscoring the diversity of cellular 
signaling in different tumor settings and the need to develop novel targeted treatment strategies. 
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Appendix 1: Changes in cell adhesion in U87MG cells with SPRY2 depletion 
A1-1. Results 
SPRY2 depletion promotes non-adherent cell growth and decreases cell spreading. To 
determine the effect of decreased SPRY2 expression, SPRY2 was depleted by stable expression 
of SPRY2-targeting shRNA in U87MG cells (Figure 4-S1A). It was observed that SPRY2 
depletion caused morphological changes to cells in culture (Figure A1-1). While U87MG cells with 
dead kinase EGFRvIII expression (U87MG-DK) typically formed adherent monolayers, SPRY2 
depletion caused the cells to prefer cell-cell contacts and form spheres that could become 
detached from the surface and continue to proliferate in suspension. This effect was also 
observed with SPRY2 depletion in SF188 cells that express wild-type EGFR. The non-adherent 
proliferation of cells with SPRY2 depletion was similar to the growth observed in U87MG cells 
with high expression levels of EGFRvIII (U87MG-H). Cells with SPRY2 knockdown had a smaller 
spread area (Figure A1-1B) and spread less quickly (Figure A1-1C) than controls. Although U87-
H cells had reduced SPRY2 expression compared to U87MG-DK, U87MG-H cells did not have 
reduced cell spreading or cell area similarly to U87MG-DK cells with SPRY2 knockdown. As 
determined by phalloidin staining, F-actin organization was also disrupted in cells expressing 
SPRY2-targeting shRNA compared to controls (Figure A1-1D). Phalloidin staining indicated that 
the F-actin organization could be impaired somewhat in U87MG-H cells compared to control 
U87MG-DK cells.  
p38 and JNK inhibition control cell area. Treatment with the p38 inhibitor, SB203580, and 
the JNK inhibitor, SP600125, suggested that elevated JNK phosphorylation was responsible for 
the changes in cell area due to SPRY2 depletion in U87MG cells. JNK inhibition resulted in large 
actin stress fibers and strong phosphorylated paxillin staining at the cell periphery in 
immunofluorescence images of U87MG-DK cells (Figure A1-2A). p38 inhibition reduced actin 
organization and focal adhesion size. Consistent with this, JNK inhibition partially rescued the 
decreased cell area in SPRY2 knockdown cells compared to controls. (Figure A1-2B). Co-
treatment with both inhibitors averaged their contrasting effects.  
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p38 and JNK inhibition prevent formation of non-adherent cellular aggregates. We tested 
whether p38 or JNK inhibition affected the formation of cellular aggregates that proliferated as 
floating, non-adherent spheres of cells. Cells were plated as single cells in the presence of DMSO 
control, the p38 inhibitor, SB203580, or the JNK inhibitor, SP600125. Non-adherent spheres of 
cells formed in DMSO-treated wells for both U87MG-DK cells with SPRY2 knockdown and 
U87MG-H cells (Figure A1-3A). No non-adherent cells were observed with JNK inhibition, but 
proliferation was greatly reduced (in agreement with the findings in Chapter 4), and therefore it is 
possible that there were not enough cells to form spheres. However, p38 inhibition, while having 
no effect on proliferation, prevented the formation of non-adherent cell spheres. Cells appeared to 
be growing very densely or even on top on one another, but remained attached to the substrate. 
When the large multi-cellular spheres formed by U87MG-DK cells with SPRY2 knockdown were 
re-plated in the presence of p38 or JNK inhibitors, the cells continued to proliferate and grow to 
be very large spheres of cells (Figure A1-3B). Interestingly, cell spheres cultured in the presence 
of the JNK inhibitor re-attached and began growing out onto the substrate. Taken together, these 
results suggest that p38 activity promotes signaling that allows cells to proliferate in suspension. 
Adherent and non-adherent cell populations have different patterns of signaling protein 
phosphorylation. To test whether any important signaling pathways were altered between the 
cells growing attached to the substrate and those growing in non-adherent spheres, we lysed 
floating and adherent U87MG cells separately to analyze by western blotting (Figure A1-4). There 
were no floating cells for U87MG-DK cells and so only adherent cells were analyzed. There were 
decreases in focal adhesion kinase (FAK) phosphorylation in floating cells compared to adherent 
cells as would be expected for cells not forming focal adhesions. Interestingly, c-MET, ERK, and 
JNK phosphorylation were also decreased in floating cells compared to adherent cells. In 
agreement with generally opposing roles for p38 and JNK, p38 phosphorylation was significantly 
increased in floating cells compared to adherent cells. 
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A1-2. Materials and Methods 
Cell culture. U87MG cells with three different levels of EGFRvIII expression or expression 
of a kinase dead EGFRvIII were described previously (Huang et al., 2007) (Dr. Frank Furnari, 
UCSD, La Jolla, CA, USA). SF188 cells were a gift from Dr. Celeste Simon (University of 
Pennsylvania, Philadelphia, PA, USA). All cells were maintained in DMEM supplemented with 
10% fetal bovine serum, 1 mM L-Glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin 
(Life Technologies). SB203580, SP600125 (both from LC Laboratories) were reconstituted in 
DMSO and added to cells in complete media.  
Knockdown of SPRY2. Oligonucleotides encoding hairpins targeting nucleotides 2061-
2079 of human SPRY2 were purchased from IDT and cloned into pSicoR.puro (Dr. Tyler Jacks, 
MIT Koch Institute for Integrative Cancer Research, Cambridge, MA, USA; (Ventura et al., 2004)). 
A control shRNA was created using a hairpin that does not target a known human mRNA. 
Lentivirus was produced by calcium-phosphate-mediated transfection of 293FT cells (Life 
Technologies) with pSicoR.puro, pCMV-VSVg, pMDL-gp-RRE, and pRSV-Rev plasmids (Dr. 
Marilyn Farquhar, UCSD, La Jolla, CA, USA). Virus-containing supernatant was passed through 
0.45 μm syringe filters prior to addition to target cells, and target cells were selected in 1-2 μg/mL 
puromycin (Sigma). 
Western blotting. Whole cell lysates were prepared in a standard cell extraction buffer 
(Life Technologies) supplemented with protease and phosphatase inhibitors (Sigma). Total 
protein concentrations were determined by micro-bicinchoninic assay (Thermo Scientific). 
Lysates were loaded on 4-12% gradient polyacrylamide gels (Life Technologies) under 
denaturing and reducing conditions and transferred to 0.2 μm nitrocellulose membranes (Bio-
Rad). Membranes were imaged on a LI-COR Odyssey scanner (LI-COR) and stripped with 0.2 M 
NaOH as needed. 
Antibodies. Antibodies against p-paxillin (#2541), p-p38 (#4631), p-JNK (#4671), p-FAK 
(#3283), p-MET (#3126), ERK (#4695), and p-ERK T202/Y204 (#4377) were purchased from Cell 
Signaling Technology. Infrared dye-conjugated secondary antibodies were purchased from 
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Rockland Immunochemicals (Gilbertsville, PA, USA). The anti-rabbit Alexa-Fluor 488 secondary 
antibody for immunofluorescence was purchased from Life Technologies. All antibodies were 
used according to manufacturer recommendations. 
Cell spreading assay and cell area measurements. Cells were imaged 45 min after 
plating on tissue culture plastic in complete media. For inhibitor treatments, cells were pre-treated 
with inhibitors for 24 hrs prior to plating and maintained in inhibitors. The fraction of cells that 
were spread versus rounded was quantified. Cells were imaged again 16 hrs after plating and 
individual cell areas were determined using ImageJ software (NIH). 100 or more cells were 
measured per experiment. 
Immunofluorescence. Cells were plated on glass coverslips and cultured overnight in 
complete growth media with or without inhibitors. Immunofluorescence staining was performed as 
described previously (Furcht et al., 2012). Hoechst (Life Technologies) and phalloidin-Alexa488 
(Life Technologies) were used according to manufacturer recommendations. Cells were washed 
with PBS and fixed for 20 min in 4% paraformaldehyde in PBS and then permeabilized for 5 min 
with 0.25% Triton X-100 (Sigma) in PBS. Coverslips were incubated with primary antibodies for 3 
hrs at 37°C. After washing in 0.1% Tween-20 (Bio-Rad) in PBS, coverslips were incubated with 
secondary antibodies, Hoechst (Life Technologies), and phalloidin-Alexa488 (Life Technologies) 
for 1 hr at 37°C. After washing again, coverslips were mounted onto glass slides with Prolong 
Gold antifade (Life Technologies). Images were obtained with a Zeiss Axiovert 40 CFL 
microscope and 100x objective. 
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A1-3. Figures 
 
Figure A1-1. Cellular morphological changes resulting from SPRY2 knockdown. 
(A) Phase contrast images of U87MG cells with expression of dead kinase (“DK”) EGFRvIII or 
high expression of EGFRvIII and SF188 cells with control shRNA or SPRY2-targeting shRNA. (B) 
16 hrs after plating, areas of individual cells were quantified for U87MG cells with DK or high 
EGFRvIII expression and control shRNA or SPRY2-targeting shRNA. (C) Cell spreading at 20 
min was measured for U87MG cells with DK or high EGFRvIII expression and control shRNA or 
SPRY2-targeting shRNA. (D) Immunofluorescence images of U87MG cells with DK or high 
EGFRvIII expression and control shRNA or SPRY2-targeting shRNA. Cells were stained with 
Hoechst to visualize the nucleus (blue) and phalloidin-Alexa488 to visualize F-actin (green). 
Throughout the panels, data are represented as the average of three independent experiments ± 
s.e.m., and asterisks indicate p < 0.05. Images are representative of multiple cells and 
experiments. 
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Figure A1-2. Effect of p38 and JNK inhibition on cellular morphology and cell spreading. 
(A) Immunofluorescence images of U87MG cells expressing dead kinase (“DK”) EGFRvIII treated 
with DMSO, 20 μM SB203580 (“p38i”), or 20 μM SP600125 (“JNKi”). Cells were stained with 
Hoechst to visualize the nucleus (blue), phalloidin-Alexa488 to visualize F-actin (green), and an 
antibody against phosphorylated paxillin (“p-paxillin”, red). Images are representative of multiple 
cells. (B) Cell area was quantified in U87MG cells expressing DK EGFRvIII and control shRNA or 
SPRY2-targeting shRNA were treated with DMSO, 20 μM p38i, 20 μM JNKi, or both 20 μM p38i 
and 20 μM JNKi. Data are represented as the average of three independent experiments ± 
s.e.m., and asterisks indicate p < 0.05. 
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Figure A1-3. Effect of p38 and JNK inhibition on non-adherent cell culture. 
(A) U87MG cells with expression of dead kinase (“DK”) EGFRvIII or high expression of EGFRvIII 
with control shRNA or SPRY2-targeting shRNA were plated as single cells in the presence of 
DMSO, 20 μM SB203580 (“p38i”), or 20 μM SP600125 (“JNKi”). (B) U87MG cells with expression 
of DK EGFRvIII and SPRY2-targeting shRNA were cultured to form spheres and then spheres 
were re-plated in the presence of DMSO, 20 μM p38i, or 20 μM JNKi. Images are representative 
of multiple experiments. 
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Figure A1-4. Differential phosphorylation of signaling proteins in adherent and non-
adherent cell populations. 
(A) Whole cell lysates of U87MG cells with dead kinase (“DK”), low (“L”), medium (“M”), or high 
(“H”) EGFRvIII expression were probed by western blot using antibodies against the indicated 
proteins. Floating non-adherent cells were lysed separately from adherent cells. (B) Western blots 
were analyzed by densitometry. Data are represented as the average of three independent 
experiments ± s.e.m., and asterisks indicate p < 0.05. 
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Appendix 2: SPRY1 and SPRY4 expression and patient survival in GBM 
 
The TCGA GBM data set was analyzed as in Chapter 4 for changes in expression of 
other members of the sprouty family. As shown in Figure A2-1, both SPRY1 and SPRY4 
expression were elevated in GBM samples with EGFRvIII expression, similarly to what was found 
for SPRY2. When differences in patient survival were examined, high expression of SPRY4 
resulted in reduced patient survival (p = 0.00955) with a median survival time of 406 days for high 
SPRY4 expression and 434 days for low SPRY4 expression. High SPRY1 expression also 
resulted in reduced patient survival, but with a borderline significant p-value of 0.0529. The 
methods used for this study are described in section 4-3, Materials and Methods. 
 
Figure A2-1. SPRY1 and SPRY4 expression in EGFRvIII-positive samples and effect on 
patient survival. 
(A) SPRY1 and SPRY4 expression (log base 10 transformed RPKM) are higher for EGFRvIII-
positive RNA-seq samples (n = 41) than EGFRvIII-negative RNA-seq samples (n = 120) (p = 
3.64×10
-7
 with a fold change of 1.54 for SPRY1 and p = 2.96×10
-8
 and fold change of 1.69 for 
SPRY4). (B) Survival probability is shown as a function of time after diagnosis for patients 
classified by SPRY1 or SPRY4 expression, with the median SPRY1 or SPRY4 expression used 
as a cutoff (p = 0.0529 for SPRY1 and p = 0.00955 for SPRY4).  
 
 144 
BIBLIOGRAPHY 
Abella, J. V., and Park, M. (2009). Breakdown of endocytosis in the oncogenic activation of 
receptor tyrosine kinases. Am J Physiol-Endoc M 296, E973-E984. 
Adjei, A. A., Cohen, R. B., Franklin, W., Morris, C., Wilson, D., Molina, J. R., Hanson, L. J., Gore, 
L., Chow, L., Leong, S., et al. (2008). Phase I pharmacokinetic and pharmacodynamic study of 
the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-
142886) in patients with advanced cancers. J Clin Oncol 26, 2139-2146. 
Aldape, K. D., Ballman, K., Furth, A., Buckner, J. C., Giannini, C., Burger, P. C., Scheithauer, B. 
W., Jenkins, R. B., and James, C. D. (2004). Immunohistochemical detection of EGFRvIII in high 
malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp 
Neurol 63, 700-707. 
Amann, J., Kalyankrishna, S., Massion, P. P., Ohm, J. E., Girard, L., Shigematsu, H., Peyton, M., 
Juroske, D., Huang, Y., Stuart Salmon, J., et al. (2005). Aberrant epidermal growth factor 
receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65, 
226-235. 
Anastasi, S., Fiorentino, L., Fiorini, M., Fraioli, R., Sala, G., Castellani, L., Alema, S., Alimandi, 
M., and Segatto, O. (2003). Feedback inhibition by RALT controls signal output by the ErbB 
network. Oncogene 22, 4221-4234. 
Anastasi, S., Sala, G., Chen, H. P., Caprini, E., Russo, G., Iacovelli, S., Lucini, F., Ingvarsson, S., 
and Segatto, O. (2005). Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas 
enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 24, 4540-
4548. 
Arora, A., and Scholar, E. M. (2005). Role of tyrosine kinase inhibitors in cancer therapy. J 
Pharmacol Exp Ther 315, 971-979. 
Avraham, R., and Yarden, Y. (2011). Feedback regulation of EGFR signalling: decision making 
by early and delayed loops. Nat Rev Mol Cell Biol 12, 104-117. 
Barbachano, A., Ordonez-Moran, P., Garcia, J. M., Sanchez, A., Pereira, F., Larriba, M. J., 
Martinez, N., Hernandez, J., Landolfi, S., Bonilla, F., et al. (2010). SPROUTY-2 and E-cadherin 
regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene 29, 4800-4813. 
Berkers, J. A., van Bergen en Henegouwen, P. M., and Boonstra, J. (1991). Three classes of 
epidermal growth factor receptors on HeLa cells. J Biol Chem 266, 922-927. 
Berset, T. A., Hoier, E. F., and Hajnal, A. (2005). The C. elegans homolog of the mammalian 
tumor suppressor Dep-1/Scc1 inhibits EGFR signaling to regulate binary cell fate decisions. 
Genes Dev 19, 1328-1340. 
Bianco, R., Gelardi, T., Damiano, V., Ciardiello, F., and Tortora, G. (2007). Rational bases for the 
development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 39, 1416-1431. 
Birtwistle, M. R., and Kholodenko, B. N. (2009). Endocytosis and signalling: a meeting with 
mathematics. Mol Oncol 3, 308-320. 
Bonavia, R., Inda, M. M., Cavenee, W. K., and Furnari, F. B. (2011). Heterogeneity maintenance 
 
 145 
in glioblastoma: a social network. Cancer Res 71, 4055-4060. 
Brandman, O., Ferrell, J. E., Jr., Li, R., and Meyer, T. (2005). Interlinked fast and slow positive 
feedback loops drive reliable cell decisions. Science 310, 496-498. 
Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K., Herrmann, R., 
Seymour, J. F., Arthur, C., et al. (2003). Detection of BCR-ABL mutations in patients with CML 
treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the 
ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276-283. 
Bredel, M., Bredel, C., Juric, D., Harsh, G. R., Vogel, H., Recht, L. D., and Sikic, B. I. (2005). 
Functional network analysis reveals extended gliomagenesis pathway maps and three novel 
MYC-interacting genes in human gliomas. Cancer Res 65, 8679-8689. 
Carey, K. D., Garton, A. J., Romero, M. S., Kahler, J., Thomson, S., Ross, S., Park, F., Haley, J. 
D., Gibson, N., and Sliwkowski, M. X. (2006). Kinetic analysis of epidermal growth factor receptor 
somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor 
tyrosine kinase inhibitor, erlotinib. Cancer Res 66, 8163-8171. 
Castoldi, R., Ecker, V., Wiehle, L., Majety, M., Busl-Schuller, R., Asmussen, M., Nopora, A., 
Jucknischke, U., Osl, F., Kobold, S., et al. (2013). A novel bispecific EGFR/Met antibody blocks 
tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent 
antitumor activity. Oncogene 32, 5593-5601. 
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., 
Majumder, P. K., Baselga, J., and Rosen, N. (2011). AKT inhibition relieves feedback 
suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71. 
Chandramouli, S., Yu, C. Y., Yusoff, P., Lao, D. H., Leong, H. F., Mizuno, K., and Guy, G. R. 
(2008). Tesk1 interacts with Spry2 to abrogate its inhibition of ERK phosphorylation downstream 
of receptor tyrosine kinase signaling. J Biol Chem 283, 1679-1691. 
Chang, X., Izumchenko, E., Solis, L. M., Kim, M. S., Chatterjee, A., Ling, S., Monitto, C. L., 
Harari, P. M., Hidalgo, M., Goodman, S. N., et al. (2013). The Relative Expression of Mig6 and 
EGFR Is Associated with Resistance to EGFR Kinase Inhibitors. PLoS One 8, e68966. 
Chung, B. M., Raja, S. M., Clubb, R. J., Tu, C., George, M., Band, V., and Band, H. (2009). 
Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling 
pathway promotes interaction with Src. BMC Cell Biol 10, 84. 
Claes, A., Idema, A. J., and Wesseling, P. (2007). Diffuse glioma growth: a guerilla war. Acta 
Neuropathologica 114, 443-458. 
Damke, H., Baba, T., Warnock, D. E., and Schmid, S. L. (1994). Induction of Mutant Dynamin 
Specifically Blocks Endocytic Coated Vesicle Formation. J Cell Biol 127, 915-934. 
De Witt Hamer, P. C. (2010). Small molecule kinase inhibitors in glioblastoma: a systematic 
review of clinical studies. Neuro Oncol 12, 304-316. 
Dougherty, M. K., Muller, J., Ritt, D. A., Zhou, M., Zhou, X. Z., Copeland, T. D., Conrads, T. P., 
Veenstra, T. D., Lu, K. P., and Morrison, D. K. (2005). Regulation of raf-1 by direct feedback 
phosphorylation. Mol Cell 17, 215-224. 
Douville, E., and Downward, J. (1997). EGF induced SOS phosphorylation in PC12 cells involves 
 
 146 
P90 RSK-2. Oncogene 15, 373-383. 
Dutta, P. R., and Maity, A. (2007). Cellular responses to EGFR inhibitors and their relevance to 
cancer therapy. Cancer Lett 254, 165-177. 
Eblaghie, M. C., Lunn, J. S., Dickinson, R. J., Munsterberg, A. E., Sanz-Ezquerro, J. J., Farrell, E. 
R., Mathers, J., Keyse, S. M., Storey, K., and Tickle, C. (2003). Negative feedback regulation of 
FGF signaling levels by Pyst1/MKP3 in chick embryos. Current Biology 13, 1009-1018. 
Ebner, R., and Derynck, R. (1991). Epidermal Growth-Factor and Transforming Growth Factor-
Alpha - Differential Intracellular Routing and Processing of Ligand-Receptor Complexes. Cell 
Regul 2, 599-612. 
Edwin, F., Anderson, K., Ying, C., and Patel, T. B. (2009). Intermolecular interactions of Sprouty 
proteins and their implications in development and disease. Mol Pharmacol 76, 679-691. 
Edwin, F., and Patel, T. B. (2008). A novel role of Sprouty 2 in regulating cellular apoptosis. J Biol 
Chem 283, 3181-3190. 
Edwin, F., Singh, R., Endersby, R., Baker, S. J., and Patel, T. B. (2006). The tumor suppressor 
PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem 281, 
4816-4822. 
Egan, J. E., Hall, A. B., Yatsula, B. A., and Bar-Sagi, D. (2002). The bimodal regulation of 
epidermal growth factor signaling by human Sprouty proteins. Proc Natl Acad Sci U S A 99, 6041-
6046. 
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., 
Gale, C. M., Zhao, X., Christensen, J., et al. (2007). MET amplification leads to gefitinib 
resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043. 
Ercan, D., Xu, C., Yanagita, M., Monast, C. S., Pratilas, C. A., Montero, J., Butaney, M., 
Shimamura, T., Sholl, L., Ivanova, E. V., et al. (2012). Reactivation of ERK signaling causes 
resistance to EGFR kinase inhibitors. Cancer Discov 2, 934-947. 
Felder, S., LaVin, J., Ullrich, A., and Schlessinger, J. (1992). Kinetics of binding, endocytosis, and 
recycling of EGF receptor mutants. J Cell Biol 117, 203-212. 
Feng, Y. H., Tsao, C. J., Wu, C. L., Chang, J. G., Lu, P. J., Yeh, K. T., Shieh, G. S., Shiau, A. L., 
and Lee, J. C. (2010). Sprouty2 protein enhances the response to gefitinib through epidermal 
growth factor receptor in colon cancer cells. Cancer Sci 101, 2033-2038. 
Ferby, I., Reschke, M., Kudlacek, O., Knyazev, P., Pante, G., Amann, K., Sommergruber, W., 
Kraut, N., Ullrich, A., Fassler, R., and Klein, R. (2006). Mig6 is a negative regulator of EGF 
receptor-mediated skin morphogenesis and tumor formation (vol 12, pg 568, 2006). Nat Med 12, 
862-862. 
Ferguson, S. M., and De Camilli, P. (2012). Dynamin, a membrane-remodelling GTPase. Nat Rev 
Mol Cell Biol 13, 75-88. 
Ferrara, N., and Kerbel, R. S. (2005). Angiogenesis as a therapeutic target. Nature 438, 967-974. 
Fiorentino, L., Pertica, C., Fiorini, M., Talora, C., Crescenzi, M., Castellani, L., Alema, S., 
Benedetti, P., and Segatto, O. (2000). Inhibition of ErbB-2 mitogenic and transforming activity by 
 
 147 
RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell 
Biol 20, 7735-7750. 
Fiorini, M., Ballaro, C., Sala, G., Falcone, G., Alema, S., and Segatto, O. (2002). Expression of 
RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and 
post-translational control. Oncogene 21, 6530-6539. 
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., 
Lee, R. J., Grippo, J. F., Nolop, K., and Chapman, P. B. (2010). Inhibition of mutated, activated 
BRAF in metastatic melanoma. N Engl J Med 363, 809-819. 
Fong, C. W., Chua, M. S., McKie, A. B., Ling, S. H., Mason, V., Li, R., Yusoff, P., Lo, T. L., Leung, 
H. Y., So, S. K., and Guy, G. R. (2006a). Sprouty 2, an inhibitor of mitogen-activated protein 
kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 66, 2048-2058. 
Fong, C. W., Chua, M. S., McKie, A. B., Ling, S. H. M., Mason, L., Li, R., Yusoff, P., Lo, T. L., 
Leung, H. Y., So, S. K. S., and Guy, G. R. (2006b). Sprouty 2, an inhibitor of mitogen-activated 
protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 66, 2048-
2058. 
Frederick, L., Wang, X. Y., Eley, G., and James, C. D. (2000). Diversity and frequency of 
epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60, 1383-1387. 
French, A. R., and Lauffenburger, D. A. (1996). Intracellular receptor/ligand sorting based on 
endosomal retention components. Biotechnol Bioeng 51, 281-297. 
French, A. R., Sudlow, G. P., Wiley, H. S., and Lauffenburger, D. A. (1994). Postendocytic 
trafficking of epidermal growth factor-receptor complexes is mediated through saturable and 
specific endosomal interactions. J Biol Chem 269, 15749-15755. 
French, A. R., Tadaki, D. K., Niyogi, S. K., and Lauffenburger, D. A. (1995). Intracellular 
trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of 
the receptor/ligand interaction. J Biol Chem 270, 4334-4340. 
Frosi, Y., Anastasi, S., Ballaro, C., Varsano, G., Castellani, L., Maspero, E., Polo, S., Alema, S., 
and Segatto, O. (2010). A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase 
suppression and receptor degradation. J Cell Biol 189, 557-571. 
Furcht, C. M., Rojas, A. R. M., Nihalani, D., and Lazzara, M. J. (2012). Diminished functional role 
and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating 
mutations. Oncogene 32, 2346-2355. 
Furcht, C.M., Buonato, J. M., Skuli, N., Matthew, L.K., Rojas, A.R.M., Simon, M.C., and Lazzara, 
M.J. (In press). Multivariate Signaling Regulation by SHP2 Differentially Controls Proliferation and 
Therapeutic Response in Glioma Cells. J Cell Sci. 
Gay, B., Suarez, S., Weber, C., Rahuel, J., Fabbro, D., Furet, P., Caravatti, G., and Schoepfer, J. 
(1999). Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility. J Biol 
Chem 274, 23311-23315. 
Gex-Fabry, M., and DeLisi, C. (1984). Receptor-mediated endocytosis: a model and its 
implications for experimental analysis. Am J Physiol 247, R768-779. 
Grassian, A. R., Schafer, Z. T., and Brugge, J. S. (2011). ErbB2 stabilizes epidermal growth 
 
 148 
factor receptor (EGFR) expression via Erk and Sprouty2 in extracellular matrix-detached cells. J 
Biol Chem 286, 79-90. 
Greulich, H., Chen, T. H., Feng, W., Janne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., 
Frank, D. A., Hahn, W. C., Sellers, W. R., and Meyerson, M. (2005). Oncogenic transformation by 
inhibitor-sensitive and -resistant EGFR mutants. Plos Medicine 2, 1167-1176. 
Gross, I., Bassit, B., Benezra, M., and Licht, J. D. (2001). Mammalian sprouty proteins inhibit cell 
growth and differentiation by preventing ras activation. J Biol Chem 276, 46460-46468. 
Guha, U., Chaerkady, R., Marimuthu, A., Patterson, A. S., Kashyap, M. K., Harsha, H. C., Sato, 
M., Bader, J. S., Lash, A. E., Minna, J. D., et al. (2008). Comparisons of tyrosine phosphorylated 
proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci 
U S A 105, 14112-14117. 
Guo, A., Villen, J., Kornhauser, J., Lee, K. A., Stokes, M. P., Rikova, K., Possemato, A., Nardone, 
J., Innocenti, G., Wetzel, R., et al. (2008). Signaling networks assembled by oncogenic EGFR 
and c-Met. Proc Natl Acad Sci U S A 105, 692-697. 
Hackel, P. O., Gishizky, M., and Ullrich, A. (2001). Mig-6 is a negative regulator of the epidermal 
growth factor receptor signal. Biol Chem 382, 1649-1662. 
Hacohen, N., Kramer, S., Sutherland, D., Hiromi, Y., and Krasnow, M. A. (1998). sprouty encodes 
a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 
92, 253-263. 
Haglund, K., Schmidt, M. H., Wong, E. S., Guy, G. R., and Dikic, I. (2005). Sprouty2 acts at the 
Cbl/CIN85 interface to inhibit epidermal growth factor receptor downregulation. EMBO Rep 6, 
635-641. 
Haj, F. G., Verveer, P. J., Squire, A., Neel, B. G., and Bastiaens, P. I. (2002). Imaging sites of 
receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science 295, 
1708-1711. 
Hanafusa, H., Torii, S., Yasunaga, T., Matsumoto, K., and Nishida, E. (2004). Shp2, an SH2-
containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling 
by dephosphorylating and inactivating the inhibitor Sprouty. J Biol Chem 279, 22992-22995. 
Hanafusa, H., Torii, S., Yasunaga, T., and Nishida, E. (2002). Sprouty1 and Sprouty2 provide a 
control mechanism for the Ras/MAPK signalling pathway. Nat Cell Biol 4, 850-858. 
Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 
646-674. 
Haugh, J. M. (2002). Localization of receptor-mediated signal transduction pathways: the inside 
story. Mol Interv 2, 292-307. 
Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., 
Eisenberg, P. D., Selaru, P., Wilner, K. D., and Gadgeel, S. M. (2010). A phase II study of PD-
0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung 
cancer. Clin Cancer Res 16, 2450-2457. 
Hendriks, B. S., Griffiths, G. J., Benson, R., Kenyon, D., Lazzara, M., Swinton, J., Beck, S., 
Hickinson, M., Beusmans, J. M., Lauffenburger, D., and de Graaf, D. (2006). Decreased 
 
 149 
internalisation of ErbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity 
to gefitinib. Iee P Syst Biol 153, 457-466. 
Hendriks, B. S., Wiley, H. S., and Lauffenburger, D. (2003). HER2-mediated effects on EGFR 
endosomal sorting: analysis of biophysical mechanisms. Biophys J 85, 2732-2745. 
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Jr., Di Maria, M. V., Veve, R., Bremmes, R. M., 
Baron, A. E., Zeng, C., and Franklin, W. A. (2003). Epidermal growth factor receptor in non-small-
cell lung carcinomas: correlation between gene copy number and protein expression and impact 
on prognosis. J Clin Oncol 21, 3798-3807. 
Holgren, C., Dougherty, U., Edwin, F., Cerasi, D., Taylor, I., Fichera, A., Joseph, L., Bissonnette, 
M., and Khare, S. (2010). Sprouty-2 controls c-Met expression and metastatic potential of colon 
cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene 29, 
5241-5253. 
Hopkins, S., Linderoth, E., Hantschel, O., Suarez-Henriques, P., Pilia, G., Kendrick, H., Smalley, 
M. J., Superti-Furga, G., and Ferby, I. (2012). Mig6 is a sensor of EGF receptor inactivation that 
directly activates c-Abl to induce apoptosis during epithelial homeostasis. Dev Cell 23, 547-559. 
Hsieh, M. Y., Yang, S., Raymond-Stinz, M. A., Edwards, J. S., and Wilson, B. S. (2010). Spatio-
temporal modeling of signaling protein recruitment to EGFR. BMC Syst Biol 4, 57. 
Huang, H. J. S., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X. D., Huang, C. M., Gill, 
G. N., Wiley, H. S., and Cavenee, W. K. (1997). The enhanced tumorigenic activity of a mutant 
epidermal growth factor receptor common in human cancers is mediated by threshold levels of 
constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272, 2927-2935. 
Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Brewer, Z. E., Cavenee, W. K., Furnari, F. 
B., and White, F. M. (2007). Quantitative analysis of EGFRvIII cellular signaling networks reveals 
a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A 104, 12867-
12872. 
Itakura, Y., Sasano, H., Shiga, C., Furukawa, Y., Shiga, K., Mori, S., and Nagura, H. (1994). 
Epidermal growth factor receptor overexpression in esophageal carcinoma. An 
immunohistochemical study correlated with clinicopathologic findings and DNA amplification. 
Cancer 74, 795-804. 
Johnson, H., Del Rosario, A. M., Bryson, B. D., Schroeder, M. A., Sarkaria, J. N., and White, F. 
M. (2012). Molecular characterization of EGFR and EGFRvIII signaling networks in human 
glioblastoma tumor xenografts. Mol Cell Proteomics 11, 1724-1740. 
Kholodenko, B. N., Demin, O. V., Moehren, G., and Hoek, J. B. (1999). Quantification of short 
term signaling by the epidermal growth factor receptor. J Biol Chem 274, 30169-30181. 
Kholodenko, B. N., Hancock, J. F., and Kolch, W. (2010). Signalling ballet in space and time. Nat 
Rev Mol Cell Biol 11, 414-426. 
Kim, H. J., and Bar-Sagi, D. (2004). Modulation of signalling by Sprouty: a developing story. Nat 
Rev Mol Cell Biol 5, 441-450. 
Kim, H. J., Taylor, L. J., and Bar-Sagi, D. (2007). Spatial regulation of EGFR signaling by 
Sprouty2. Curr Biol 17, 455-461. 
 
 150 
Kirchhausen, T., Macia, E., and Pelish, H. E. (2008). Use of dynasore, the small molecule 
inhibitor of dynamin, in the regulation of endocytosis. Methods Enzymol 438, 77-93. 
Kirkham, M., and Parton, R. G. (2005). Clathrin-independent endocytosis: new insights into 
caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta 1746, 349-363. 
Kobayashi, S., Boggon, T. J., Dayaram, T., Janne, P. A., Kocher, O., Meyerson, M., Johnson, B. 
E., Eck, M. J., Tenen, D. G., and Halmos, B. (2005). EGFR mutation and resistance of non-small-
cell lung cancer to gefitinib. N Engl J Med 352, 786-792. 
Koochekpour, S., Jeffers, M., Rulong, S., Taylor, G., Klineberg, E., Hudson, E. A., Resau, J. H., 
and Woude, G. F. V. (1997). Met and hepatocyte growth factor scatter factor expression in 
human gliomas. Cancer Res 57, 5391-5398. 
Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., and 
Mitsudomi, T. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with 
non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12, 5764-5769. 
Kwak, H. J., Kim, Y. J., Chun, K. R., Woo, Y. M., Park, S. J., Jeong, J. A., Jo, S. H., Kim, T. H., 
Min, H. S., Chae, J. S., et al. (2011). Downregulation of Spry2 by miR-21 triggers malignancy in 
human gliomas. Oncogene 30, 2433-2442. 
Lao, D. H., Chandramouli, S., Yusoff, P., Fong, C. W., Saw, T. Y., Tai, L. P., Yu, C. Y., Leong, H. 
F., and Guy, G. R. (2006). A Src homology 3-binding sequence on the C terminus of Sprouty2 is 
necessary for inhibition of the Ras/ERK pathway downstream of fibroblast growth factor receptor 
stimulation. J Biol Chem 281, 29993-30000. 
Lazzara, M. J., Lane, K., Chan, R., Jasper, P. J., Yaffe, M. B., Sorger, P. K., Jacks, T., Neel, B. 
G., and Lauffenburger, D. A. (2010). Impaired SHP2-mediated extracellular signal-regulated 
kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth 
factor receptor-activating mutations. Cancer Res 70, 3843-3850. 
Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., Pastorino, S., Purow, B. W., 
Christopher, N., Zhang, W., et al. (2006). Tumor stem cells derived from glioblastomas cultured in 
bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do 
serum-cultured cell lines. Cancer Cell 9, 391-403. 
Lee, M. J., Ye, A. S., Gardino, A. K., Heijink, A. M., Sorger, P. K., MacBeath, G., and Yaffe, M. B. 
(2012). Sequential application of anticancer drugs enhances cell death by rewiring apoptotic 
signaling networks. Cell 149, 780-794. 
Lee, Y., Scheck, A. C., Cloughesy, T. F., Lai, A., Dong, J., Farooqi, H. K., Liau, L. M., Horvath, S., 
Mischel, P. S., and Nelson, S. F. (2008). Gene expression analysis of glioblastomas identifies the 
major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 1, 52. 
Lemmon, M. A., and Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. Cell 
141, 1117-1134. 
Li, A., Walling, J., Kotliarov, Y., Center, A., Steed, M. E., Ahn, S. J., Rosenblum, M., Mikkelsen, 
T., Zenklusen, J. C., and Fine, H. A. (2008a). Genomic changes and gene expression profiles 
reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol 
Cancer Res 6, 21-30. 
Li, B., and Dewey, C. N. (2011). RSEM: accurate transcript quantification from RNA-Seq data 
 
 151 
with or without a reference genome. BMC Bioinformatics 12, 323. 
Li, X., Huang, Y., Jiang, J., and Frank, S. J. (2008b). ERK-dependent threonine phosphorylation 
of EGF receptor modulates receptor downregulation and signaling. Cell Signal 20, 2145-2155. 
Li, Z., Dong, Q., Wang, Y., Qu, L., Qiu, X., and Wang, E. (2012). Downregulation of Mig-6 in 
nonsmall-cell lung cancer is associated with EGFR signaling. Mol Carcinog 7, 522-534. 
Lito, P., Pratilas, C. A., Joseph, E. W., Tadi, M., Halilovic, E., Zubrowski, M., Huang, A., Wong, 
W. L., Callahan, M. K., Merghoub, T., et al. (2012). Relief of profound feedback inhibition of 
mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer 
Cell 22, 668-682. 
Liu, N., Matsumoto, M., Kitagawa, K., Kotake, Y., Suzuki, S., Shirasawa, S., Nakayama, K. I., 
Nakanishi, M., Niida, H., and Kitagawa, M. (2012). Chk1 phosphorylates the tumour suppressor 
Mig-6, regulating the activation of EGF signalling. EMBO J 31, 2365-2377. 
Lo, T. L., Fong, C. W., Yusoff, P., McKie, A. B., Chua, M. S., Leung, H. Y., and Guy, G. R. (2006). 
Sprouty and cancer: the first terms report. Cancer Lett 242, 141-150. 
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, 
B. W., and Kleihues, P. (2007). The 2007 WHO classification of tumours of the central nervous 
system. Acta Neuropathol 114, 97-109. 
Lund, K. A., Opresko, L. K., Starbuck, C., Walsh, B. J., and Wiley, H. S. (1990). Quantitative 
analysis of the endocytic system involved in hormone-induced receptor internalization. J Biol 
Chem 265, 15713-15723. 
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., 
Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004). Activating mutations in 
the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to 
gefitinib. N Engl J Med 350, 2129-2139. 
Ma, W., Trusina, A., El-Samad, H., Lim, W. A., and Tang, C. (2009). Defining network topologies 
that can achieve biochemical adaptation. Cell 138, 760-773. 
Macdonald-Obermann, J. L., and Pike, L. J. (2009). The intracellular juxtamembrane domain of 
the epidermal growth factor (EGF) receptor is responsible for the allosteric regulation of EGF 
binding. J Biol Chem 284, 13570-13576. 
Makkinje, A., Quinn, D. A., Chen, A., Cadilla, C. L., Force, T., Bonventre, J. V., and Kyriakis, J. M. 
(2000). Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and 
activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as 
diabetic nephropathy. Possible role in the response to persistent stress. J Biol Chem 275, 17838-
17847. 
Mason, J. M., Morrison, D. J., Bassit, B., Dimri, M., Band, H., Licht, J. D., and Gross, I. (2004). 
Tyrosine phosphorylation of Sprouty proteins regulates their ability to inhibit growth factor 
signaling: a dual feedback loop. Mol Biol Cell 15, 2176-2188. 
Mason, J. M., Morrison, D. J., Basson, M. A., and Licht, J. D. (2006). Sprouty proteins: 
multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol 
16, 45-54. 
 
 152 
Mellinghoff, I. K., Cloughesy, T. F., and Mischel, P. S. (2007). PTEN-mediated resistance to 
epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 13, 378-381. 
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., 
Yoshimoto, K., Huang, J. H., Chute, D. J., et al. (2005). Molecular determinants of the response 
of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353, 2012-2024. 
Minowada, G., Jarvis, L. A., Chi, C. L., Neubuser, A., Sun, X., Hacohen, N., Krasnow, M. A., and 
Martin, G. R. (1999). Vertebrate Sprouty genes are induced by FGF signaling and can cause 
chondrodysplasia when overexpressed. Development 126, 4465-4475. 
Mirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., 
Wang, N. J., Neve, R. M., Guan, Y., et al. (2009). Basal subtype and MAPK/ERK kinase (MEK)-
phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to 
MEK inhibition. Cancer Res 69, 565-572. 
Mitsudomi, T., and Yatabe, Y. (2007). Mutations of the epidermal growth factor receptor gene and 
related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors 
sensitivity in lung cancer. Cancer Sci 98, 1817-1824. 
Miyoshi, K., Wakioka, T., Nishinakamura, H., Kamio, M., Yang, L., Inoue, M., Hasegawa, M., 
Yonemitsu, Y., Komiya, S., and Yoshimura, A. (2004). The Sprouty-related protein, Spred, inhibits 
cell motility, metastasis, and Rho-mediated actin reorganization. Oncogene 23, 5567-5576. 
Monast, C. S., Furcht, C. M., and Lazzara, M. J. (2012). Computational analysis of the regulation 
of EGFR by protein tyrosine phosphatases. Biophys J 102, 2012-2021. 
Mosesson, Y., Mills, G. B., and Yarden, Y. (2008). Derailed endocytosis: an emerging feature of 
cancer. Nat Rev Cancer 8, 835-850. 
Nagashima, T., Ushikoshi-Nakayama, R., Suenaga, A., Ide, K., Yumoto, N., Naruo, Y., 
Takahashi, K., Saeki, Y., Taiji, M., Tanaka, H., et al. (2009). Mutation of epidermal growth factor 
receptor is associated with MIG6 expression. FEBS J 276, 5239-5251. 
Ng, C., Jackson, R. A., Buschdorf, J. P., Sun, Q., Guy, G. R., and Sivaraman, J. (2008). 
Structural basis for a novel intrapeptidyl H-bond and reverse binding of c-Cbl-TKB domain 
substrates. EMBO J 27, 804-816. 
Nguyen, J. T., Porter, M., Amoui, M., Miller, W. T., Zuckermann, R. N., and Lim, W. A. (2000). 
Improving SH3 domain ligand selectivity using a non-natural scaffold. Chem Biol 7, 463-473. 
Nicholson, R. I., Gee, J. M., and Harper, M. E. (2001). EGFR and cancer prognosis. Eur J Cancer 
37 Suppl 4, S9-15. 
Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., and Huang, H. 
J. (1994). A mutant epidermal growth factor receptor common in human glioma confers enhanced 
tumorigenicity. Proc Natl Acad Sci U S A 91, 7727-7731. 
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., 
De Feo, G., Caponigro, F., and Salomon, D. S. (2006). Epidermal growth factor receptor (EGFR) 
signaling in cancer. Gene 366, 2-16. 
Noro, R., Gemma, A., Kosaihira, S., Kokubo, Y., Chen, M., Seike, M., Kataoka, K., Matsuda, K., 
Okano, T., Minegishi, Y., et al. (2006). Gefitinib (IRESSA) sensitive lung cancer cell lines show 
 
 153 
phosphorylation of Akt without ligand stimulation. BMC Cancer 6, 277. 
Northrup, S. H., and Erickson, H. P. (1992). Kinetics of protein-protein association explained by 
Brownian dynamics computer simulation. Proc Natl Acad Sci U S A 89, 3338-3342. 
Ordonez-Moran, P., Irmisch, A., Barbachano, A., Chicote, I., Tenbaum, S., Landolfi, S., 
Tabernero, J., Huelsken, J., Munoz, A., and Palmer, H. G. (2013). SPROUTY2 is a beta-catenin 
and FOXO3a target gene indicative of poor prognosis in colon cancer. Oncogene 15, 1975-1987. 
Owens, D. M., and Keyse, S. M. (2007). Differential regulation of MAP kinase signalling by dual-
specificity protein phosphatases. Oncogene 26, 3203-3213. 
Ozaki, K., Kadomoto, R., Asato, K., Tanimura, S., Itoh, N., and Kohno, M. (2001). ERK pathway 
positively regulates the expression of Sprouty genes. Biochem Biophys Res Commun 285, 1084-
1088. 
Ozaki, K., Miyazaki, S., Tanimura, S., and Kohno, M. (2005). Efficient suppression of FGF-2-
induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms. J 
Cell Sci 118, 5861-5871. 
Padron, D., Sato, M., Shay, J. W., Gazdar, A. F., Minna, J. D., and Roth, M. G. (2007). Epidermal 
growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, 
poor ubiquitylation, and down-regulation but are efficiently internalized. Cancer Res 67, 7695-
7702. 
Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., 
Lindeman, N., Boggon, T. J., et al. (2004). EGFR mutations in lung cancer: correlation with 
clinical response to gefitinib therapy. Science 304, 1497-1500. 
Pante, G., Thompson, J., Lamballe, F., Iwata, T., Ferby, I., Barr, F. A., Davies, A. M., Maina, F., 
and Klein, R. (2005). Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/Met-induced 
cell migration and neurite growth. J Cell Biol 171, 337-348. 
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, 
V., Fulton, L., et al. (2004). EGF receptor gene mutations are common in lung cancers from 
"never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl 
Acad Sci U S A 101, 13306-13311. 
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., and 
Varmus, H. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is 
associated with a second mutation in the EGFR kinase domain. PLoS Med 2, e73. 
Parachoniak, C. A., Luo, Y., Abella, J. V., Keen, J. H., and Park, M. (2011). GGA3 functions as a 
switch to promote Met receptor recycling, essential for sustained ERK and cell migration. Dev 
Cell 20, 751-763. 
Patel, D., Lahiji, A., Patel, S., Franklin, M., Jimenez, X., Hicklin, D. J., and Kang, X. (2007). 
Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal 
growth factor receptor vIII on the cell surface. Anticancer Res 27, 3355-3366. 
Petrelli, A., Gilestro, G. F., Lanzardo, S., Comoglio, P. M., Migone, N., and Giordano, S. (2002). 
The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 
416, 187-190. 
 
 154 
Pratilas, C. A., Taylor, B. S., Ye, Q., Viale, A., Sander, C., Solit, D. B., and Rosen, N. (2009). 
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated 
transcriptional output of the pathway. Proc Natl Acad Sci U S A 106, 4519-4524. 
Raingeaud, J., Whitmarsh, A. J., Barrett, T., Derijard, B., and Davis, R. J. (1996). MKK3- and 
MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal 
transduction pathway. Mol Cell Biol 16, 1247-1255. 
Ramsay, A. G., Marshall, J. F., and Hart, I. R. (2007). Integrin trafficking and its role in cancer 
metastasis. Cancer Metast Rev 26, 567-578. 
Reich, A., Sapir, A., and Shilo, B. (1999). Sprouty is a general inhibitor of receptor tyrosine kinase 
signaling. Development 126, 4139-4147. 
Rinehart, J., Adjei, A. A., Lorusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., 
Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004). Multicenter phase II study of the oral 
MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and 
pancreatic cancer. J Clin Oncol 22, 4456-4462. 
Robertson, S. E., Setty, S. R., Sitaram, A., Marks, M. S., Lewis, R. E., and Chou, M. M. (2006). 
Extracellular signal-regulated kinase regulates clathrin-independent endosomal trafficking. Mol 
Biol Cell 17, 645-657. 
Rubin, C., Litvak, V., Medvedovsky, H., Zwang, Y., Lev, S., and Yarden, Y. (2003). Sprouty fine-
tunes EGF signaling through interlinked positive and negative feedback loops. Curr Biol 13, 297-
307. 
Sargin, B., Choudhary, C., Crosetto, N., Schmidt, M. H. H., Grundler, R., Rensinghoff, M., 
Thiessen, C., Tickenbrock, L., Schwable, J., Brandts, C., et al. (2007). Flt3-dependent 
transformation by inactivating c-Cbl mutations in AML. Blood 110, 1004-1012. 
Sathornsumetee, S., Reardon, D. A., Desjardins, A., Quinn, J. A., Vredenburgh, J. J., and Rich, J. 
N. (2007). Molecularly targeted therapy for malignant glioma. Cancer 110, 13-24. 
Sayed, D., Rane, S., Lypowy, J., He, M., Chen, I. Y., Vashistha, H., Yan, L., Malhotra, A., Vatner, 
D., and Abdellatif, M. (2008). MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. 
Mol Biol Cell 19, 3272-3282. 
Schmidt, M. H., and Dikic, I. (2005). The Cbl interactome and its functions. Nat Rev Mol Cell Biol 
6, 907-918. 
Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B., Kalra, A., 
Paragas, V., Bukhalid, R., et al. (2009). Therapeutically targeting ErbB3: a key node in ligand-
induced activation of the ErbB receptor-PI3K axis. Sci Signal 2, ra31. 
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., and Moasser, M. M. 
(2007). Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. 
Nature 445, 437-441. 
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., and Sawyers, C. L. (2004). Overriding 
imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401. 
Sharma, B., Joshi, S., Sassano, A., Majchrzak, B., Kaur, S., Aggarwal, P., Nabet, B., Bulic, M., 
Stein, B. L., McMahon, B., et al. (2012). Sprouty proteins are negative regulators of interferon 
 
 155 
(IFN) signaling and IFN-inducible biological responses. J Biol Chem 287, 42352-42360. 
Sheng, Q., and Liu, J. (2011). The therapeutic potential of targeting the EGFR family in epithelial 
ovarian cancer. Br J Cancer 104, 1241-1245. 
Shilo, B. Z. (2005). Regulating the dynamics of EGF receptor signaling in space and time. 
Development 132, 4017-4027. 
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, 
H., Hirano, H., Kuratsu, J., et al. (2003). Prognostic value of epidermal growth factor receptor in 
patients with glioblastoma multiforme. Cancer Res 63, 6962-6970. 
Sibenaller, Z. A., Etame, A. B., Ali, M. M., Barua, M., Braun, T. A., Casavant, T. L., and Ryken, T. 
C. (2005). Genetic characterization of commonly used glioma cell lines in the rat animal model 
system. Neurosurg Focus 19, E1. 
Siegel, R., Naishadham, D., and Jemal, A. (2013). Cancer statistics, 2013. CA Cancer J Clin 63, 
11-30. 
Sigismund, S., Argenzio, E., Tosoni, D., Cavallaro, E., Polo, S., and Di Fiore, P. P. (2008). 
Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for 
degradation. Dev Cell 15, 209-219. 
Sigismund, S., Woelk, T., Puri, C., Maspero, E., Tacchetti, C., Transidico, P., Di Fiore, P. P., and 
Polo, S. (2005). Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci U 
S A 102, 2760-2765. 
Siker, M. L., Wang, M., Porter, K., Nelson, D. F., Curran, W. J., Michalski, J. M., Souhami, L., 
Chakravarti, A., Yung, W. K., Delrowe, J., et al. (2011). Age as an independent prognostic factor 
in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of 
Surgeons National Cancer Data Base comparison. J Neurooncol 104, 351-356. 
Slape, C., Liu, L. Y., Beachy, S., and Aplan, P. D. (2008). Leukemic transformation in mice 
expressing a NUP98-HOXD13 transgene is accompanied by spontaneous mutations in Nras, 
Kras, and Cbl. Blood 112, 2017-2019. 
Sorkin, A., and Goh, L. K. (2009). Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 
315, 683-696. 
Sorkin, A., and von Zastrow, M. (2009). Endocytosis and signalling: intertwining molecular 
networks. Nat Rev Mol Cell Biol 10, 609-622. 
Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, 
J., Fischer, F., Frommolt, P., et al. (2009). PTEN loss contributes to erlotinib resistance in EGFR-
mutant lung cancer by activation of Akt and EGFR. Cancer Res 69, 3256-3261. 
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. 
A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012). Survival in BRAF V600-mutant 
advanced melanoma treated with vemurafenib. N Engl J Med 366, 707-714. 
Soubeyran, P., Kowanetz, K., Szymkiewicz, I., Langdon, W. Y., and Dikic, I. (2002). Cbl-CIN85-
endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 416, 183-
187. 
 
 156 
Starbuck, C., and Lauffenburger, D. A. (1992). Mathematical model for the effects of epidermal 
growth factor receptor trafficking dynamics on fibroblast proliferation responses. Biotechnol Prog 
8, 132-143. 
Sutterluty, H., Mayer, C. E., Setinek, U., Attems, J., Ovtcharov, S., Mikula, M., Mikulits, W., 
Micksche, M., and Berger, W. (2007). Down-regulation of Sprouty2 in non-small cell lung cancer 
contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and 
-independent mechanisms. Mol Cancer Res 5, 509-520. 
Swaminathan, G., and Tsygankov, A. Y. (2006). The Cbl family proteins: ring leaders in regulation 
of cell signaling. J Cell Physiol 209, 21-43. 
Tabatabai, G., and Weller, M. (2011). Glioblastoma stem cells. Cell Tissue Res 343, 459-465. 
Taniguchi, K., Ayada, T., Ichiyama, K., Kohno, R., Yonemitsu, Y., Minami, Y., Kikuchi, A., 
Maehara, Y., and Yoshimura, A. (2007). Sprouty2 and Sprouty4 are essential for embryonic 
morphogenesis and regulation of FGF signaling. Biochem Biophys Res Commun 352, 896-902. 
Theodosiou, A., and Ashworth, A. (2002). MAP kinase phosphatases. Genome Biol 3, 
REVIEWS3009. 
Therneau, T. M., and Grambsch, P. M. (2000). Modeling survival data : extending the Cox model,  
(New York: Springer). 
Thiessen, B., Stewart, C., Tsao, M., Kamel-Reid, S., Schaiquevich, P., Mason, W., Easaw, J., 
Belanger, K., Forsyth, P., McIntosh, L., and Eisenhauer, E. (2010). A phase I/II trial of GW572016 
(lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and 
molecular correlation. Cancer Chemother Pharmacol 65, 353-361. 
Tracy, S., Mukohara, T., Hansen, M., Meyerson, M., Johnson, B. E., and Janne, P. A. (2004). 
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer 
Res 64, 7241-7244. 
Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., and Engelman, J. A. 
(2012). MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB 
receptors. Cancer Res 72, 3228-3237. 
Turro, E., Lewin, A., Rose, A., Dallman, M. J., and Richardson, S. (2010). MMBGX: a method for 
estimating expression at the isoform level and detecting differential splicing using whole-transcript 
Affymetrix arrays. Nucleic Acids Res 38, e4. 
Tykocinski, E. S., Grant, R. A., Kapoor, G. S., Krejza, J., Bohman, L. E., Gocke, T. A., Chawla, 
S., Halpern, C. H., Lopinto, J., Melhem, E. R., and O'Rourke, D. M. (2012). Use of magnetic 
perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression 
in glioblastoma. Neuro Oncol 14, 613-623. 
Ventura, A., Meissner, A., Dillon, C. P., McManus, M., Sharp, P. A., Van Parijs, L., Jaenisch, R., 
and Jacks, T. (2004). Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl 
Acad Sci U S A 101, 10380-10385. 
Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., 
Ding, L., Golub, T., Mesirov, J. P., et al. (2010). Integrated genomic analysis identifies clinically 
relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and 
 
 157 
NF1. Cancer Cell 17, 98-110. 
Vieira, A. V., Lamaze, C., and Schmid, S. L. (1996). Control of EGF receptor signaling by clathrin-
mediated endocytosis. Science 274, 2086-2089. 
Vivanco, I., Robins, H. I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P. L., Kubek, S., 
Oldrini, B., Chheda, M. G., Yannuzzi, N., et al. (2012). Differential sensitivity of glioma- versus 
lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2, 458-471. 
Walsh, A. M., and Lazzara, M. J. (2013). Regulation of EGFR Trafficking and Cell Signaling by 
Sprouty2 and MIG6 in Lung Cancer Cells. J Cell Sci 126, 4339-4348. 
Wang, Z., Longo, P. A., Tarrant, M. K., Kim, K., Head, S., Leahy, D. J., and Cole, P. A. (2011). 
Mechanistic insights into the activation of oncogenic forms of EGF receptor. Nat Struct Mol Biol 
18, 1388-1393. 
Wen, P. Y., and Kesari, S. (2008). Malignant gliomas in adults. N Engl J Med 359, 492-507. 
Wheeler, D. L., Dunn, E. F., and Harari, P. M. (2010). Understanding resistance to EGFR 
inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7, 493-507. 
Wieduwilt, M. J., and Moasser, M. M. (2008). The epidermal growth factor receptor family: biology 
driving targeted therapeutics. Cell Mol Life Sci 65, 1566-1584. 
Wiley, H. S., and Cunningham, D. D. (1981). A steady state model for analyzing the cellular 
binding, internalization and degradation of polypeptide ligands. Cell 25, 433-440. 
Wiley, H. S., and Cunningham, D. D. (1982). The endocytotic rate constant. A cellular parameter 
for quantitating receptor-mediated endocytosis. J Biol Chem 257, 4222-4229. 
Wiley, H. S., Shvartsman, S. Y., and Lauffenburger, D. A. (2003). Computational modeling of the 
EGF-receptor system: a paradigm for systems biology. Trends Cell Biol 13, 43-50. 
Wong, E. S., Fong, C. W., Lim, J., Yusoff, P., Low, B. C., Langdon, W. Y., and Guy, G. R. (2002). 
Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and 
consequently enhances Ras/ERK signalling. EMBO J 21, 4796-4808. 
Workman, C., Jensen, L. J., Jarmer, H., Berka, R., Gautier, L., Nielser, H. B., Saxild, H. H., 
Nielsen, C., Brunak, S., and Knudsen, S. (2002). A new non-linear normalization method for 
reducing variability in DNA microarray experiments. Genome Biol 3, research0048. 
Wu, X., Alexander, P. B., He, Y., Kikkawa, M., Vogel, P. D., and McKnight, S. L. (2005). 
Mammalian sprouty proteins assemble into large monodisperse particles having the properties of 
intracellular nanobatteries. Proc Natl Acad Sci U S A 102, 14058-14062. 
Yang, S., Qu, S., Perez-Tores, M., Sawai, A., Rosen, N., Solit, D. B., and Arteaga, C. L. (2006). 
Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor 
receptors. Cancer Res 66, 6990-6997. 
Yao, L., Xu, W., and Li, J. Y. (2010). [Research advance on fludarabine resistance mechanisms 
in chronic lymphocytic leukemia cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 18, 821-824. 
Yarden, Y., and Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nat Rev Mol 
 
 158 
Cell Biol 2, 127-137. 
Yigzaw, Y., Poppleton, H. M., Sreejayan, N., Hassid, A., and Patel, T. B. (2003). Protein-tyrosine 
phosphatase-1B (PTP1B) mediates the anti-migratory actions of Sprouty. J Biol Chem 278, 284-
288. 
Ying, H. Q., Zheng, H. W., Scott, K., Wiedemeyer, R., Yan, H. Y., Lim, C., Huang, J., Dhakal, S., 
Ivanova, E., Xiao, Y. H., et al. (2010). Mig-6 controls EGFR trafficking and suppresses 
gliomagenesis. Proc Natl Acad Sci U S A 107, 6912-6917. 
Yun, C. H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. K., Meyerson, 
M., and Eck, M. J. (2008). The T790M mutation in EGFR kinase causes drug resistance by 
increasing the affinity for ATP. Proc Natl Acad Sci U S A 105, 2070-2075. 
Yusoff, P., Lao, D. H., Ong, S. H., Wong, E. S., Lim, J., Lo, T. L., Leong, H. F., Fong, C. W., and 
Guy, G. R. (2002). Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of 
Raf. J Biol Chem 277, 3195-3201. 
Zhang, K., Zhang, J., Han, L., Pu, P., and Kang, C. (2012). Wnt/beta-catenin signaling in glioma. 
J Neuroimmune Pharmacol 7, 740-749. 
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., and Kuriyan, J. (2006). An allosteric mechanism 
for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149. 
Zhang, X., Pickin, K. A., Bose, R., Jura, N., Cole, P. A., and Kuriyan, J. (2007a). Inhibition of the 
EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450, 741-744. 
Zhang, Y. W., Staal, B., Su, Y., Swiatek, P., Zhao, P., Cao, B., Resau, J., Sigler, R., Bronson, R., 
and Vande Woude, G. F. (2007b). Evidence that MIG-6 is a tumor-suppressor gene. Oncogene 
26, 269-276. 
Zhu, H., Acquaviva, J., Ramachandran, P., Boskovitz, A., Woolfenden, S., Pfannl, R., Bronson, R. 
T., Chen, J. W., Weissleder, R., Housman, D. E., and Charest, A. (2009). Oncogenic EGFR 
signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl 
Acad Sci U S A 106, 2712-2716. 
 
 
